



Office of Research

Annual Report of Grants and Contracts Fiscal Year 2014

July 1, 2013 - June 30, 2014



**UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
OFFICE OF RESEARCH
ANNUAL REPORT**

CONFIDENTIAL

This report is intended for internal management purposes only and contains confidential information. Questions or requests for summary reports should be directed to Diego Vazquez, Assistant Vice Provost, Office of Research at 508-856-5600.



DATE: August 1, 2014

TO: Distribution

FROM: Jean A. King, Ph.D.
Associate Provost for Biomedical Science Research

RE: FY2014 Annual Report of Grants and Contracts

The Office of Research is pleased to provide the FY2014 Annual Report of Grants & Contracts for the University of Massachusetts Medical School. This report summarizes the dollars amounts for grants and contracts that were active during the period July 1, 2013 through June 30, 2014.

Sponsored research funding totaled \$244,233,504. Direct costs comprised \$178,948,154 of that total, with \$65,390,875 in indirect costs.

A comparison of FY2013 and FY2014 shows an increase in both total and NIH funding.

Funding	FY 2013	FY 2014	% of Change
Total	\$242,336,429	\$244,233,504	0.83%
NIH	\$133,010,628	\$135,153,390	1.69%

If you have comments or questions regarding this report or require further information, please contact Diego Vazquez at 508-856-5600.

TABLE OF CONTENTS

Summary Statement of Grants & Contracts	1
Summary of Grants & Contracts by Research Unit – NIH & All Sources	3
NIH Grants by Award Type	5
Summary Statement of NIH Projects and Subawards on Program Project (P01) Grants	7
Summary Listing by Sponsor Category	9
Graph 1, Research Funding Total Dollars FY2005-2014	17
Graph 2, Research Funding Total by Sponsor Type FY2014	19
Graph 3, Federal Research Funding FY2014	21
Graph 4, Research Funding – Direct and Indirect Dollars FY2005-2014	23
Graph 5, Proposals and Progress Reports Submitted FY2005-2014	25
Grants & Contracts Detail	
<u>Basic Departments</u>	
Biochemistry and Molecular Pharmacology	29
Cancer Biology	31
Cell Biology	32
Microbiology and Physiological Systems	33
Molecular Medicine	35
Neurobiology	38
Pathology	40
Quantitative Health Sciences	42
<u>Clinical Departments</u>	
Anesthesiology	44
Emergency Medicine	45
Family Medicine and Community Health	46
Medicine	47
Cardiovascular Medicine	48
Dermatology	51
Diabetes	52
Endocrinology	53
Gastroenterology	54
General Medicine	57
Geriatric Medicine	58
Hematology & Oncology	59
Hospital Medicine	60
Infectious Disease & Immunology	61
Preventive and Behavioral Medicine	64
Pulmonary Medicine	66
Rheumatology	67
Neurology	69
Neurosurgery	73
Obstetrics & Gynecology	74
Orthopedics	75
Pediatrics	76
Psychiatry	79
Brudnick Neuropsychiatric Institute	82
Radiation Oncology	83
Radiology	84
Surgery	86
<u>Research Institutes & Centers</u>	
Advanced Therapeutics Cluster	
Gene Therapy Center	89
Program in Systems Biology	90
RNA Therapeutics Institute	91
Diabetes Center of Excellence	92
MASS Biologics of UMMS	93
Meyers Primary Care Institute	94
Program in Bioinformatics & Integrative Biology	96
Program in Gene Function & Expression	97
UMASS Cancer Center of Excellence	
Cancer Research Office (CRO)	99
Center for Clinical & Translational Science	103
Wellstone Program	104
<u>Administration</u>	
Environmental Health and Safety	105
Faculty Affairs	106
Library	107
Office of Global Health	108
Office of Research	
Animal Medicine	109
School Services	110
<u>Graduate Schools</u>	
Graduate School of Biomedical Sciences	111
Graduate School of Nursing	112
<u>Commonwealth Medicine</u>	
Center for Health Law and Economics	113
Center for Health Policy and Research	114
Area Health Education Center	115
NE AIDS Education and Training Center	116
Shriver Center	117

**UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
SUMMARY STATEMENT OF GRANTS & CONTRACTS***

	<u>June 30, 2013</u>		<u>June 30, 2014</u>	
Total Direct	\$177,289,886		\$178,848,716	
Total Indirect	\$65,046,543		\$65,384,788	
Total Dollars	\$242,336,429		\$244,233,504	
 Federal-NIH	\$133,010,628	54.9%	\$135,153,390	55.3%
Federal-Other	<u>\$53,649,233</u>	22.1%	<u>\$58,100,233</u>	23.8%
	\$186,659,861	77.0%	\$193,253,623	79.1%
Foundations	\$21,376,086	8.8%	\$24,967,217	10.2%
Industry	\$9,376,269	3.9%	\$9,919,133	4.1%
Other	\$24,924,213	10.3%	\$16,093,531	6.6%
		100.0%		100.0%
<hr/>				
Total Number of Projects	990	100.0%	1067	100.0%
Federal	553	55.9%	579	54.3%
Foundations	152	15.4%	183	17.2%
Industry	211	21.3%	220	20.6%
Other	74	7.5%	85	8.0%

*Clinical Studies are included based on CASH RECEIVED - Fiscal Year To Date

Breakout of "Other" Category	Amount
City/State	11,464,478
Colleges/Universities	3,189,582
Hospitals/Medical Centers	1,439,471
Total	16,093,531

UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
GRANTS and CONTRACTS BY RESEARCH UNIT-NIH AND ALL SOURCES
as of June 30, 2014

<u>Department/Division</u>	<u># of NIH</u>	<u>Total \$ NIH</u>	<u># ALL</u>	<u>Total \$ All Sources</u>
<u>Basic Science Departments</u>				
Biochemistry & Molecular Pharmacology	30	\$9,145,918	46	\$11,259,264
Cancer Biology	15	\$4,699,892	23	\$5,735,367
Cell Biology	13	\$3,997,850	19	\$5,133,341
Microbiology & Physiological	18	\$7,169,152	33	\$9,999,270
Molecular Medicine	36	\$13,062,884	56	\$17,126,155
Neurobiology	18	\$5,472,976	29	\$6,974,176
Pathology	36	\$12,500,170	39	\$13,136,281
Quantitative Health Sciences	11	\$4,089,052	23	\$5,030,463
Subtotal Basic Science	177	\$60,137,894	268	\$74,394,317
<u>Clinical Departments</u>				
Anesthesiology	0	\$0	5	\$196,640
Emergency Medicine	7	\$3,593,629	13	\$4,206,679
Family Medicine & Community Health	2	\$346,189	13	\$4,292,992
Medicine	3	\$416,796	9	\$1,845,773
Cardiovascular Medicine	8	\$2,500,415	47	\$4,375,113
Dermatology	2	\$124,416	10	\$756,169
Diabetes	2	\$440,712	15	\$1,681,384
Endocrinology	2	\$1,078,687	7	\$2,630,927
Gastroenterology	14	\$2,909,903	36	\$4,318,789
General Medicine	7	\$4,985,664	13	\$7,292,881
Geriatric Medicine	1	\$126,342	5	\$337,862
Hematology & Oncology	2	\$608,510	4	\$650,198
Hospital Medicine	0	\$0	2	\$60,936
Infectious Disease & Immunology	32	\$8,692,279	53	\$11,030,013
Preventive & Behavioral Medicine	14	\$2,906,894	29	\$4,520,263
Pulmonary Medicine	1	\$403,025	2	\$519,679
Rheumatology	6	\$1,496,963	20	\$2,229,896
Subtotal Medicine	94	\$26,690,606	252	\$42,249,883
Neurology	8	\$2,657,251	53	\$5,800,549
Neurosurgery	0	\$0	2	\$13,587
Obstetrics & Gynecology	0	\$0	5	\$106,361
Orthopedics	2	\$212,677	10	\$3,506,979
Pediatrics	5	\$977,920	40	\$2,933,948
Psychiatry	12	\$2,946,258	55	\$8,034,031
Brudnick Neuropsychiatric Institute	15	\$2,831,349	17	\$2,917,349
Subtotal Psychiatry	27	\$5,777,607	72	\$10,951,380
Radiation Oncology	0	\$0	4	\$336,750
Radiology	8	\$2,483,416	22	\$3,390,067
Surgery	1	\$387,595	35	\$1,753,952
Subtotal Clinical Departments	154	\$43,126,890	526	\$79,739,767
<u>Research Institutes, Centers & Programs</u>				
<u>Advanced Therapeutics Cluster (ATC)</u>				
Gene Therapy Center	6	\$2,190,235	18	\$4,615,453
Program in Systems Biology	6	\$2,256,664	10	\$2,616,267
RNA Therapeutics Institute	10	\$2,240,198	21	\$7,188,905
Subtotal Advanced Therapeutics Cluster	22	\$6,687,097	49	\$14,420,625
Diabetes Center of Excellence	6	\$1,690,737	14	\$3,113,713
MassBiologics Laboratory of UMMS	3	\$2,845,538	6	\$5,597,034
Meyers Primary Care Institute	1	\$217,800	24	\$2,247,414
Program in Bioinformatics & Integrative Biology	6	\$2,961,349	14	\$3,738,809
Program in Gene Function & Expression	18	\$6,357,533	33	\$9,052,383
UMASS Cancer Center of Excellence				
Cancer Research Office (CRO)	0	\$0	36	\$710,489
Subtotal UMASS Cancer Center of Excellence				
UMASS Center for Clinical & Translational Science	5	\$3,965,783	5	\$3,965,783
Wellstone Program	9	\$2,544,662	13	\$2,837,557
Subtotal Research Institutes & Centers	70	\$27,270,499	194	\$45,683,807
<u>Administration</u>				
Environmental Health & Safety	0	\$0	1	\$157,500
Faculty Affairs	0	\$0	1	\$125,000
Library	1	\$1,309,466	2	\$1,359,466
Office of Global Health	0	\$0	1	\$274,072

UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
GRANTS and CONTRACTS BY RESEARCH UNIT-NIH AND ALL SOURCES
as of June 30, 2014

Animal Medicine	2	\$509,159	2	\$509,159
School Services	1	\$109,080	2	\$118,954
Subtotal Administration	4	\$1,927,705	9	\$2,544,151

Department/Division

Schools

Graduate School of Biomedical Sciences	1	\$404,168	2	\$451,173
Graduate School of Nursing	1	\$376,394	4	\$1,729,976
Subtotal Schools	2	\$780,562	6	\$2,181,149

Commonwealth Medicine¹

Center for Health Law & Economics	0	\$0	4	\$3,662,063
Center for Health Policy & Research	3	\$489,365	24	\$29,051,433
Area Health Education Center	0	\$0	4	\$1,032,760
NE AIDS Education & Training Ctr	0	\$0	1	\$1,699,154
Shriver Center	5	\$1,420,475	31	\$4,244,903
Subtotal Commonwealth Medicine	8	\$1,909,840	64	\$39,690,313

TOTAL GRANTS & CONTRACTS	415	\$ 135,153,390	1067	\$ 244,233,504
-------------------------------------	------------	-----------------------	-------------	-----------------------

¹ Total does not reflect State Grants & Contracts Revenue

UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL

NIH AWARDS BY TYPE

	June 30, 2012	June 30, 2013	June 30, 2014
Basic Research Grants	233	205	202
(R00, R01 R03, R24, RC1, RC2, RC4, U01, U10, UM1)	\$ 99,228,789	\$ 85,232,478	\$ 82,048,817
Research Contracts	2	3	4
	\$ 3,134,043	\$ 6,011,030	\$ 3,128,070
Exploratory Awards	24	25	39
(R21, R21/R33, R33, R34, R56, UH2)	\$ 5,468,764	\$ 6,092,247	\$ 10,297,500
Merit Awards	14	12	11
(R37)	\$ 7,026,043	\$ 6,085,544	\$ 5,722,308
Career Development Awards	9	10	13
(KL2, K01, K08, K23, K99)	\$ 1,258,849	\$ 1,503,242	\$ 2,148,823
Program Projects & CTR Grants	19	15	14
(P01, P30, P60, U19, U24, U54, UL1)	\$ 33,748,636	\$ 23,101,400	\$ 25,138,511
Training & Education Grants	6	6	6
(R25, T32)	\$ 1,029,594	\$ 968,064	\$ 1,000,931
Fellowships	17	15	23
(F30, F31, F32)	\$ 735,671	\$ 684,777	\$ 918,572
Other Awards	3	3	5
(DP1, R13, U41)	\$ 54,380	\$ 3,331,846	\$ 3,674,834
Infrastructure & Instrumentation	2	-	2
(G20, S10)	\$ 1,065,642	\$ -	\$ 1,075,024
Total Number of Awards	329	294	319
Total Research Dollars	\$ 152,750,411	\$ 133,010,628	\$ 135,153,390

University of Massachusetts Medical School
Office of Research
Summary Statement of NIH Projects and Subawards on Program Project (P01) Grants
As of June 30, 2014

Department	PI Name	Sponsor	Grant #	Budget Start Date	Budget End Date	Amount
Biochemistry & Molecular Pharmacology	Schiffer, Celia	University of Minnesota	P01-GM091743	1/2/2014	12/31/2014	\$405,541
Cell Biology	Craig, Roger	University of Vermont	P01-HL059408	2/1/2014	1/31/2015	\$421,747
Diabetes Center of Excellence	Brehm, Michael	NIAID	P01 AI04662	6/1/2014	5/31/2015	\$137,761
Diabetes Center of Excellence	Greiner, Dale	NIAID	P01 AI04662	6/1/2014	5/31/2015	\$668,576
Gene Therapy	Flotte, Terrence	University of Florida	P01-HL059412	9/1/2008	10/31/2014	\$376,676
Gene Therapy	Gao, Guangping	SCRIPPS	P01-AG100263	4/1/2014	3/31/2015	\$540,434
Medicine	Konz, Richard	NIAID	P01 AI04932	7/1/2013	6/30/2014	\$158,878
Medicine/Cardiovascular Medicine	Freedman, Jane	Boston University	P01-AI078894	8/1/2013	7/31/2014	\$204,759
Medicine/General Medicine	Lu, Shan	NIAID	P01 AI08227	8/1/2013	7/31/2014	\$1,644,969
Medicine/General Medicine	Wang, Shixia	New York University	P01-AI100151	8/1/2013	7/31/2014	\$1,091,385
Medicine/Infectious Disease & Immunology	Ennis, Francis	University of Rhode Island	P01-AI034533	7/18/2013	6/30/2014	\$33,431
Medicine/Infectious Disease & Immunology	Green, Sharone	University of Rhode Island	P01-AI034533	7/18/2013	6/30/2014	\$130,537
Medicine/Infectious Disease & Immunology	Latz, Eicke	NIAMS	P01 AR05025	7/1/2013	6/30/2014	\$114,342
Medicine/Infectious Disease & Immunology	Mathew, Anuja	University of Rhode Island	P01-AI034533	7/18/2013	6/30/2014	\$66,483
Medicine/Infectious Disease & Immunology	Silverman, Neal	Sanford-Burnham Research Institute	P01-AG033561	4/1/2014	3/31/2015	\$102,678
Medicine/Infectious Disease & Immunology	Srikiatkachorn, Anon	University of Rhode Island	P01-AI034533	7/18/2013	6/30/2014	\$214,106

University of Massachusetts Medical School
Office of Research
Summary Statement of NIH Projects and Subawards on Program Project (P01) Grants
As of June 30, 2014

Department	PI Name	Sponsor	Grant #	Budget Start Date	Budget End Date	Amount
Medicine/Rheumatology	Marshak-Rothstein, Ann	NIAMS	P01 AR05025	7/1/2013	6/30/2014	\$1,196,203
Microbiology & Physiological Systems	McCormick, Beth	Massachusetts General Hospital	P01-DK033506	9/1/2013	8/31/2014	\$264,507
Microbiology & Physiological Systems	Sassetti, Christopher	Texas A&M University	P01-AI095208	9/1/2013	8/31/2014	\$198,997
Molecular Medicine	Clapham, Paul	NIAID	P01 AI08227	8/1/2013	7/31/2014	\$381,588
Molecular Medicine	Davis, Roger	NIAID	P01 AI04662	6/1/2014	5/31/2015	\$307,055
Molecular Medicine	Luzuriaga, Katherine	NIAID	P01 AI04932	7/1/2013	6/30/2014	\$806,428
Pathology	Dutton, Richard	NIAID	P01 AI04653	9/1/2013	8/31/2014	\$469,314
Pathology	Selin, Liisa	NIAID	P01 AI04662	6/1/2014	5/31/2015	\$483,024
Pathology	Selin, Liisa	NIAID	P01 AI04932	7/1/2013	6/30/2014	\$374,893
Pathology	Swain, Susan	NIAID	P01 AI04653	9/1/2013	8/31/2014	\$1,344,656
Pathology	Swain, Susan	University of Connecticut Health Center	P01-AG021600	6/1/2013	5/31/2014	\$426,055
Pathology	Welsh, Raymond	NIAID	P01 AI04662	6/1/2014	5/31/2015	\$307,878
Pediatrics	Greenough, Thomas	NIAID	P01 AI04932	7/1/2013	6/30/2014	\$264,300
Total						<u>\$13,137,201</u>

Office of Research
Summary Listing of Grants: By Sponsor Type
As of June 30, 2014

Sponsor	# of Proj.	Direct Costs	Indirect Costs	Total Costs
City/State				
EOHHS	8	\$8,966,892	\$840,350	\$9,807,242
EOLWD	1	\$112,383	\$20,229	\$132,612
MDDC	1	\$22,727	\$2,273	\$25,000
MDE	1	\$33,318	\$6,682	\$40,000
MDEEC	1	\$6,105	\$1,095	\$7,200
MDMH	1	\$126,050	\$23,950	\$150,000
MDPH	4	\$518,843	\$67,916	\$586,759
MEMA	1	\$157,500	\$0	\$157,500
NHINSUR	1	\$29,413	\$7,648	\$37,061
STATE OF VT	1	\$382,061	\$96,043	\$478,104
STME	1	\$19,841	\$5,159	\$25,000
WPS	1	\$17,143	\$857	\$18,000
	22	\$10,392,276	\$1,072,202	\$11,464,478
Colleges/Universities				
COLUMBIA	2	\$97,000	\$0	\$97,000
DUKE	2	\$54,041	\$29,959	\$84,000
GEORGIA	1	\$10,000	\$6,400	\$16,400
HARVARD	1	\$90,000	\$9,000	\$99,000
HOPKINS	1	\$85,000	\$0	\$85,000
INDIANAU	2	\$273,338	\$35,346	\$308,684
JDC	1	\$36,532	\$15,343	\$51,875
MCOW	1	\$9,000	\$2,700	\$11,700
MSSM	1	\$29,584	\$2,367	\$31,951
MUSC	1	\$4,615	\$1,385	\$6,000
NYU	1	\$62,108	\$12,422	\$74,530
RUTGERS	1	\$78,125	\$52,149	\$130,274
SUNY	1	\$12,345	\$0	\$12,345
TEXASAM	1	\$65,000	\$6,500	\$71,500
TUFTS	1	\$51,905	\$10,381	\$62,286
UAB	3	\$118,622	\$74,879	\$193,501
UCOPENHAGEN	1	\$320,833	\$0	\$320,833
UCSD	1	\$28,268	\$11,732	\$40,000
UCSF	1	\$50,350	\$2,014	\$52,364
UEDINBUR	3	\$149,396	\$53,783	\$203,179
UFLORIDA	1	\$22,727	\$2,273	\$25,000
UMASS/AMHERST	1	\$22,500	\$0	\$22,500
UMASS/BOSTON	1	\$13,844	\$3,599	\$17,443
UFLORIDA	1	\$13,394	\$4,019	\$17,413
UWASH	1	\$247,125	\$24,712	\$271,837
WEILL	1	\$357,934	\$35,793	\$393,727
WPI	2	\$191,522	\$126,658	\$318,180
WYSS	2	\$142,550	\$28,510	\$171,060
	37	\$2,637,658	\$551,924	\$3,189,582

Office of Research
Summary Listing of Grants: By Sponsor Type
As of June 30, 2014

Sponsor	# of Proj.	Direct Costs	Indirect Costs	Total Costs
Federal Research (NON-PHS)				
ARMY	1	\$187,500	\$120,938	\$308,438
DAMD	2	\$480,933	\$308,823	\$789,756
DARPA	4	\$3,394,403	\$726,764	\$4,121,167
DOD	4	\$386,667	\$239,508	\$626,175
FEDBOP	3	\$17,704,432	\$2,780,312	\$20,484,744
NSF	4	\$430,319	\$246,715	\$677,034
USDE	2	\$1,376,082	\$249,194	\$1,625,276
VA	3	\$1,145,813	\$0	\$1,145,813
	23	\$25,106,149	\$4,672,254	\$29,778,403
Federal Research (PHS)				
AHRQ	7	\$3,385,023	\$1,304,258	\$4,689,281
CDC	4	\$652,558	\$141,747	\$794,305
DHHS	1	\$496,310	\$38,905	\$535,215
HRSA	16	\$6,885,202	\$351,198	\$7,236,400
NIH	415	\$90,082,293	\$45,071,097	\$135,153,390
NIH-Subs	110	\$8,618,590	\$5,265,602	\$13,884,192
SAMHSA	2	\$759,520	\$128,189	\$887,709
SSA	1	\$247,671	\$47,057	\$294,728
	556	\$111,127,167	\$52,348,053	\$163,475,220
NIH-Subcontracts				
AAPED	1	\$2,652	\$1,711	\$4,363
BAYLORRI	3	\$341,319	\$226,637	\$567,956
BAYSTATE	1	\$14,368	\$9,267	\$23,635
BIDMC	4	\$225,244	\$115,173	\$340,417
BIMR	1	\$62,418	\$40,260	\$102,678
BMC	1	\$103,172	\$66,545	\$169,717
BROADINST	1	\$49,081	\$32,394	\$81,475
BU	5	\$516,365	\$323,846	\$840,211
BUMEDC	2	\$36,448	\$24,488	\$60,936
BWH	2	\$47,638	\$31,633	\$79,271
CCF	1	\$243,400	\$76,777	\$320,177
CHOP	1	\$38,385	\$11,515	\$49,900
DUKE	2	\$81,469	\$21,181	\$102,650
ECOLLEGE	1	\$39,728	\$26,453	\$66,181
EMORY	1	\$26,212	\$6,328	\$32,540
EOHHS	1	\$71,278	\$5,702	\$76,980
FIU	1	\$26,702	\$17,756	\$44,458
HPHC	1	\$39,215	\$25,294	\$64,509
HSPH	2	\$187,329	\$124,211	\$311,540
ICFLLC	1	\$45,455	\$4,545	\$50,000
IIT	1	\$249,474	\$167,771	\$417,245
JDGLADSTONE	1	\$133,588	\$86,195	\$219,783
KAISER	3	\$48,440	\$32,294	\$80,734
KFRI	2	\$152,275	\$101,517	\$253,792

Office of Research
Summary Listing of Grants: By Sponsor Type
As of June 30, 2014

Sponsor	# of Proj.	Direct Costs	Indirect Costs	Total Costs
NIH-Subcontracts (cont'd)				
KKI	2	\$110,882	\$46,017	\$156,899
MAYO	1	\$12,430	\$8,266	\$20,696
MDPH	1	\$34,082	\$6,475	\$40,557
MGH	5	\$389,136	\$252,180	\$641,316
MIRIAM	1	\$77,802	\$51,350	\$129,152
NORC	1	\$558,722	\$372,947	\$931,669
NORTHWESTERN	2	\$99,615	\$25,570	\$125,185
NYU	2	\$452,376	\$296,632	\$749,008
POLARIS	2	\$73,243	\$34,157	\$107,400
PSU	1	\$17,911	\$12,089	\$30,000
RUSH	1	\$10,041	\$6,702	\$16,743
RUTGERS	1	\$107,510	\$69,343	\$176,853
SCHEPENS	1	\$35,325	\$22,564	\$57,889
SCRIPPS	2	\$323,130	\$217,304	\$540,434
SFU	1	\$142,200	\$91,719	\$233,919
SIGMOVIR	1	\$76,508	\$51,005	\$127,513
SLOAN	1	\$11,521	\$7,604	\$19,125
TEXASAM	1	\$119,878	\$79,119	\$198,997
TUFTS	1	\$56,760	\$17,028	\$73,788
TULANE	1	\$11,721	\$7,883	\$19,604
UAB	5	\$314,595	\$203,655	\$518,250
UCONN	1	\$255,889	\$170,166	\$426,055
UCSF	2	\$62,397	\$36,071	\$98,468
UFLORIDA	2	\$221,843	\$146,342	\$368,185
UMASS/AMHERST	2	\$21,544	\$14,337	\$35,881
UMASS/LOWELL	1	\$64,544	\$41,631	\$106,175
UMICHIGAN	2	\$29,265	\$19,354	\$48,619
UMINNESOTA	1	\$246,017	\$159,524	\$405,541
UMISSMED	2	\$30,361	\$20,388	\$50,749
UNCAROLINA	1	\$48,858	\$32,776	\$81,634
UNH	2	\$92,350	\$38,060	\$130,410
UPENN	1	\$211,727	\$140,798	\$352,525
UPITTSBURGH	3	\$173,287	\$111,061	\$284,348
URHODE	4	\$250,944	\$166,613	\$417,557
UROCHESTER	1	\$6,429	\$4,147	\$10,576
USOFLORIDA	1	\$2,683	\$402	\$3,085
UTORONTO	1	\$36,348	\$24,323	\$60,671
UTAH	1	\$62,564	\$41,605	\$104,169
UVM	1	\$256,381	\$165,366	\$421,747
UWASH	1	\$101,990	\$67,313	\$169,303
VAN	3	\$495,927	\$320,467	\$816,394
WASHU	2	\$92,050	\$61,469	\$153,519
WPI	1	\$38,149	\$24,287	\$62,436
	110	\$8,618,590	\$5,265,602	\$13,884,192

Office of Research
Summary Listing of Grants: By Sponsor Type
As of June 30, 2014

Sponsor	# of Proj.	Direct Costs	Indirect Costs	Total Costs
Hospitals/Medical Centers				
BAYSTATE	2	\$45,384	\$18,647	\$64,031
BWH	2	\$32,645	\$8,211	\$40,856
DANA FARBER	1	\$769	\$231	\$1,000
EMMC	1	\$22,051	\$0	\$22,051
HANMS	1	\$130,644	\$13,064	\$143,708
HEALTHLINK	1	\$69,822	\$24,089	\$93,911
HPHC	10	\$195,004	\$130,101	\$325,105
MCOW	1	\$1,111	\$289	\$1,400
MGH	3	\$550,946	\$69,372	\$620,318
MHMH	1	\$44,396	\$4,440	\$48,836
MMC	1	\$30,000	\$0	\$30,000
RIH	1	\$18,195	\$5,459	\$23,654
W&I	1	\$19,525	\$5,076	\$24,601
	26	\$1,160,492	\$278,979	\$1,439,471
Industrial				
AASTROM	1	\$16,584	\$4,975	\$21,559
ABBOTT/CV	3	\$121,425	\$35,877	\$157,302
ABBVIE	6	\$487,642	\$338,105	\$825,747
ABIOMED	1	\$14,603	\$3,797	\$18,400
ABT	1	\$558,979	\$106,206	\$665,185
ACADIA	1	\$973	\$253	\$1,226
ACCUVEIN	1	\$15,080	\$4,524	\$19,604
AGALIMMUNE	1	\$85,567	\$34,227	\$119,794
AGTC	1	\$2,994	\$778	\$3,772
AIRXPAND	1	\$7,254	\$2,176	\$9,430
ALEXION	1	\$2,308	\$692	\$3,000
ALPHA	1	\$5,962	\$1,788	\$7,750
AMGEN	1	\$3,188	\$957	\$4,145
AMGENLTD	1	\$11,468	\$2,982	\$14,450
ANDROMEDA	1	\$676	\$203	\$879
APATECH	1	\$3,294	\$856	\$4,150
ARDEA	3	\$32,175	\$9,652	\$41,827
ARIAD	1	\$6,354	\$1,906	\$8,260
ASTELLAS	2	\$6,709	\$2,012	\$8,721
ASTRAZENECA	1	\$6,354	\$1,906	\$8,260
AUTISMCONS	2	\$71,866	\$9,693	\$81,559
AVEO	1	\$23,689	\$7,106	\$30,795
BANYANBIO	1	\$4,500	\$1,350	\$5,850
BAYERHEALTH	1	\$6,354	\$1,906	\$8,260
BHR	1	\$24,818	\$6,453	\$31,271
BIOGEN-IDEC	6	\$46,494	\$13,852	\$60,346
BIOMETBIO	1	\$7,025	\$2,108	\$9,133
BIOTRONIK	5	\$85,436	\$24,282	\$109,718
BIPI	1	\$72,289	\$47,711	\$120,000
BOLTONMED	2	\$6,360	\$1,908	\$8,268
BRI	1	\$50,000	\$5,000	\$55,000
BRISTOL	5	\$14,099	\$4,148	\$18,247
BRUINBIO	1	\$97,692	\$29,308	\$127,000
BSC	4	\$89,820	\$31,327	\$121,147
CAPRICOR	1	\$6,731	\$2,019	\$8,750
CARDIORENT	1	\$4,437	\$1,331	\$5,768
CELGENE	4	\$16,908	\$5,072	\$21,980

Office of Research
Summary Listing of Grants: By Sponsor Type
As of June 30, 2014

Sponsor	# of Proj.	Direct Costs	Indirect Costs	Total Costs
Industrial (cont'd)				
CELLERANT	1	\$105,120	\$31,536	\$136,656
CENTOCOR	1	\$19,614	\$5,099	\$24,713
CHELSEA	1	\$6,269	\$1,881	\$8,150
CODMAN	1	\$4,250	\$1,275	\$5,525
COMBE	1	\$30,015	\$19,985	\$50,000
COOK	6	\$22,401	\$6,402	\$28,803
CORDIS	1	\$794	\$206	\$1,000
COVIDIEN	1	\$2,308	\$692	\$3,000
CSS	1	\$3,654	\$1,096	\$4,750
CYBERON	1	\$8,100	\$2,106	\$10,206
CYTOKINETICS	1	\$46,147	\$13,844	\$59,991
DAVOL	1	\$31,354	\$9,407	\$40,761
DEPUY	1	\$159	\$41	\$200
DERMASCI	1	\$15,528	\$4,658	\$20,186
DIOGENIX	1	\$13,077	\$3,923	\$17,000
DRREEDYS	1	\$38,610	\$11,583	\$50,193
DSTL	1	\$116,377	\$78,069	\$194,446
DUAL	1	\$12,000	\$8,100	\$20,100
EBADC	1	\$14,608	\$5,259	\$19,867
EDEN	1	\$105,739	\$70,228	\$175,967
EISAI	1	\$1,542	\$401	\$1,943
EMMES	1	\$27,857	\$7,243	\$35,100
EOSHEALTH	1	\$7,692	\$2,308	\$10,000
FIDIA	1	\$4,266	\$1,109	\$5,375
FURIEX	1	\$1,654	\$496	\$2,150
GENENTECH	4	\$108,367	\$56,040	\$164,407
GENFIT	1	\$19,334	\$5,801	\$25,135
GENZYME	2	\$28,526	\$7,416	\$35,942
GIDYNAM	1	\$3,077	\$923	\$4,000
GILEAD	2	\$5,926	\$1,778	\$7,704
GLAXOSMITH	4	\$21,022	\$5,711	\$26,733
GLIKNIK	1	\$5,970	\$4,030	\$10,000
GROVE INST	1	\$62,866	\$12,573	\$75,439
HALOZYME	1	\$11,979	\$3,594	\$15,573
HCRI	1	\$6,369	\$1,656	\$8,025
HOFFMANN	2	\$46,086	\$13,825	\$59,911
HOPEPHARM	1	\$61,846	\$18,554	\$80,400
JANSSEN	4	\$26,665	\$7,100	\$33,765
LDR SPINE	1	\$7,600	\$2,280	\$9,880
LIGAND	1	\$141,535	\$42,460	\$183,995
LILLY	1	\$1,687	\$438	\$2,125
LOMBARD	1	\$2,381	\$619	\$3,000
MATHEMATICA	2	\$136,382	\$86,688	\$223,070
MCNEIL	1	\$87,650	\$0	\$87,650
MEDIVECTOR	3	\$236,782	\$158,078	\$394,860
MEDPACE	1	\$5,219	\$1,566	\$6,785
MEDTRONICS	6	\$54,313	\$15,070	\$69,383
MERCK	4	\$632,500	\$346,177	\$978,677
MICROVENTION	1	\$2,500	\$750	\$3,250
MICRUS	1	\$540	\$140	\$680
MILLENNIUM	1	\$308	\$92	\$400
MODERNA	1	\$240,000	\$160,000	\$400,000
NEOMEND	1	\$13,497	\$4,049	\$17,546
NERI	1	\$1,071	\$279	\$1,350

Office of Research
Summary Listing of Grants: By Sponsor Type
As of June 30, 2014

Sponsor	# of Proj.	Direct Costs	Indirect Costs	Total Costs
Industrial (cont'd)				
NEUREN	1	\$7,500	\$2,250	\$9,750
NEWTON	1	\$1,914	\$1,274	\$3,188
NOVARTIS	3	\$143,271	\$91,631	\$234,902
NOVO	8	\$109,151	\$31,292	\$140,443
OMNITEC	1	\$41,717	\$20,983	\$62,700
PFIZER	17	\$939,464	\$190,552	\$1,130,016
PHARMACYC	1	\$8,841	\$2,652	\$11,493
PHILIPS	2	\$384,710	\$125,290	\$510,000
PRAXIS	1	\$106,151	\$44,052	\$150,203
PROTEON	1	\$900	\$270	\$1,170
REMEDY	1	\$1,923	\$577	\$2,500
ROCHE	2	\$116,462	\$74,673	\$191,135
S&SS	3	\$30,955	\$16,243	\$47,198
SANOFIPAST	1	\$1,831	\$549	\$2,380
SCHERING	1	\$709	\$185	\$894
SEARLE	1	\$100,000	\$0	\$100,000
SEASIDE	2	\$30,420	\$9,125	\$39,545
SMITH & NEPHEW	1	\$38,290	\$26,803	\$65,093
SPECTRUM	1	\$8,064	\$2,420	\$10,484
STJUDE	5	\$80,456	\$22,064	\$102,520
STRYKER	1	\$4,615	\$1,385	\$6,000
T2BIOSYS	1	\$1,923	\$577	\$2,500
TAKEDA	2	\$6,364	\$1,777	\$8,141
THRESHOLD	1	\$5,034	\$1,309	\$6,343
TMRI	1	\$74,074	\$25,926	\$100,000
TRANS1	1	\$2,852	\$855	\$3,707
TYRX	1	\$7,684	\$1,998	\$9,682
VENTIRX	1	\$9,038	\$2,712	\$11,750
VERSARTIS	1	\$2,779	\$834	\$3,613
VERTEX	4	\$212,261	\$63,336	\$275,597
VIACORD	1	\$25,000	\$19,500	\$44,500
VIROPHARMA	1	\$7,205	\$2,161	\$9,366
	220	\$7,140,798	\$2,778,335	\$9,919,133
Non-Profit Foundations/Corporations				
ACDS	1	\$5,000	\$0	\$5,000
ACS	5	\$544,315	\$70,785	\$615,100
ADA	4	\$277,152	\$32,494	\$309,646
ADGAP	1	\$34,091	\$3,409	\$37,500
ADI	1	\$82,899	\$31,501	\$114,400
AFM	1	\$24,000	\$0	\$24,000
AHA	6	\$292,482	\$13,818	\$306,300
ALPHA1	1	\$50,000	\$0	\$50,000
ALSA	6	\$510,000	\$0	\$510,000
ALSTA	13	\$1,633,099	\$0	\$1,633,099
AMCHP	2	\$6,000	\$0	\$6,000
AMERSKIN	1	\$15,000	\$0	\$15,000
AOAHS	1	\$5,000	\$0	\$5,000
APSSPR	1	\$25,000	\$0	\$25,000
ARNOLDGOLD	1	\$5,000	\$0	\$5,000
ARTHRITIS	3	\$188,889	\$11,111	\$200,000
ASH	3	\$250,000	\$0	\$250,000
ATAXIA	1	\$50,000	\$0	\$50,000


Office of Research
Summary Listing of Grants: By Sponsor Type
As of June 30, 2014

Sponsor	# of Proj.	Direct Costs	Indirect Costs	Total Costs
Non-Profit Foundations/Corporations (cont'd)				
BURRWELL	2	\$147,005	\$0	\$147,005
CAKF	1	\$51,000	\$0	\$51,000
CARRINO	1	\$25,000	\$0	\$25,000
CFF	3	\$130,124	\$5,938	\$136,062
CHDI	3	\$1,299,981	\$171,722	\$1,471,703
CHPMC	1	\$3,246	\$260	\$3,506
CJCA	1	\$21,739	\$3,261	\$25,000
CMSC	2	\$10,000	\$0	\$10,000
CONCERN	1	\$60,000	\$0	\$60,000
CRDF	2	\$110,594	\$11,060	\$121,654
CRI	1	\$54,500		\$54,500
DFF	1	\$9,091	\$909	\$10,000
DONAGHUE	1	\$60,860	\$6,090	\$66,950
ELLISON	3	\$392,593	\$204,656	\$597,249
FEMHC	1	\$100,000	\$0	\$100,000
FFB	1	\$100,000	\$0	\$100,000
FSF	2	\$112,500	\$0	\$112,500
FSH	1	\$43,895	\$0	\$43,895
FST	1	\$65,634	\$19,690	\$85,324
GATES	4	\$1,884,682	\$156,694	\$2,041,376
GOG	1	\$47,587	\$7,138	\$54,725
HEALTHRES	1	\$50,743	\$18,267	\$69,010
HELMSLEY	3	\$815,867	\$69,087	\$884,954
HFSP	5	\$401,818	\$28,788	\$430,606
HHWF	1	\$54,500	\$0	\$54,500
HOOD	3	\$368,637	\$36,363	\$405,000
HUGHES	11	\$4,815,625	\$2,156,112	\$6,971,737
HUSSMAN	1	\$100,000	\$0	\$100,000
HYUNDAIHOPE	1	\$125,000		\$125,000
IAI	1	\$21,022	\$1,051	\$22,073
INTEL	1	\$9,874	\$0	\$9,874
IRRFI	1	\$91,857	\$4,593	\$96,450
JACKSON	1	\$136,364	\$13,636	\$150,000
JACKSONFDN	1	\$48,196	\$32,130	\$80,326
JAEB	3	\$9,750	\$975	\$10,725
JAPAN	1	\$11,000	\$0	\$11,000
JDRF	1	\$136,364	\$13,636	\$150,000
JGSF	1	\$1,440	\$0	\$1,440
JOHN MERCK	1	\$250,000	\$0	\$250,000
JRGOS	1	\$10,000	\$0	\$10,000
JSMF	1	\$4,010	\$1,030	\$5,040
KIMMEL	1	\$86,957	\$13,043	\$100,000
KING	1	\$47,500	\$0	\$47,500
KLARMAN	1	\$30,000	\$0	\$30,000
LEUKEMIA	2	\$157,143	\$7,857	\$165,000
LHRMA FDN	1	\$60,000	\$0	\$60,000
LIFE	1	\$56,000	\$0	\$56,000
LRI	1	\$250,000	\$0	\$250,000
LUK	1	\$36,669	\$3,667	\$40,336
MACF	3	\$407,795	\$61,169	\$468,964
MAHB	1	\$22,474	\$2,697	\$25,171
MATHERS	1	\$181,262	\$0	\$181,262
MDA	2	\$300,000	\$30,000	\$330,000
MEMRI	1	\$51,168	\$34,016	\$85,184


Office of Research
Summary Listing of Grants: By Sponsor Type
As of June 30, 2014

Sponsor	# of Proj.	Direct Costs	Indirect Costs	Total Costs
Non-Profit Foundations/Corporations (cont'd)				
MFOX	1	\$103,805	\$25,951	\$129,756
MOD	2	\$201,515	\$20,151	\$221,666
MOTOR	1	\$24,000	\$0	\$24,000
NARSAD	1	\$30,000	\$0	\$30,000
NCBH	1	\$3,832	\$1,380	\$5,212
NHF	1	\$9,737	\$0	\$9,737
NLMFF	1	\$22,727	\$2,273	\$25,000
NMDP	2	\$7,977	\$2,393	\$10,370
NNDC	2	\$26,000	\$0	\$26,000
NNRI/FFB	1	\$45,261	\$0	\$45,261
NOONAN	1	\$72,727	\$7,273	\$80,000
NTSAD	1	\$260,464	\$12,347	\$272,811
OMEGA	1	\$5,000	\$0	\$5,000
PCORI	3	\$810,800	\$189,544	\$1,000,344
PEW	1	\$55,200	\$4,800	\$60,000
PEW TRUSTS	2	\$85,556	\$4,444	\$90,000
PHYSICIAN	1	\$56,588	\$8,488	\$65,076
PRA	1	\$109,181	\$16,377	\$125,558
PROJALS	1	\$100,000	\$0	\$100,000
RETT	1	\$227,709	\$22,771	\$250,480
RSNA R&E	1	\$3,000	\$0	\$3,000
RSSFF	3	\$285,714	\$14,286	\$300,000
RTI Triangle	1	\$6,558	\$4,361	\$10,919
SARC	1	\$38,500	\$9,625	\$48,125
SFVAFRE	1	\$10,625	\$2,975	\$13,600
SLOANF	1	\$125,000	\$0	\$125,000
SRBAER	1	\$46,729	\$3,271	\$50,000
STANLEY	1	\$219,418	\$30,560	\$249,978
TAY SACHS	1	\$224,719	\$11,236	\$235,955
THRASHER	1	\$105,349	\$7,374	\$112,723
US/IBSF	1	\$9,565	\$1,435	\$11,000
WHITEHALL	1	\$73,927	\$1,073	\$75,000
	183	\$21,284,176	\$3,683,041	\$24,967,217
TOTAL - ALL SPONSOR TYPES	1067	\$178,848,716	\$65,384,788	\$244,233,504


University of Massachusetts Medical School Total Dollars for Research Funding Fiscal Years 2005-2014




University of Massachusetts Medical School Research Funding FY 2014




University of Massachusetts Medical School Federal Research Funding FY 2014



University of Massachusetts Medical School Research Funding FY 2005-2014



University of Massachusetts Medical School Proposals and Progress Reports Submitted FY2005-FY2014



GRANTS AND CONTRACTS DETAIL

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Biochemistry & Molecular Pharmacology	Bolon, Daniel	INDIANAU	1127342	5/1/2012	4/30/2015	5/1/2014	10/31/2014	Evolutionary responses of bacteria to long-term culture	\$21,040	\$13,572	\$34,612
		NIH	1 R21 CA175664-01A1	12/1/2013	11/30/2015	12/1/2013	11/30/2014	Functional effects of all possible point mutations in oncogenes	\$130,500	\$72,772	\$203,272
		UCSF	7814sc/NIH	9/1/2013	8/31/2015	9/1/2013	8/31/2014	Investigating the fitness landscape of all possible point mutants in the Vif gene	\$55,280	\$34,220	\$89,500
	Carruthers, Anthony Gilmore, James	NIH	2 R01 DK044888-21A1	9/15/2013	8/31/2017	9/15/2013	8/31/2014	How glucose transporter structure affects its function	\$174,000	\$116,000	\$290,000
		NIH	5 R01 GM035687-27	7/1/2010	6/30/2015	7/1/2013	6/30/2014	Protein Translocation Across the Endoplasmic Reticulum	\$207,919	\$134,107	\$342,026
		NIH	5 R01 GM043768-25	8/10/2011	5/31/2015	6/1/2014	5/31/2015	Assembly and Transfer of N-Linked Oligosaccharides	\$237,000	\$152,865	\$389,865
	Han, Gang	HFSP	RGY0090/2014	5/1/2014	4/30/2017	5/1/2014	4/30/2015	Wireless optogenetic interrogation on non-image forming photoreceptor function by Nano-antennae	\$75,757	\$7,576	\$83,333
		NIH	1 R01 MH103133-01	9/26/2013	7/31/2017	9/26/2013	7/31/2014	Wireless Optogenetics by relay nano-illuminators	\$200,000	\$133,333	\$333,333
	Kobertz, William	NIH	1 R21 DC012927-01A1	7/1/2013	6/30/2015	7/1/2013	6/30/2014	Calmodulation of Auditory Potassium Channels	\$150,000	\$99,750	\$249,750
		NIH	5 R01 GM070650-09	12/1/2010	11/30/2014	12/1/2013	11/30/2014	K ⁺ channel complexes: assembly, trafficking and function	\$207,202	\$133,645	\$340,847
	Mandon, Elisabet	ALSTA		7/1/2012	6/30/2015	7/1/2013	6/30/2014	Mitochondrial targeting and Import of SOD1 in ALS	\$98,886	\$0	\$98,886
	Massi, Francesca	NIH	5 R01 GM098763-03	9/15/2011	8/31/2016	9/1/2013	8/31/2014	Structure, dynamics and function of RNA binding proteins	\$183,350	\$118,261	\$301,611
	Matthews, C. Robert	GENENTECH		6/1/2011	12/31/2014	1/1/2014	12/31/2014	The role of Sequence in Determining the Disulfide Bond Status of Variable Heavy Chains in Monoclonal Antibodies	\$58,824	\$41,176	\$100,000
		NIH	5 R01 GM054836-16	5/1/2010	10/30/2014	5/1/2013	4/30/2014	Folding and Aggregation Mechanisms of human Cu, Zn Superoxide Dismutase	\$194,882	\$125,699	\$320,581
		NIH	2 R01 GM023303-37A1	1/1/2014	12/31/2017	1/1/2014	12/31/2014	Folding and Stability of TIM Barrel Proteins	\$228,241	\$152,922	\$381,163
		NSF	MCB-1121942	8/1/2011	7/31/2014	8/1/2013	7/31/2014	Folding of Dihydrofolate Reductase and the Response Regulators	\$144,234	\$93,031	\$237,265
		NSF	MCB-1051344	1/1/2011	12/31/2015	1/1/2014	12/31/2014	Research Coordination Network: Protein Folding and Dynamics	\$50,000	\$0	\$50,000
	McCollum, Dannel	NIH	5 R01 GM058406-16	5/1/2012	2/29/2016	3/1/2014	2/28/2015	Regulation of Cytokinesis in Fission Yeast	\$248,199	\$166,707	\$414,906
	Miller, Stephen	GATES		5/1/2013	10/31/2014	5/1/2013	10/31/2014	Delivery of novel drugs into parasitic nematodes	\$100,000	\$0	\$100,000
		NIH	5 R01 GM087460-05	4/1/2009	3/31/2015	4/1/2013	3/31/2014	Delivery and Triggered Activation of Near-IR Fluorophores for Live Cell Imaging	\$179,701	\$115,908	\$295,609
		NIH	5 R01 EB013270-03	9/26/2011	8/31/2015	9/1/2013	8/31/2014	Enhanced synthetic luciferin substrates for firefly luciferase	\$212,175	\$136,853	\$349,028
	Munson, Mary	NIH	5 R01 GM068803-09	7/1/2010	6/30/2015	7/1/2013	6/30/2014	Structure and Function of the Exocyst Complex	\$200,135	\$129,087	\$329,222
	Pauff, Steven	AHA	13PRE13970011	1/1/2013	12/31/2014	1/1/2014	12/31/2014	Design of Near-Infrared Imaging Reagents for the Detection of Nitric Oxide in Live Cells and Organisms	\$22,000	\$0	\$22,000
	Pederson, Thoru	NSF	MCB-0151398-003	4/1/2011	3/31/2014	4/1/2013	3/31/2014	Probing New Dimensions of the Nucleolus	\$164,130	\$105,864	\$269,994
	Pryciak, Peter	NIH	5 R01 GM057769-16	9/1/2011	8/31/2015	9/1/2013	8/31/2014	Yeast Pheromone Signal Transduction	\$212,776	\$137,241	\$350,017

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Biochemistry & Molecular Pharmacology	Ragland, Debra	NIH	1 F31 GM111101-01	6/10/2014	6/9/2017	6/10/2014	6/9/2015	The Interdependence of Drug Resistant HIV-1 Protease	\$29,351	\$0	\$29,351
	Rando, Oliver	MATHERS		10/1/2012	9/30/2014	10/1/2013	9/30/2014	The Inheritance of Acquired Characters in Mammals	\$181,262	\$0	\$181,262
		MOD	1-FY14-238	6/1/2014	5/31/2017	6/1/2014	5/31/2015	Role of the tRNA Fragments in Paternal Dietary Effects on Offspring Metabolism	\$133,333	\$13,333	\$146,666
		NIH	5 R01 DA033664-03	4/1/2012	3/31/2017	4/1/2014	3/31/2015	Transgenerational Effects of Nicotine [MPI]	\$87,352	\$56,343	\$143,695
		NIH	1 R01 HD080224-01A1	4/14/2014	2/28/2019	4/14/2014	2/28/2015	Dietary effects on the sperm epigenome	\$328,796	\$221,390	\$550,186
		NIH	5 R01 GM079205-07	3/8/2013	2/28/2017	3/1/2014	2/28/2015	Chromatin dynamics in yeast	\$260,786	\$157,679	\$418,465
	Rhind, Nick	NIH	5 R01 GM098815-03	5/15/2012	2/29/2016	3/1/2014	2/28/2015	The Regulation of DNA Replication Kinetics	\$190,000	\$127,616	\$317,616
		NIH	5 R01 GM069957-09	4/1/2010	3/31/2014	4/1/2013	3/31/2014	Mechanism of the S-Phase DNA Damage Checkpoint	\$191,070	\$123,240	\$314,310
	Ross, Alonzo	NIH	5 R01 NS021716-29	8/1/2010	5/31/2015	6/1/2014	5/31/2015	Enhancing glioma chemotherapy by suppressing Notch signaling	\$212,231	\$136,889	\$349,120
	Ryder, Sean	NIH	5 R01 GM098643-03	4/1/2012	3/31/2015	4/1/2014	3/31/2015	Comparative HTS to identify small molecule effectors of cell fate specification	\$188,000	\$121,260	\$309,260
	Sagerstrom, Charles	NIH	5 R01 NS038183-15	6/1/2012	5/31/2017	6/1/2014	5/31/2015	Molecular Analysis of Hindbrain Development	\$216,563	\$139,683	\$356,246
		NIH	5 R01 HD065081-04	2/5/2011	1/31/2016	2/1/2014	1/31/2015	Genetic Regulation of Rhombomere Formation	\$206,550	\$133,225	\$339,775
	Schiffer, Celia	NIH	5 R01 AI085051-05	5/1/2010	4/30/2015	5/1/2014	4/30/2015	Drug Resistance in HCV NS3/4A - Inhibitor binding versus substrate recognition	\$247,500	\$159,638	\$407,138
		NIH	5 R01 GM064347-13	9/1/2010	10/31/2014	8/1/2013	7/31/2014	Elucidating the Interplay of Protease Substrate Recognition and Drug Resistance	\$251,149	\$133,280	\$384,429
		UMINNESOTA	H001786602/NIH	3/1/2011	12/31/2015	1/1/2014	12/31/2014	Structural Characterization of APOBEC3's Atomic Interactions - Project 3	\$246,017	\$159,524	\$405,541
	Soumana, Djade	NIH	5 F31 GM103259-02	1/24/2013	1/23/2016	1/24/2014	1/23/2015	HCV Protease: from atomic mechanism for drug resistance to novel drug design	\$29,190	\$0	\$29,190
	Vallaster, Markus	NIH	5 F32 DA034414-02	1/22/2013	1/21/2016	1/22/2014	1/21/2015	Transgenerational effects of nicotine in F1 generation of exposed fathers in mice	\$57,541	\$0	\$57,541
	Xu, Zuoshang	ALSA	14-LGCA-185	2/1/2014	1/31/2015	2/1/2014	1/31/2015	AAV Therapeutic Agents for ALS	\$100,000	\$0	\$100,000
		NIH	5 R21 NS082683-02	4/1/2013	3/31/2015	4/1/2014	3/31/2015	Modeling Mutant Profilin1 Toxicity and ALS in vivo	\$148,500	\$99,866	\$248,366
	Zitzewitz, Jill Ann	ALSA	2316	8/1/2013	7/31/2014	8/1/2013	7/31/2014	Developing Small Molecule Screening Assays for Identifying Potential Therapeutics to Treat ALS	\$80,000	\$0	\$80,000
		ALSTA		7/1/2012	6/30/2014	7/1/2013	6/30/2014	Molecular Dissection of TDP-43: Probing Structure, Dynamics and Aggregation for Therapeutic Intervention	\$114,287	\$0	\$114,287
Biochemistry & Molecular Pharmacology Total									\$7,255,709	\$4,003,555	\$11,259,264

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Cancer Biology	Baehrecke, Eric	ELLISON	AG-SS-2761-11	11/1/2011	10/31/2015	11/1/2013	10/31/2014	Role of autophagy and bioenergetics in stem cell maintenance and aging	\$150,000	\$96,750	\$246,750
		NIH	5 R01 AI099708-02	9/24/2012	8/31/2017	9/1/2013	8/31/2014	Interplay between the Endocrine and Innate Systems of Drosophila [MPI]	\$73,748	\$46,326	\$120,074
		NIH	5 R01 CA159314-04	6/16/2011	3/31/2016	4/1/2014	3/31/2015	Function of Atg6 and autophagy in growth control	\$201,275	\$129,823	\$331,098
		NIH	5 R01 GM079431-09	2/1/2011	1/31/2015	2/1/2014	1/31/2015	Genetic Regulation of Autophagic Cell Death	\$215,000	\$138,675	\$353,675
	Bergmann, Andreas	NIH	5 R01 GM068016-12	4/1/2013	3/31/2017	4/1/2014	3/31/2015	Genetic Control of Programmed Cell Death in Drosophila	\$269,546	\$179,234	\$448,780
		NIH	1 R01 GM107789-01	9/1/2013	6/30/2017	9/1/2013	6/30/2014	Role of apoptosis for regenerative proliferation	\$265,552	\$174,485	\$440,037
	Kelliher, Michelle	DUAL		2/10/2014	8/9/2014	2/10/2014	8/9/2014	Small Molecule PP2A Activator TRC-382 for the Treatment of High-Risk T-Cell Acute Lymphoblastic Leukemia (T-ALL)	\$12,000	\$8,100	\$20,100
		HYUNDAIHOPE		9/1/2013	12/1/2015	9/1/2013	8/31/2014	Therapeutic Strategies for Relapsed Pediatric T-ALL	\$125,000	\$0	\$125,000
		NIH	2 R01 AI075118-06	12/1/2013	11/30/2018	12/1/2013	11/30/2014	Rip Proteins in Innate Immune Signaling	\$250,000	\$167,292	\$417,292
		NIH	5 R01 CA096899-08	8/17/2011	6/30/2016	7/1/2013	6/30/2014	Mechanism(s) of TAL1- and NOTCH1-mediated Leukemogenesis	\$182,715	\$117,852	\$300,567
	Mao, Junhao	ACS	RSG-11-040-01-DDC	1/1/2011	12/31/2014	1/1/2014	12/31/2014	Hedgehog-Gli-Activation in Rhabdomyosarcoma	\$150,000	\$30,000	\$180,000
		NIH	1 R01 DK099510-01A1	4/1/2014	3/31/2019	4/15/2014	3/31/2015	Growth and patterning in the gut mesenchyme	\$217,500	\$143,778	\$361,278
	Mercado-Matos, Jose	NIH	1 F31 CA180706-01	9/16/2013	9/15/2017	9/16/2013	9/15/2014	The Impact of IRS2-microtubule interactions in the progression of breast cancer	\$26,847		\$26,847
	Mercurio, Arthur	DOD	W81XWH-12-1-0308	8/15/2012	8/14/2015	8/15/2013	8/14/2014	Neuropilin-2: A Novel Biomarker and Therapeutic Target for Aggressive Prostate Cancer	\$125,000	\$80,625	\$205,625
		NIH	5 R01 CA168464-03	7/9/2012	4/30/2017	5/1/2014	4/30/2015	VEGF Signaling in Mammary Tumorigenesis	\$201,275	\$135,525	\$336,800
		NIH	5 R01 CA159856-03	7/9/2012	4/30/2017	5/1/2014	4/30/2015	Mechanisms of Carcinoma Differentiation and Invasion	\$201,275	\$135,525	\$336,800
		ACS	PF-13-247-01-LIB	7/1/2013	6/30/2016	7/1/2013	6/30/2014	GSI Treatment in Relapsed T-ALL and Mechanisms of GSI Resistance	\$48,000	\$0	\$48,000
	Shaw, Leslie	NIH	5 R01 CA142782-05	7/5/2010	4/30/2015	5/1/2014	4/30/2015	IRS-2 Function in Tumor Progression and Metastasis	\$195,237	\$125,928	\$321,165
		NIH	5 R01 CA177167-02	7/1/2013	4/30/2018	5/1/2014	4/30/2015	Autophagy-independent function of Beclin 1 in Breast Cancer	\$201,275	\$135,861	\$337,136
	Socolovsky, Merav	ASH		4/1/2013	3/31/2014	4/1/2013	3/31/2014	Molecular Analysis of the Erythropoietic Stress Response in Vivo	\$100,000	\$0	\$100,000
		LEUKEMIA	1728-13	7/1/2012	6/30/2017	7/1/2013	6/30/2014	An S phase-dependent epigenetic switch in erythropoiesis	\$104,762	\$5,238	\$110,000
		NIH	5 R21 HL113978-02	1/22/2013	12/31/2014	1/1/2014	12/31/2014	The Role of RB Family Proteins in an S Phase-Dependent Erythroid Commitment Step	\$122,500	\$82,075	\$204,575
		NIH	5 R01 DK099281-02	6/7/2013	3/31/2017	4/1/2014	3/31/2015	DNA Replication and Genome-Wide Demethylation in Erythropoiesis	\$217,500	\$146,268	\$363,768
Cancer Biology Total								\$3,656,007	\$2,079,360	\$5,735,367	

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Cell Biology	Craig, Roger	NIH	5 R01 AR034711-22	7/1/2009	6/30/2014	7/1/2013	6/30/2014	Structural Basis of Muscle Regulation	\$203,148	\$131,030	\$334,178
		UVM	23326SUB50686/NIH	2/1/2010	1/31/2015	2/1/2014	1/31/2015	Project 1: cMyBP-C and Native Thick Filament Structure	\$256,381	\$165,366	\$421,747
		WASHU	116617 G003102/NIH	7/1/2012	4/30/2017	5/1/2014	4/30/2015	Mechanisms Controlling the Super-Relaxed State	\$22,084	\$14,243	\$36,327
	Florman, Harvey	NIH	5 R01 HD046948-09	7/1/2010	6/30/2015	7/1/2013	6/30/2014	Regulators of the Sperm Acrosome Reaction	\$182,208	\$117,524	\$299,732
	Imbalzano, Anthony	NIH	5 R01 GM056244-16	9/1/2011	6/30/2015	7/1/2013	6/30/2014	Transcription Factor Function in Chromatin	\$229,844	\$145,747	\$375,591
		NIH	1 R21 CA185926-01	2/1/2014	1/31/2016	2/1/2014	1/31/2015	Discovery of BRG1 Inhibitors for Breast Cancer Therapy [MPI]	\$108,750	\$72,953	\$181,703
	Jiang, Jun	HOOD		3/1/2014	2/28/2016	3/1/2014	2/28/2015	Trisomy Correction in Down's syndrome Mouse Models	\$68,182	\$6,818	\$75,000
	Jones, Stephen	NIH	5 R01 CA077735-14	7/5/2010	4/30/2015	5/1/2014	4/30/2015	The Role of MDM Proteins in Cell Growth and Tumorigenesis	\$186,079	\$120,021	\$306,100
	Lawrence, Jeanne	HOOD		2/1/2014	1/31/2016	2/1/2014	1/31/2015	Trisomy Silencing for Down Syndrome Translational Research and Hope for Chromosome Therapy	\$232,273	\$22,727	\$255,000
		JOHN MERCK		10/1/2013	9/30/2017	10/1/2013	9/30/2014	Accelerating Down Syndrome Progress by Translating Dosage Compensation to Trisomy	\$250,000	\$0	\$250,000
		NIH	5 R01 GM107604-02	8/1/2013	3/31/2017	4/1/2014	3/31/2015	The repeat genome in interphase chromosome structure and regulation	\$190,000	\$127,776	\$317,776
	Nickerson, Jeffrey	NIH	1 R21 CA185926-01	2/1/2014	1/31/2016	2/1/2014	1/31/2015	Discovery of BRG1 Inhibitors for Breast Cancer Therapy [MPI]	\$0	\$0	\$0
		UFLORIDA	UF-EIES-1203043-UMA/NI	8/1/2012	7/31/2016	8/1/2013	7/31/2014	Mechanical communication Between the Nucleus and the ECM	\$59,220	\$38,197	\$97,417
	Odgren, Paul	NIH	1 R01 AR061504-01A1	9/16/2013	8/31/2015	9/16/2013	8/31/2014	Pre-osteoclast fusion	\$212,500	\$141,755	\$354,255
		NIH	5 R01 GM094874-04	9/1/2010	8/31/2014	9/1/2013	8/31/2014		\$191,070	\$123,240	\$314,310
	Sluder, Greenfield	NIH	5 R01 GM030758-32	9/15/2011	6/30/2015	7/1/2013	6/30/2014	Epiblast Complementation Chimeras Control of centrosome duplication and G1 arrest after prolonged prometaphase	\$254,629	\$164,236	\$418,865
	Witman, George	NIH	5 R37 GM030626-33	7/15/2012	6/30/2017	7/1/2013	6/30/2014	Flagellar Motility and Assembly	\$405,616	\$269,735	\$675,351
		NIH	5 T32 HD007439-20	5/1/2011	4/30/2016	5/1/2014	4/30/2015	Cell and Molecular Biology of Reproduction	\$100,700	\$8,056	\$108,756
	Zhang, Hong	NIH	5 R01 CA131210-05	7/1/2009	6/30/2015	7/1/2013	6/30/2014	Genetic Pathways of Replicative Senescence and its Function in Tumorigenesis	\$189,199	\$122,034	\$311,233
Cell Biology Total									\$3,341,883	\$1,791,458	\$5,133,341

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Microbiology & Physiological Systems	Behar, Samuel	BWH	109216/NIH	5/24/2013	4/30/2015	5/1/2014	4/30/2015	Role of Type II NKT Cells During M. Tuberculosis Infection	\$30,192	\$20,380	\$50,572
		NIH	7 R01 AI085669-04	7/1/2013	6/30/2015	7/1/2013	6/30/2014	Tim3 and Mycobacterium Tuberculosis	\$337,451	\$224,405	\$561,856
		NIH	7 R21 AI100766-02	7/1/2013	6/30/2015	7/1/2013	6/30/2014	The effect of type I IFN and IL-12 signaling on T cell immunity to tuberculosis	\$198,801	\$132,202	\$331,003
		NIH	1 R01 AI106725-01	8/2/2013	7/31/2017	8/2/2013	7/31/2014	Regulation of CD8+ T cell immunity to tuberculosis	\$363,525	\$242,047	\$605,572
		NIH	5 R01 AI098637-04	4/1/2013	1/31/2017	2/1/2014	1/31/2015	Apoptosis and efferocytosis: regulators of immunity to tuberculosis	\$296,218	\$199,207	\$495,425
	Brass, Abraham	BIPI		12/4/2012	12/3/2014	12/4/2012	12/3/2014	A Genetic Strategy to Find Host Factors that Modulate Human Rhinovirus	\$72,289	\$47,711	\$120,000
		BURRWELL	1012374	7/1/2013	6/30/2018	7/1/2013	6/30/2014	Defining Dengue Virus' dependencies: Discovery and Characterization of host factors required for viral replication	\$100,000	\$0	\$100,000
		MGH	223539	10/1/2013	9/30/2015	11/14/2013	9/30/2014	A genetic approach to optimizing the antigenicity of HIV-1 envelope immunogens	\$393,553	\$37,262	\$430,815
		NIH	5 R01 AI091786-04	5/16/2012	8/31/2016	9/1/2013	8/31/2014	The Role of IFITM3 in the Anti-viral Host Response	\$253,764	\$169,145	\$422,909
		ROCHE		6/25/2012	6/24/2014	6/25/2013	6/24/2014	Identification of Host Factors that Modulate HBV Infection, Replication, and Antigen Production	\$100,894	\$70,626	\$171,520
	Jacobson, Allan	NIH	5 R37 GM027757-35	4/1/2010	3/31/2015	4/1/2014	3/31/2015	Messenger RNA Metabolism in Yeast	\$410,494	\$261,877	\$672,371
		US/IBSF	2009306	10/1/2010	9/30/2014	10/1/2013	9/30/2014	A Novel Role for Promoters in Cytoplasmic mRNA Decay	\$9,565	\$1,435	\$11,000
	Kowalik, Timothy	UAB	000402815-001/NIH	9/15/2011	6/30/2014	7/1/2013	6/30/2014	CMV Vaccines: Reinfection and Antigenic Variation	\$95,372	\$61,515	\$156,887
	Leonard, Jack	NIH	5 R01 AA018814-05	9/30/2009	8/31/2014	9/1/2013	8/31/2014	The Effects of Alcohol on JNK Mediated Inflammatory Signaling in Glial Cells	\$210,182	\$135,567	\$345,749
	Long, Jarukit	NIH	5 F32 AI093049-03	7/1/2011	6/30/2014	7/1/2013	6/30/2014	Exogenous Carbohydrates are Required for Survival for M. Tuberculosis	\$55,670	\$0	\$55,670
	Maldonado-Contreras, Ana Luisa	KING		7/1/2013	6/30/2015	7/1/2013	6/30/2014	A novel platform for a vaccine against gastrointestinal bacterial diseases	\$47,500	\$0	\$47,500
	McCormick, Beth	MGH	219936/NIH	9/23/2011	8/31/2016	9/1/2013	8/31/2014	Barrier Function of the GI Tract in Health and Disease	\$160,795	\$103,712	\$264,507
		NIH	5 R01 DK056754-14	9/20/2010	8/31/2015	9/1/2013	8/31/2014	Intestinal Inflammation Induced by Pathogens	\$178,020	\$114,823	\$292,843
		NIH	1 R56 AI107804-01	8/1/2013	7/31/2014	8/1/2013	7/31/2014	Salmonella Pathogenesis and Processing of Secreted Effectors by Caspase-3	\$247,083	\$164,516	\$411,599
	Morrison, Trudy	SIGMOVIR	R41-AI109926/NIH	2/15/2014	1/31/2015	2/15/2014	1/31/2015	Development of VLP Vaccines for RSV	\$76,508	\$51,005	\$127,513
	Sanderson, Michael	NIH	5 R01 HL103405-04	9/1/2010	6/30/2015	7/1/2013	6/30/2014	A multi-scale approach to airway hyperresponsiveness: from molecule to organ	\$745,925	\$109,395	\$855,320
		HSPH	109669-5064861/NIH	7/2/2013	6/30/2018	7/2/2013	6/30/2014	Decoding the roles of critical genes of unknown function in M. tuberculosis	\$169,129	\$112,471	\$281,600
	Sassetti, Christopher	HUGHES		9/1/2009	8/31/2015	9/1/2013	8/31/2014	Howard Hughes Medical Institute	\$300,000	\$103,980	\$403,980

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Microbiology & Physiological Systems	Sassetti, Christopher	NIH	5 R01 AI064282-07	5/10/2013	4/30/2018	5/1/2014	4/30/2015	Tuberculosis Pathogenesis and Drug Response	\$250,000	\$168,334	\$418,334
		TEXASAM	S110040	10/28/2010	10/31/2015	11/2/2013	10/31/2014	Target Identification for Tuberculosis Drug Discovery	\$65,000	\$6,500	\$71,500
		TEXASAM	/NIH	9/1/2012	8/31/2016	9/1/2013	8/31/2014	Structure-based Discovery of Critical Vulnerabilities of Mycobacteria	\$119,878	\$79,119	\$198,997
		WEILL	13121673-2	12/1/2010	10/31/2014	11/1/2013	10/31/2014	Conditional M. Tuberculosis Knockdown Mutants for TB Drug Development	\$357,934	\$35,793	\$393,727
	Stavnezer, Janet	NIH	5 R21 AI099988-02	8/21/2012	7/31/2014	8/1/2013	7/31/2014	Function of the AID C terminus in Ig class switching	\$141,000	\$94,001	\$235,001
		NIH	5 R01 AI023283-28	5/1/2010	4/30/2015	5/1/2013	4/30/2014	Molecular Basis of Immunoglobulin Heavy Chain Switch	\$259,588	\$167,434	\$427,022
	Szabady, Rose	NIH	5 F32 DK098973-02	6/19/2013	6/18/2016	6/19/2014	6/18/2015	Epithelial-derived mediators of neutrophil infiltration in the intestine	\$58,946	\$0	\$58,946
	Woodland, Robert	NIH	5 R01 AI084800-05	9/29/2009	8/31/2014	9/1/2013	8/31/2014	HIV vaccine development using humanized mice	\$245,025	\$158,041	\$403,066
	Zhuge, Ronghua	NIH	5 R01 HL117104-02	8/1/2013	4/30/2017	5/1/2014	4/30/2015	Cellular and Molecular Mechanisms of better tastant-induced bronchodilation	\$245,000	\$164,966	\$409,966
		NIH	1 R01 DK098586-01	8/15/2013	6/30/2015	8/15/2013	6/30/2014	Function and regulation of elemental Ca2+ signaling in urethral smooth muscle	\$100,000	\$66,500	\$166,500
Microbiology & Physiological Systems Total									\$6,695,301	\$3,303,969	\$9,999,270

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Molecular Medicine	Ambros, Victor	ELLISON	AG-SS-3036-12	1/1/2013	12/31/2016	1/1/2014	12/31/2014	MicroRNA Pathways and Stress Resistance in C. elegans	\$150,000	\$100,499	\$250,499
		NIH	1 R01 GM104904-01A1	6/1/2014	3/31/2018	6/1/2014	3/31/2015	microRNA gene networks regulating responses environment	\$283,536	\$191,151	\$474,687
	Ceol, Craig	NIH	5 R01 GM034028-28	4/1/2010	3/31/2014	4/1/2013	3/31/2014	Genetic Control of Animal Development	\$238,767	\$154,004	\$392,771
		ACS	RSG-12-150-01-DDC	7/1/2012	6/30/2016	7/1/2013	6/30/2014	Epigenetic Determinants of Melanoma Initiation and Maintenance	\$150,000	\$30,000	\$180,000
		DOD	W81XWH-13-1-0107	7/1/2013	6/30/2015	7/1/2013	6/30/2014	Uncovering the Role of BMP Signaling in Melanocyte Development and Melanoma Tumorigenesis	\$120,000	\$79,800	\$199,800
		KIMMEL		7/1/2013	6/30/2015	7/1/2013	6/30/2014	Genetic and cellular bases of melanoma initiation and maintenance	\$86,957	\$13,043	\$100,000
	Clapham, Paul	NIH	1 R01 AR063850-01A1	7/1/2013	6/30/2018	7/1/2013	6/30/2014	Use of comparative genomics to identify novel regulators of melanoma progression	\$212,500	\$141,313	\$353,813
		NIH	5 R01 AI089334-04	2/10/2011	1/31/2016	2/1/2014	1/31/2015	HIV-1 R5 envelope determinants and properties that affect transmission	\$253,195	\$157,757	\$410,952
		NIH	5 R01 NS084910-02	4/1/2013	3/31/2018	4/1/2014	3/31/2015	Neurotropic HIV-1 Reservoirs Inside and Outside the Brain	\$249,229	\$153,054	\$402,283
		NIH	5 P01 AI082274-05	8/7/2009	7/31/2015	8/1/2013	7/31/2014	Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env: Project 1	\$231,968	\$149,620	\$381,588
	Cohen, Jessica	NIH	5 F32 DK098879-02	2/12/2013	2/11/2016	2/12/2014	2/11/2015	Chemically-conjugated glucan particles for delivery of therapeutic siRNA	\$53,282	\$0	\$53,282
	Corvera, Silvia	NIH	5 R01 DK089101-03	8/1/2011	5/31/2016	6/1/2013	5/31/2014	Adipose Tissue Angiogenesis and Metabolic Disease	\$213,748	\$137,867	\$351,615
	Czech, Michael	ADA	7-12-MN-14	7/1/2012	6/30/2016	7/1/2013	6/30/2014	Role of the STE20 kinase Map4K4 in adipocyte function and whole body metabolism	\$45,000	\$0	\$45,000
		NIH	5 R01 DK085753-05	9/21/2009	8/31/2014	9/1/2013	8/31/2014	Oral Delivery Vehicles for RNAi Therapies	\$699,592	\$451,235	\$1,150,827
		NIH	5 R37 DK030898-30	7/1/2012	6/30/2017	7/1/2013	6/30/2014	Insulin Signaling and Metabolic Regulation in Adipocytes	\$299,150	\$198,935	\$498,085
		PFIZER	8500293889/1400	4/16/2013	4/15/2014	4/16/2013	4/15/2014	Map4k4 as a Therapeutic Target for Cardiovascular Disease	\$286,900	\$43,036	\$329,936
	Davis, Roger	UCOPENHAGEN		12/1/2011	11/30/2014	12/1/2013	11/30/2014	Gene and regulatory RNA expression in obese humans	\$320,833	\$0	\$320,833
		HUGHES		9/1/1997	8/31/2014	9/1/2013	8/31/2014	Howard Hughes Medical Institute	\$937,976	\$433,077	\$1,371,053
		NIH	5 P01 AI046629-14	6/1/2010	5/31/2015	6/1/2014	5/31/2015	Viral Infection Influence on Transplantation Tolerance: Project 3	\$186,660	\$120,395	\$307,055
								Breast Tumor Ablation by Selective Autophagic Degradation of Postmitotic Midbodies	\$187,500	\$120,938	\$308,438
	Doxsey, Stephen	ARMY	W81XWH-12-1-0070	5/1/2012	4/30/2014	5/1/2013	4/30/2014	Targeting Midbodies in Ovarian Cancer Stem Cells as a Therapeutic Strategy	\$100,000	\$64,500	\$164,500
		DOD	W81XWH-12-1-0291	9/30/2012	9/29/2014	9/30/2013	9/29/2014	Mitotic functions of cilia proteins	\$242,003	\$134,930	\$376,933
		NIH	5 R01 GM051994-18	4/15/2011	3/31/2015	4/1/2014	3/31/2015	Mechanistic target of rapamycin complex 2 pathways in brown fat growth and regulation	\$90,000	\$13,500	\$103,500
		ADA	1-13-BS-066	1/1/2013	12/31/2015	1/1/2014	12/31/2014	Mechanistic Target of Rapamycin Pathways in Metabolism and Energy Expenditure	\$245,000	\$162,925	\$407,925
	Guertin, David	NIH	1 R01 DK094004-01A1	7/5/2013	6/30/2018	7/5/2013	6/1/2014	Nutrient Sensing Pathways in Stem Cell Function and Tissue Regeneration	\$245,000	\$162,925	\$407,925
		PEW		7/1/2010	6/30/2014	7/1/2013	6/30/2014		\$55,200	\$4,800	\$60,000

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Molecular Medicine	Hehnly, Heidi	NIH	1 K99 GM107355-01	7/1/2013	8/31/2015	7/1/2013	6/30/2014	Mother Centriole Appendages Regulate the AMIS Compartment and Cilogenesis	\$79,343	\$6,347	\$85,690
	Ip, Y. Tony	NIH	5 R01 DK083450-05	5/17/2010	4/30/2015	5/1/2014	4/30/2015	Genetic Analysis of Damage-Induced Intestinal Stem Cell Division in Drosophila	\$184,883	\$119,250	\$304,133
	Kim, Jason	GEORGIA	U24 DK076169-08S2	10/1/2013	9/30/2014	10/1/2013	9/30/2014	Development of a Standardized Protocol to Evaluate Energy Expenditures in Mice	\$10,000	\$6,400	\$16,400
		NIH	5 U24 DK093000-04	9/16/2011	5/31/2016	6/1/2014	5/31/2015	UMass Mouse Metabolic Phenotyping Center: Metabolism Core	\$139,842	\$90,198	\$230,040
		NIH	5 U24 DK093000-04	9/16/2011	5/31/2016	6/1/2014	5/31/2015	UMass Mouse Metabolic Phenotyping Center: Administrative Core	\$56,088	\$36,177	\$92,265
		TULANE	TUL-HSC-531-13/14/NIH	4/1/2014	3/31/2019	4/1/2014	3/31/2015	TRPV1- Dependent Autonomic Control In Diabetes	\$11,721	\$7,883	\$19,604
	Lambright, David	NIH	5 R01 GM056324-17	5/1/2011	4/30/2015	5/1/2014	4/30/2015	Structural Basis for Rab GTPase Regulated Membrane Trafficking	\$218,000	\$140,610	\$358,610
	Luban, Jeremy	NIH	5 DP1 DA034990-02	8/1/2012	7/31/2017	8/1/2013	7/31/2014	Human Genes that influence HIV-1 Replication, Pathogenesis, and Immunity in IVDUs	\$480,000	\$319,600	\$799,600
		NIH	1 R01 AI111809-01	4/15/2014	3/31/2018	4/15/2014	3/31/2015	Boosting cell-intrinsic innate immune recognition of HIV-1 by dendritic cells	\$380,000	\$222,424	\$602,424
	Luzuriaga, Katherine	NIH	5 P01 AI049320-12	7/15/2012	6/30/2017	7/1/2013	6/30/2014	Evolution & Maintenance of Memory CD8 T Cells: Core A	\$267,028	\$113,290	\$380,318
		NIH	5 P01 AI049320-12	7/15/2012	6/30/2017	7/1/2013	6/30/2014	Evolution & Maintenance of Memory CD8 T Cells: Project 1	\$255,922	\$170,188	\$426,110
		NIH	5 R01 AI097265-03	2/9/2012	1/31/2017	2/1/2014	1/31/2015	HIV-1 Evolution and Functional Correlates of MTCT	\$626,613	\$163,677	\$790,290
	McJunkin, Katherine	NIH	5 F32 GM097895-03	4/12/2011	4/11/2014	4/12/2013	4/11/2014	Genetic Analysis of Post-Transcriptional Modulators of microRNAs in C. elegans	\$53,942	\$0	\$53,942
		NIH	1 F32 CA177216-01	3/15/2014	3/14/2017	3/15/2014	3/14/2015		\$49,214	\$0	\$49,214
	Ostroff, Gary	DSTL	DSTL/AGR/00232/01 - Am	2/19/2013	2/18/2015	2/19/2014	2/18/2015	Examining melanoma cell subpopulations in tumor maintenance and drug resistance	\$116,377	\$78,069	\$194,446
		EDEN		4/29/2013	4/28/2015	4/29/2014	4/28/2015	CBM-VAXB1 A subunit vaccine for tularemia: eliciting humoral and cellular response by beta-glucan particle delivery	\$105,739	\$70,228	\$175,967
		NIH	5 U19 AI082676-05	7/6/2009	6/30/2015	7/1/2013	6/30/2014	The Eden SRA	\$37,659	\$24,290	\$61,949
	Painter, Corrie	CRI		7/1/2012	6/30/2015	7/1/2013	6/30/2014	Optimization of HIV vaccines for the induction of cross-reactive antibodies: Project 3			
								Investigating the adaptive immune response to melanoma in the zebrafish Danio rerio	\$54,500		\$54,500
	Pazour, Gregory	NIH	5 R01 GM060992-13	12/15/2010	11/30/2014	12/1/2013	11/30/2014	Intraflagellar Transport Proteins in Mice	\$259,657	\$167,479	\$427,136
		UPITTSBURGH	0028067(123009-1)/NIH	4/1/2013	3/31/2018	4/1/2014	3/31/2015	Role of Fgt Receptors in the Metanephric Mesenchyme	\$14,211	\$9,592	\$23,803
		UPITTSBURGH	0013665(123449-3)/NIH	9/1/2010	7/31/2015	8/1/2013	7/31/2014	Modeling the Genetic Basis for Human Congenital Heart Disease in Mice	\$50,120	\$33,372	\$83,492
	Peterson, Craig	NIH	5 R37 GM049650-21	8/1/2011	7/31/2016	8/1/2013	7/31/2014	Analysis of the Yeast SWI1, SWI2, and SWI3 Proteins	\$319,356	\$205,985	\$525,341
		NIH	5 R01 GM054096-16	4/12/2010	9/30/2014	4/1/2013	3/31/2015	Yeast Chromatin Structure and Function	\$234,868	\$151,491	\$386,359
		NIH	3 R01 GM054096-16S1	4/12/2010	9/30/2014	4/1/2013	4/30/2015	Yeast Chromatin Structure and Function	\$78,289	\$52,845	\$131,134
	Richter, Joel	NIH	5 R01 GM046779-24	4/1/2012	3/31/2016	4/1/2014	3/31/2015		\$235,000	\$151,575	\$386,575
		NIH	5 R01 NS079415-02	4/1/2013	3/31/2018	2/1/2014	1/31/2015	Polyadenylation and Translational Control Mechanisms of Translation in the CNS	\$257,914	\$170,343	\$428,257

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Molecular Medicine	Sheehan, Keri	NIH	1 F31 AI108414-01	7/1/2013	6/10/2015	7/1/2013	6/30/2014	Molecular and functional correlates of HIV-1 transmission in MTCT	\$52,190	\$0	\$52,190
	Theurkauf, William	NIH	5 R01 HD049116-10	3/18/2010	1/31/2015	2/1/2014	1/31/2015	piRNA biogenesis and function in germline development [MPI]	\$325,795	\$210,138	\$535,933
	Van, Christopher	ACS	PF-13-393-01-DMC	1/1/2014	12/31/2016	1/1/2014	12/31/2014	Defining how Ito80 stabilizes stalled-replication forks	\$61,500	\$0	\$61,500
	Walker, Amy	NIH	5 R01 DK084352-05	7/15/2011	4/30/2016	5/1/2014	4/30/2015	Mechanisms of Metabolic Control in C. elegans	\$221,500	\$142,868	\$364,368
	Yawe, Joseph	NIH	5 F31 DK096948-03	6/1/2012	5/31/2015	6/1/2014	5/31/2015	Targeting osteopontin as a regulator of macrophage infiltration and inflammation	\$29,190	\$0	\$29,190
Molecular Medicine Total									\$11,205,457	\$5,920,698	\$17,126,155

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Neurobiology	Alkema, Mark	NIH	2 R01 GM084491-06A1	6/1/2014	4/30/2018	6/1/2014	4/30/2015	Molecular and neuronal mechanisms of complex behaviors	\$209,349	\$141,120	\$350,469
	Barbagallo, Belinda	NIH	5 F31 NS076326-03	7/1/2011	6/30/2014	7/1/2013	6/30/2014	Identifying excitotoxic mechanisms in a C. elegans model of axon destabilization	\$28,746	\$0	\$28,746
	Benard, Claire	ELLISON	AG-NS-0840-11	7/20/2011	7/19/2015	7/20/2013	7/19/2014	Protecting the Nervous System from Aging and Neurodegeneration	\$92,593	\$7,407	\$100,000
		NIH	5 R01 AG041870-03	9/30/2012	5/31/2017	6/1/2014	5/31/2015	Molecular mechanisms of nervous system protection	\$205,000	\$138,375	\$343,375
	Budnik, Vivian	CHDI	A-7950	6/1/2014	5/31/2015	6/1/2014	5/31/2015	Molecular Mechanisms of Exosome Transfer Across Cells	\$86,944	\$12,292	\$99,236
		NIH	2 R56 NS063228-04	5/1/2013	4/30/2014	5/1/2013	4/30/2014	The Frizzled Nuclear Import Pathway in Synapse Development	\$250,000	\$165,938	\$415,938
		NIH	1 R01 NS085993-01	9/30/2013	6/30/2017	9/30/2013	6/30/2014	Nuclear export of RNAs by nuclear envelope budding	\$200,000	\$133,334	\$333,334
		NIH	2 R37 MH070000-11	1/1/2014	12/31/2018	1/1/2014	12/31/2014	The Wingless Transduction Pathway in Synapse Development	\$250,000	\$167,500	\$417,500
	Emery, Patrick	ALSTA	2013-F-022	5/1/2014	4/30/2016	5/1/2014	4/30/2015	The molecular function of Ataxin-2 and Poly-glutamine domain I Drosophila and Mammals	\$100,000	\$0	\$100,000
		NIH	5 R01 GM100091-02	8/6/2012	6/30/2016	7/1/2013	6/30/2014	The role of RNA binding proteins in the control of Drosophila circadian rhythms	\$183,350	\$121,928	\$305,278
		NIH	2 R01 GM066777-10A1	5/1/2014	2/28/2018	5/1/2014	2/28/2015	Circadian photoreception in Drosophila melanogaster	\$208,761	\$138,414	\$347,175
	Francis, Michael	NIH	5 R01 NS064263-05	9/15/2009	3/31/2015	4/1/2013	3/31/2014	Analysis of Nicotinic Acetylcholine Receptor Function in C. elegans	\$206,872	\$133,432	\$340,304
	Freeman, Marc	ALSTA	2013-S-001	5/10/2013	5/10/2015	5/10/2013	5/9/2014	The role of SARM in axon degeneration and ALS	\$125,000	\$0	\$125,000
		HUGHES MFOX		11/1/2009	10/31/2015	9/1/2013	8/31/2014	Howard Hughes Medical Institute	\$400,000	\$216,625	\$616,625
				11/1/2013	10/31/2015	11/1/2013	10/31/2014	Inhibiting axon degeneration in rodent models of Parkinson's disease through deletion of Sarm1	\$103,805	\$25,951	\$129,756
		NIH	2 R01 NS059991-06A1	9/1/2013	6/30/2018	9/1/2013	6/30/2014	Molecular Mechanisms of Axon Degeneration	\$218,750	\$145,833	\$364,583
		NIH	5 R01 NS053538-09	2/1/2011	12/31/2015	1/1/2014	12/31/2014	Molecular genetic analysis of astrocyte development and function	\$216,563	\$139,683	\$356,246
	Kushkuley, Jacob	HUGHES	57008063	6/1/2014	6/1/2015	6/1/2014	6/1/2015	Role of Sarm1 in functional loss and recovery after nervous system injury	\$40,000	\$0	\$40,000
	Li, Hong-Sheng	NIH	5 R01 AG022508-10	9/15/2009	8/31/2014	9/1/2013	8/31/2014	Functional analysis of the CAMTA Transcription Factors	\$184,347	\$118,904	\$303,251
		NIH	5 R01 EY021796-03	4/1/2012	2/28/2015	3/1/2014	2/28/2015	Neuron-glia interactions in Drosophila visual neuropiles	\$245,000	\$158,025	\$403,025
	Lois, Carlos	NIH	5 R24 GM089700-03	5/1/2011	4/30/2015	5/1/2013	4/30/2014	Transgenesis in songbirds for the genetic manipulation of neuronal circuits	\$229,091	\$72,910	\$302,001
		NIH	5 R21 HD074536-02	8/13/2012	7/31/2014	8/1/2013	7/31/2014	Investigating the role of CNTNAP2 gene in vocal learning in mutant songbirds	\$118,625	\$78,984	\$197,609
		NIH	1 R21 NS084851-01	7/1/2013	6/30/2015	7/1/2013	6/30/2014	A genetic strategy to record cell-cell interactions	\$150,000	\$99,750	\$249,750
	Maloney, Rachel	NIH	1 F32 NS082202-01A1	7/1/2013	6/30/2016	7/1/2013	6/30/2014	Mechanisms of Dfrizzled-RNP Nuclear Egress	\$52,190	\$0	\$52,190
	Neukomm, Lukas	CAKF		7/1/2012	6/30/2014	7/1/2013	6/30/2014	Genetic Pathways Mediating Axon Death	\$51,000	\$0	\$51,000
	Reppert, Steven	DOD	FA9550-10-1-0480	9/1/2010	8/31/2014	6/1/2014	8/31/2014	Navigational Strategies of Migrating Monarch Butterflies	\$41,667	\$14,583	\$56,250

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Neurobiology	Weaver, David	NIH	5 R01 NS056125-07	4/1/2013	3/31/2018	4/1/2014	3/31/2015	Mechanisms of Circadian rhythmicity in CLOCK-Deficient Mice	\$216,563	\$145,639	\$362,202
	Xiang, Yang	HFSP	RGY0090/2014	1/1/2014	12/31/2016	5/1/2014	4/30/2015	Wireless optogenetic interrogation on non-image forming photoreceptor function by Nano-antennae	\$121,212	\$12,121	\$133,333
	Zhang, Yong	ATAXIA		1/1/2014	12/31/2014	1/1/2014	12/31/2014	The role of Ataxin-2 in the regulation of circadian behavior and sleep in mice	\$50,000	\$0	\$50,000
Neurobiology Total									\$4,585,428	\$2,388,748	\$6,974,176

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Pathology	Berg, Leslie	NIH	5 R01 AI084987-04	9/30/2010	8/31/2015	9/1/2013	8/31/2014	Regulation of conventional versus innate CD8+ T cell development	\$232,650	\$150,059	\$382,709
		NIH	5 R01 AI083505-04	12/1/2010	11/30/2015	12/1/2013	11/30/2014	ITK: an emerging target for treatment of T cell-mediated autoimmune disease [MPI]	\$172,431	\$111,218	\$283,649
		NIH	5 R01 AI101048-02	5/25/2013	4/30/2017	5/1/2014	4/30/2015	Plasticity of T helper cell differentiation	\$250,000	\$168,333	\$418,333
		NIH	1 R01 AI106833-01A1	4/15/2014	3/31/2018	4/15/2014	3/31/2015	Regulation of anti-viral T cell responses by IRF4	\$250,000	\$168,126	\$418,126
	Calvo-Calle, Jaime	NIH	5 U19 AI057319-10	4/1/2009	3/31/2014	4/1/2013	3/31/2014	Cellular Immunity to Category A-C Viruses in Humans: Project 4	\$176,619	\$113,919	\$290,538
	Chan, Francis	NIH	5 R01 AI083497-04	4/1/2010	12/31/2014	4/1/2013	3/31/2014	Programmed Necrosis in Immune Responses	\$232,650	\$150,059	\$382,709
	Dutton, Richard	NIH	5 P01 AI046530-14	9/1/2010	8/31/2014	9/1/2013	8/31/2014	T Cell Memory to Pathogens: Generation and Function: Core B	\$62,225	\$40,135	\$102,360
		NIH	5 P01 AI046530-14	9/1/2010	8/31/2014	9/1/2013	8/31/2014	T Cell Memory to Pathogens: Generation and Function: Project 2	\$223,072	\$143,882	\$366,954
	Huseby, Eric	NIH	1 U19 AI109858-01	3/1/2014	2/28/2019	3/1/2014	2/28/2015	CD4 T Cells in anti-viral immunity and immune pathology [Core C]	\$137,498	\$92,354	\$229,852
	Kang, Joonsoo	NIH	5 R01 DK095077-03	4/15/2012	3/31/2017	4/1/2014	3/31/2015	Origin and control of self-reactive TCRs	\$217,500	\$140,288	\$357,788
		NIH	5 R01 AI101301-02	1/1/2013	12/31/2017	1/1/2014	12/31/2014	Gene circuits programming IL-17 production in innate lymphocytes	\$250,000	\$167,500	\$417,500
		NIH	5 R01 AI083505-04	12/1/2010	11/30/2015	12/1/2013	11/30/2014	ITK: an emerging target for treatment of T cell-mediated autoimmune disease [MPI]	\$172,431	\$111,218	\$283,649
	McKinstry, Karl	AHA	14SDG18600020	1/1/2014	12/31/2017	1/1/2014	12/31/2014	Requirements for influenza vaccine induction of unique lung-resistant memory CD4 T cells with novel function	\$70,000	\$7,000	\$77,000
	Rock, Kenneth	NIH	1 R56 AI110374-01	5/1/2014	4/30/2015	5/1/2014	4/30/2015	Mechanisms of positive and negative thymic selection of CD8 T cells	\$166,750	\$112,279	\$279,029
		NIH	5 R01 AI043543-15	7/17/2009	6/30/2015	7/1/2013	6/30/2014	Immunobiology of CTL Responses to Exogenous Antigen	\$230,324	\$148,559	\$378,883
		NIH	5 R01 AI078287-05	6/15/2009	5/31/2015	6/1/2013	5/31/2014	How Cell Death and Sterile Particulates Stimulate Inflammation and Disease	\$230,324	\$148,559	\$378,883
	Selin, Liisa	NIH	1 U19 AI109858-01	3/1/2014	2/28/2019	3/1/2014	2/28/2015	CD4 T cells in anti-viral immunity and immune pathology [Project 3]	\$285,284	\$191,616	\$476,900
		NIH	5 P01 AI046629-14	6/1/2010	5/31/2015	6/1/2014	5/31/2015	Viral Infection Influence on Transplantation Tolerance: Project 4	\$361,707	\$121,317	\$483,024
		NIH	5 P01 AI049320-12	7/15/2012	6/30/2017	7/1/2013	6/30/2014	Evolution & Maintenance of Memory CD8 T Cells: Project 2	\$225,161	\$149,732	\$374,893
	Stern, Lawrence	BAYLORRI	41000411338/NIH	5/1/2013	4/30/2014	5/1/2013	4/30/2014	T Cells raised to influenza H1 that cross-react with hepcocretin	\$79,954	\$53,102	\$133,056
		NIH	5 U19 AI057319-10	4/1/2009	3/31/2014	4/1/2013	3/31/2014	Cellular Immunity to Category A-C Viruses in Humans: Project 5 (Tech Dev)	\$445,899	\$233,720	\$679,619
		NIH	5 R37 AI038996-17	4/1/2013	3/31/2018	4/1/2014	3/31/2015	Structure and Function of MHC Proteins	\$250,000	\$168,126	\$418,126
		NIH	5 R01 MH097543-02	3/20/2012	2/28/2014	3/1/2013	2/28/2014	Small molecule probes of ERAP-1	\$25,000	\$16,125	\$41,125
		NIH	1 U19 AI109858-01	3/1/2014	2/28/2019	3/1/2014	2/28/2015	CD4 T cells in anti-viral immunity and immune pathology [Project 4]	\$281,260	\$188,913	\$470,173
		NIH	5 U19 AI057319-10	4/1/2009	3/31/2014	4/1/2013	3/31/2014	Cellular Immunity to Category A-C Viruses in Humans: Core E2	\$63,843	\$41,179	\$105,022
		NIH	1 U19 AI109858-01	3/1/2014	2/28/2019	3/1/2014	2/28/2015	CD4 T cells in anti-viral immunity and immune pathology [Core B]	\$95,095	\$63,872	\$158,967
	Swain, Susan	NIH	5 R37 AG025805-10	9/15/2010	5/31/2015	9/1/2013	5/31/2014	Impact of aging on naïve CD4 T cell function	\$259,462	\$167,353	\$426,815

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs		
Pathology	Swain, Susan	NIH	5 P01 AI046530-14	9/1/2010	8/31/2014	9/1/2013	8/31/2014	T Cell Memory to Pathogens: Generation and Function: Project 4	\$339,545	\$0	\$339,545		
		NIH	5 P01 AI046530-14	9/1/2010	8/31/2014	9/1/2013	8/31/2014	T Cell Memory to Pathogens: Generation and Function: Project 3	\$422,786	\$0	\$422,786		
		NIH	5 R37 AG025805-11	9/15/2010	5/31/2015	6/1/2014	5/31/2015	Impact of aging on naïve CD4 T cell function	\$274,564	\$177,094	\$451,658		
		NIH	5 P01 AI046530-14	9/22/2009	8/31/2014	9/1/2013	8/31/2014	T Cell Memory to Pathogens: Generation and Function: Project 1	\$305,738	\$197,201	\$502,939		
		NIH	1 U19 AI109858-01	3/1/2014	2/28/2019	3/1/2014	2/28/2015	CD4 T cells in anti-viral immunity and immune pathology [Project 2]	\$285,286	\$191,616	\$476,902		
		NIH	5 P01 AI046530-14	9/1/2010	8/31/2014	9/1/2013	8/31/2014	T Cell Memory to Pathogens: Generation and Function: Core A	\$48,259	\$31,127	\$79,386		
	Welsh, Raymond	UCONN	/NIH	6/1/2013	5/31/2017	6/1/2013	5/31/2014	Impact of Aging on CD4 Immunity to Flu	\$255,889	\$170,166	\$426,055		
		NIH	1 U19 AI109858-01	3/1/2014	2/28/2019	3/1/2014	2/28/2015	CD4 T cells in anti-viral immunity and immune pathology [Core A]	\$47,129	\$31,655	\$78,784		
		NIH	5 R01 AI081675-27	7/17/2009	6/30/2014	7/1/2013	6/30/2014	Virus Induced Immunopathology	\$230,324	\$148,559	\$378,883		
		NIH	1 U19 AI109858-01	3/1/2014	2/28/2019	3/1/2014	2/28/2015	CD4 T cells in anti-viral immunity and immune pathology [Project 1]	\$285,284	\$191,616	\$476,900		
		NIH	5 R37 AI017672-34	4/1/2009	3/31/2014	4/1/2013	3/31/2014	Immunity and Virus Disease	\$230,324	\$148,559	\$378,883		
		NIH	5 P01 AI046629-14	6/1/2010	5/31/2015	6/1/2014	5/31/2015	Viral Infection Influence on Transplantation Tolerance: Project 2	\$187,160	\$120,718	\$307,878		
Pathology Total									\$8,359,427	\$4,776,854	\$13,136,281		

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Quantitative Health Sciences	Allison, Jeroan	NIH	5 P60 MD006912-03	6/14/2012	1/31/2017	2/1/2014	1/31/2015	UMass Center for Health Equity Intervention Research: Administrative Core	\$136,536	\$68,971	\$205,507
		NIH	5 P60 MD006912-03	6/14/2012	1/31/2017	2/1/2014	1/31/2015	UMass Center for Health Equity Intervention Research: Research Core	\$418,985	\$99,796	\$518,781
		UAB	000413884-008/NIH	9/30/2011	8/31/2016	9/1/2013	8/31/2014	UAB Deep South Arthritis and Musculoskeletal CERTs	\$19,929	\$12,854	\$32,783
	Anatchkova, Milena	LHRMA FDN		7/1/2013	6/30/2014	7/1/2013	6/30/2014	Estimating Patient Reported Labor Market Outcomes from Health Variables	\$60,000	\$0	\$60,000
	Fang, Julia Hua	NIH	5 R01 DA033323-02	7/15/2013	5/31/2016	6/1/2014	5/31/2015	DISC: Describe Smoking Cessation in RCT Multi-Component Behavioral Intervention	\$142,500	\$90,945	\$233,445
	Frendl, Daniel	NIH	1 F30 AG047772-01A1	6/15/2014	6/14/2017	6/15/2014	6/14/2015	Functional Health Predictors of Other Cause Mortality Risk in Prostate Cancer	\$27,291	\$0	\$27,291
	Goldberg, Robert	NIH	5 R01 HL035434-29	8/25/2010	6/30/2015	7/1/2013	6/30/2014	Worcester Heart Attack Study	\$344,306	\$222,077	\$566,383
		NIH	5 R01 HL035434-29S	8/25/2010	6/30/2015	7/1/2013	6/30/2014	Worcester Heart Attack Study	\$61,642	\$40,992	\$102,634
	Houston, Thomas	NIH	1 R25 CA172009-01A1	6/1/2014	5/31/2019	6/1/2014	5/31/2015	Worcester Heart Attack Study Implementation Research Training Program in Cancer Prevention and Control [MPI]	\$54,845	\$4,388	\$59,233
		PCORI	1IP2PI000582-01	10/31/2012	12/31/2014	10/31/2013	12/31/2014	Patient Experience Recommender System for Persuasive Communication Tailoring	\$262,411	\$47,531	\$309,942
	Kiefe, Catarina	NIH	5 U01 HL105268-04/NIH	9/30/2010	7/31/2015	8/1/2013	7/31/2014	TRACE-CORE	\$919,326	\$435,722	\$1,355,048
		UAB	000501394-002/NIH	7/1/2013	6/30/2018	7/1/2013	6/30/2014	Coronary Artery Risk Development in Young Adults (CARDIA) Study - CC (Coordinating Center)	\$37,041	\$24,632	\$61,673
	Lapane, Kate	MEMRI	HHSN26820100020C	7/1/2012	6/14/2014	6/15/2013	6/14/2014	Efficacy of CAM on Patient Centered Outcomes	\$51,168	\$34,016	\$85,184
		NIH	1 R21 AG046839-01	1/15/2014	12/31/2015	1/15/2014	12/31/2014	In-hospital Antipsychotic Use among Elderly Patients Discharged to Nursing Homes	\$150,000	\$100,500	\$250,500
	Lines, Lisa	AHRQ	1 R36 HS022194-01	5/1/2013	4/30/2014	5/1/2013	4/30/2014	Outpatient Emergency Department Utilization: Prevalence and Predictive Models	\$38,466	\$2,751	\$41,217
	Person, Sharina	UAB	000421737-001	8/1/2013	7/31/2018	8/1/2013	7/31/2014	Network for Tobacco Control Among Women in Parana, Brazil	\$7,631	\$4,922	\$12,553
		UMISSMED	66102700414-04UMASS/NIH	6/1/2013	5/31/2018	5/1/2014	4/30/2015	Coordinating Center, Jackson Heart Study Renewal	\$19,837	\$13,390	\$33,227
	Rao, Sowmya	MGH	220601/NIH	4/19/2012	3/31/2015	10/1/2013	3/31/2014	Examining Disparities in Cancer Screening for Persons with Disabilities	\$36,517	\$23,553	\$60,070
		MGH	219625/NIH	9/30/2011	9/29/2016	9/30/2013	9/29/2014	Global TravEpiNet: Global Traveler's Health Surveillance, Application Consortium	\$31,108	\$20,064	\$51,172
	Sadasivam, Rajani	NIH	1 K01 CA172677-01A1	8/8/2013	7/31/2018	8/8/2013	7/31/2014	Developing Smokers for Smoker (S4S): A Collective Intelligence tailoring system	\$130,364	\$10,429	\$140,793
	Volkman, Julie	SFVAFRE		1/1/2014	7/18/2014	1/1/2014	12/31/2014	Technology and collaborative care improve the use of hormone therapy (HT) in postmenopausal women Veterans	\$10,625	\$2,975	\$13,600
	Ware, Jr., John	AHRQ	1 R21 HS023117-01	5/1/2014	4/30/2015	5/1/2014	4/30/2015	Measuring Multimorbidity with Individualized Disease-specific QOL Impact Scales	\$111,899	\$68,091	\$179,990

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Quantitative Health Sciences	Yu, Hong	NIH	5 R01 GM095476-05	3/14/2013	4/30/2016	5/1/2014	4/30/2015	Exploring Natural Language Processing, Image Processing, Machine Learning, and Us	\$409,120	\$220,317	\$629,437
Quantitative Health Sciences Total									\$3,481,547	\$1,548,916	\$5,030,463

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Anesthesiology	Heard, Stephen	BANYANBIO		1/10/2013	6/30/2049			A Prospective Clinical Evaluation of Biomarkers of Traumatic Brain Injury (ALERT-TBI)	\$4,500	\$1,350	\$5,850
		BIDMC	01026696/NIH	9/1/2012	6/30/2015	7/1/2013	6/30/2014	EPVent 2 - a Phase II Trial of Esophageal Pressure Guided Ventilation	\$70,842	\$18,419	\$89,261
		DRREEDYS		8/20/2013	8/19/2018			A Randomized, Double-Blind, Placebo Controlled Efficacy, Safety and Tolerability Study of up to 20ml of DFA-02 in Patients Undergoing Abdominal Surgery	\$38,610	\$11,583	\$50,193
		MHMH		6/19/2013	6/18/2018			Reduction in 30-Day Postoperative Healthcare-Associated Infections Through Use of a Novel Hand Hygiene System	\$44,396	\$4,440	\$48,836
		T2BIOSYS		5/10/2013	6/1/2014			Detecting Infections Rapidly and Easily for Candidemai Trial (DIRECT Study)-Part 2- Prospective Collection of Fresh Whole Blood for the Creation of Contrived Candida Positive Specimens	\$1,923	\$577	\$2,500
Anesthesiology Total									\$160,271	\$36,369	\$196,640

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Emergency Medicine	Bird, Steven	NIH	1 U01 NS083452-01	9/1/2013	8/31/2017	9/1/2013	8/31/2014	Pharmacotherapy to counterACT parathion-induced NMJ dysfunction	\$552,803	\$223,268	\$776,071
		NIH	3 U01 NS083452-01S1	9/1/2013	8/31/2017	9/1/2013	8/31/2014	Pharmacotherapy to counterACT parathion-induced NMJ dysfunction	\$49,900	\$33,184	\$83,084
	Boudreaux, Edwin	MIRIAM	R01CA156699/NIH	8/19/2011	6/30/2016	7/1/2013	6/30/2014	System-based Tracking and Treatment for Emergency Patients Who Smoke: STTEPS	\$77,802	\$51,350	\$129,152
		NIH	5 U01 MH088278-05	9/30/2009	5/31/2015	6/1/2013	5/31/2014	Emergency Department Safety Assessment and Follow-Up Evaluation (EDSAFE)	\$1,379,705	\$215,264	\$1,594,969
		NIH	3 U01 MH088278-05S1	9/30/2009	5/31/2015	6/13/2013	5/31/2014	Emergency Department Safety Assessment and Follow-Up Evaluation (EDSAFE)	\$100,908	\$61,967	\$162,875
	Boyer, Edward	POLARIS	R41AA022305/NIH	9/25/2012	8/31/2014	3/1/2014	8/31/2014	Remote Brief Intervention and Referral to Treatment for Alcohol Misuse (R-BIRT)	\$37,317	\$24,815	\$62,132
		NIH	5 R01 DA031081-03	9/15/2011	7/31/2015	8/1/2013	7/31/2014	A Mobile, Personalized Intervention with Real-Time Adaptation to HAART Adherence	\$304,899	\$126,345	\$431,244
		NIH	5 R01 DA033769-02	5/1/2012	8/31/2015	9/1/2013	8/31/2014	iMStrong, an Innovative Remote Monitoring System for Detecting Cocaine Use	\$247,413	\$164,323	\$411,736
		NIH	5 K23 HL101991-05	8/15/2010	5/31/2015	6/1/2014	5/31/2015	Acute Decompensated Heart Failure: Treatment Timing and Effects on Outcomes	\$123,750	\$9,900	\$133,650
		WPI	14-215700-00	9/25/2013	9/24/2015	9/25/2013	9/24/2014	Wearable Wireless Sensor for Multi-Scale Physiological Monitoring	\$156,222	\$103,888	\$260,110
	Volturo, Gregory	ACCUVEIN		12/11/2013	6/30/2049			A Prospective, Randomized, Controlled Comparison of First Attempt Success between AccuVein Vein Illumination Device (AV-400) and Conventional Techniques for IV Placement in Multiple Patient Populations	\$15,080	\$4,524	\$19,604
		PFIZER		11/22/2013	11/21/2018			Streptococcus Pneumoniae Serotypes in Adults 18 Years and Older with Radiographically-Confirmed Community-Acquired Pneumonia (CAP)	\$41,848	\$12,554	\$54,402
	Ward, Jeanine	MCNEIL		9/13/2012	4/30/2015			MicroRNA Profiles in Acetaminophen Toxicity	\$87,650	\$0	\$87,650
Emergency Medicine Total									\$3,175,297	\$1,031,382	\$4,206,679

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Family Medicine & Community Health	Baldor, Robert	HRSA	5 D56 HP20784-04-00	9/1/2010	6/30/2015	7/1/2013	6/30/2014	Pre-Doctoral Training in Primary Care	\$232,462	\$19,348	\$251,810
		HRSA	1 T89 HP20748-01-00	9/30/2010	9/29/2015	9/30/2010	9/29/2015	Affordable Care Act: Primary Care Residency Expansion	\$960,000	\$0	\$960,000
	DiFranza, Joseph	FIU	800001069-02/NIH	11/27/2013	6/30/2014	11/27/2013	6/30/2014	Development of Dependence in Young Waterpipe Smokers	\$26,702	\$17,756	\$44,458
	Ferguson, Warren	SLOAN	BD516343/NIH	9/15/2012	8/31/2014	9/1/2013	8/31/2014	The impact of Physician non-English Language Proficiency Level on Cancer Screening	\$11,521	\$7,604	\$19,125
	Hargraves, Lee	NIH	5 P60 MD006912-03	6/14/2012	1/31/2017	2/1/2014	1/31/2015	UMass Center for Health Equity Intervention Research: Project 3	\$125,475	\$84,173	\$209,648
	Ledwith, James	HRSA	5 D58 HP20799-04-00	9/1/2010	6/30/2015	7/1/2013	6/30/2014	Residency Training in Primary Care	\$139,633	\$11,171	\$150,804
	Luckmann, Roger	PCORI		10/31/2012	12/31/2014	10/31/2013	12/31/2014	Direct Engagement of Stakeholders in Translating CER into Clinical Guidelines	\$290,791	\$55,413	\$346,204
	Potts, Stacy	HRSA	5 D58 HP20798-04-00	9/1/2010	6/30/2015	7/1/2013	6/30/2014	Residency Training in Primary Care	\$203,563	\$16,285	\$219,848
	Saver, Barry	AHRQ	5 R18 HS018461-04	9/30/2010	7/31/2014	8/1/2013	7/31/2014	CONTrolling Disease Using Inexpensive IT	\$362,401	\$123,087	\$485,488
		PCORI		10/31/2012	12/31/2014	10/31/2013	12/31/2014	Hypertension in Diabetes: CONDUIT-HID Influence and Evidence: Understanding Consumer Choices in Preventive Care	\$257,598	\$86,600	\$344,198
	Upshur, Carol	USDE	R305A130336	7/1/2013	6/30/2017	7/1/2013	6/30/2014	Kidsteps II: Promoting school readiness through social-emotional skill building in preschool	\$654,673	\$170,215	\$824,888
		NIH	5 P60 MD006912-03	6/14/2012	1/31/2017	2/1/2014	1/31/2015	UMass Center for Health Equity Intervention Research: Education & Training Core	\$81,719	\$54,822	\$136,541
	Weinreb, Linda	HRSA	R40 MC23633-03	2/1/2012	1/31/2015	2/1/2014	1/31/2015	Meeting the Needs of Pregnant Women with PTSD in Healthy Start	\$241,534	\$58,446	\$299,980
Family Medicine & Community Health Total									\$3,588,072	\$704,920	\$4,292,992

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Medicine	Finberg, Robert	DARPA	HR0011-11-C-0095	9/16/2011	4/15/2015	4/15/2014	4/15/2015	Algorithms to Limit Viral Epidemics (ALiVE)-Team 1	\$636,360	\$363,640	\$1,000,000
		MEDIVECTOR	/NIH	12/10/2012	6/30/2049			A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Pharmacokinetics of Different dosing Regimens of Favipiravir in Healthy Adult Subjects and Adult Subjects with Uncomplicated Influenza	\$516	\$134	\$650
		MEDIVECTOR	/NIH	10/23/2013	10/22/2018			A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects with Uncomplicated Influenza	\$3,500	\$2,380	\$5,880
		MEDIVECTOR		11/1/2013	10/31/2015	11/1/2013	10/31/2014	Definition of the mechanisms of resistance to T-705 in influenza	\$232,766	\$155,564	\$388,330
		NIH	1 R13 AI112239-01	3/1/2014	2/28/2015	3/1/2014	2/28/2015	18th International Symposium on Infections in the Immunocompromised Host	\$8,000	\$0	\$8,000
		S&SS	/NIH	10/1/2013	6/30/2014			A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational anti-Influenza Immune Plasma for the Treatment of Influenza	\$8,877	\$5,904	\$14,781
		S&SS	/NIH	10/1/2013	3/31/2014			A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amanadine, Ribavirin, Oseltamivir) VS Oseltamivir for the Treatment of Influenza	\$11,613	\$7,723	\$19,336
	Konz, Richard	NIH	5 P01 AI049320-12	7/15/2012	6/30/2017	7/1/2013	6/30/2014	Evolution & Maintenance of Memory CD8 T Cells: Core C	\$95,422	\$63,456	\$158,878
	Kurt-Jones, Evelyn	NIH	5 U19 AI084048-05	9/25/2009	8/31/2015	9/1/2013	8/31/2014	Innate and Adaptive Immunity in Experimental and Human Gonococcal Infection: Core C	\$151,926	\$97,992	\$249,918
Medicine Total									\$1,148,980	\$696,793	\$1,845,773

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Cardiovascular Medicine	Aurigemma, Gerard	UAB	/NIH	4/1/2013	11/30/2013			Systolic Blood Pressure Intervention Trial (SPRINT)	\$43,470	\$28,039	\$71,509
	Barringhaus, Kurt	BWH		3/26/2010	6/30/2049			Stabilization of Plaques using Darapladib- A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events	\$27,651	\$6,913	\$34,564
	Browning, Clifford	BIOTRONIK		7/12/2013	7/11/2020			SIELLO: Safety and Performance Study of the Siello S Pacing Lead	\$14,875	\$4,463	\$19,338
	Cooper, Marcus	NIH	5 R01 DK089185-04	8/1/2010	7/31/2015	8/1/2013	7/31/2014	Mechanisms and metabolic implications of LRP130 in NAFLD	\$207,789	\$134,024	\$341,813
	Donahue, J. Kevin	NIH	7 R01 HL093486-06	3/7/2014	12/31/2014	3/7/2014	12/31/2014	Gene Transfer Approaches to Atrial Fibrillation	\$76,900	\$51,138	\$128,038
	Ennis, Cynthia	BIOTRONIK		5/20/2010	5/19/2016			Echocardiography Guided Cardiac Resynchronization Therapy Clinical Investigation	\$1,444	\$375	\$1,819
	Fisher, Daniel	MEDTRONICS		8/31/2012	6/30/2049			Product Surveillance Registry	\$8,080	\$2,424	\$10,504
		MEDTRONICS		6/29/2011	6/30/2049			Product Performance Platform Study	\$2,512	\$653	\$3,165
		ABBOTT/CV		8/29/2008	8/28/2033			XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study	\$13,760	\$3,578	\$17,338
		ABIOMED		12/17/2010	12/31/2014			USPELLA Retrospective Data Registry Study Agreement	\$14,603	\$3,797	\$18,400
		CORDIS		9/30/2009	12/31/2015			CYPRESS: A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the Cypher Stent	\$794	\$206	\$1,000
		HCRI		11/13/2009	6/30/2049			A prospective, multi-center, randomized, double-blind, trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI)	\$6,369	\$1,656	\$8,025
		LILLY		4/26/2010	6/30/2049			The TRANSLATE-ACS Study: Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome	\$1,687	\$438	\$2,125
		MEDTRONICS		1/24/2012	6/30/2049			Symplcity_HTN-3: Renal Denervation in Patients with Uncontrolled Hypertension (HTN-3)	\$15,658	\$4,697	\$20,355
		MEDTRONICS		3/29/2010	6/30/2049			Endeavor Drug Eluting Stenting: Understanding, Care, Antiplatelet Agents and Thrombotic Events	\$15,797	\$4,107	\$19,904
		MEDTRONICS		9/18/2008	9/17/2033			Patient Related Outcome with Endeavor versus Cypher Stenting Trial (PROTECT Trial)	\$11,742	\$3,053	\$14,795

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Cardiovascular Medicine	Fisher, Daniel	MEDTRONICS		4/6/2009	6/30/2049			RESOLUTE US Clinical Trial: A Clinical Evaluation of the Medtronic Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25mm to 4.2mm	\$524	\$136	\$660
	Fitzgibbons, Timothy	AHA	12FTF11260010	7/1/2012	6/30/2017	7/1/2013	6/30/2014	Developmental Gene Expression in Perivascular Fat as a Determinant of Obesity Associated Vascular Disease	\$65,000	\$0	\$65,000
	Floyd, Kevin	BIOTRONIK		6/27/2011	6/30/2049			CELESTIAL Post Approval Registry (Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar Post Approval Registry)	\$20,720	\$5,387	\$26,107
		BSC		3/6/2014	3/5/2019			Longitudinal Surveillance Study of the 4-SITE Lead/Header System	\$815	\$245	\$1,060
		STJUDE		9/1/2012	6/30/2049			ST Monitoring to Detect ACS Events in ICD Patients Study (Analyze ST) IDE Study	\$28,627	\$8,589	\$37,216
	Freedman, Jane	BU	4500001368/NIH	8/1/2011	7/31/2014	8/1/2013	7/31/2014	Role of the Innate System in Pathogen-Induced Chronic Inflammation	\$124,474	\$80,285	\$204,759
		NIH	1 UH2 TR000921-01	8/1/2013	7/31/2015	8/1/2013	7/31/2014	Extracellular RNAs: Biomarkers for Cardiovascular Risk and Disease	\$300,300	\$199,700	\$500,000
	Gore, Joel	DUKE	/NIH	6/17/2009	6/16/2034			Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE) Trial	\$17,183	\$4,467	\$21,650
	Keaney, John	NIH	5 R01 HL092122-06	7/15/2013	5/31/2017	6/1/2014	5/31/2015	Mitochondrial Modulation of Endothelial Function	\$249,827	\$168,633	\$418,460
	McManus, David	NIH	5 R01 HL098407-04	7/15/2010	6/30/2015	7/1/2013	6/30/2014	Nox4 and Vascular Homeostasis	\$282,853	\$182,440	\$465,293
		BIOTRONIK		6/21/2010	6/20/2016			The IMPACT of BIOTRONIK Home Monitoring Guided Anticoagulation on Stroke Risk in Patients with ICD and CRT-D Devices	\$11,555	\$3,004	\$14,559
		PHILIPS		3/1/2013	6/30/2015			Early Detection of Acute Decompensated Heart Failure Using a Wearable Monitor: THE SENTINEL-HF Study	\$357,692	\$107,308	\$465,000
	Meyer, Theo	UEDINBUR		5/1/2014	4/30/2015	5/1/2014	4/30/2015	ACS Risk Working Group Results of Proposal Assessment	\$109,396	\$39,383	\$148,779
		CARDIORENT		10/14/2013	10/13/2018			Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide Intravenous Infusion in Patients Suffering from Acute Decompensated Heart Failure	\$4,437	\$1,331	\$5,768
		NERI	/NIH	4/1/2006	11/30/2013			TOPCAT: Treatment of preserved cardiac function heart failure with an aldosterone antagonist.	\$1,071	\$279	\$1,350
		STJUDE		6/10/2010	12/31/2014			LAPTOP-HF: Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study	\$16,290	\$4,235	\$20,525
		AHA	13PRE13700002	1/1/2013	12/31/2014	1/1/2014	12/31/2014	Modifying cardiovascular risk through preservation and promotion of brown fat	\$22,000	\$0	\$22,000

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Cardiovascular Medicine	Ockene, Ira	PFIZER	11538663	6/1/2014	5/31/2016	6/1/2014	5/31/2015	A Physician Counseling Approach for the Improvement of Cardiovascular Risk Factor Control in Ecuador	\$158,477	\$29,431	\$187,908
	Rade, Jeffrey	ABBOTT/CV		3/25/2013	6/30/2020			US ABSORB RCT III (Randomized Controlled Trial)	\$96,758	\$29,027	\$125,785
		CAPRICOR		3/25/2014	3/24/2019			Allogenic Heart Stem Cells to Achieve Myocardial Regeneration	\$6,731	\$2,019	\$8,750
	Rosenthal, Lawrence	BIOTRONIK		3/26/2013	3/25/2018			Clinical Protocol for the ProMRI Study	\$36,842	\$11,053	\$47,895
		BSC		11/3/2011	11/2/2016			Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients	\$14,682	\$4,405	\$19,087
		STJUDE		3/15/2007	6/30/2049			OPTIMUM Lead Insulation Material Registry	\$18,550	\$4,823	\$23,373
		TYRX		2/22/2010	4/14/2014			CITADEL: AIGISRx Anti-Bacterial Envelope for Prevention of Infection Following Cardiac Rhythm Management Device Replacement with an Implantable Cardioverter-Defibrillator (ICD)	\$7,684	\$1,998	\$9,682
		UCSF	/NIH	8/1/2008	7/31/2016			Vest Prevention of Early Sudden Death Trial and Prediction of ICD Therapies Study	\$7,117	\$1,851	\$8,968
		UROCHESTER	/NIH	4/1/2011	11/30/2013			RAID-Ranolazine ICD Trial	\$6,429	\$4,147	\$10,576
	Salmoirago Blotcher, Elena	NIH	1 R21 HL119665-01	8/15/2013	7/31/2015	8/15/2013	7/31/2014	Mindfulness Training to Promote Healthy Diet and Physical Activity in Teens [MPI]	\$0	\$0	\$0
	Smith, Craig	HOPEPHARM		6/26/2013	6/25/2018			Sodium Nitrate: A safety and Efficacy Evaluation of Sodium Nitrate Injection for the Prevention of Ischemia-Reperfusion Injury Associated with Acute Myocardial Infarction	\$61,846	\$18,554	\$80,400
	Trivedi, Chinmay	MOD	5-FY12-565	2/1/2013	1/31/2015	2/1/2014	1/31/2015	Hdac3 Regulates Early Cardiac Development	\$68,182	\$6,818	\$75,000
		NIH	5 R01 HL118100-02	4/1/2013	3/31/2018	4/1/2014	3/31/2015	Regulation of Cardiac Development by Chromatin Modifying Enzymes	\$245,000	\$164,762	\$409,762
		NIH	5 R00 HL098366-05	8/10/2011	7/31/2014	8/1/2013	7/31/2014	Hdac2 and Hopx: Regulators of Cardiac Development	\$144,103	\$92,946	\$237,049
Cardiovascular Medicine Total									\$2,948,296	\$1,426,817	\$4,375,113

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Dermatology	Harris, John	ABBVIE		12/24/2013	12/23/2014	12/24/2013	12/23/2014	Testing the efficacy of Jak inhibitors as treatment for vitiligo and alopecia areata in mouse models	\$34,223	\$24,777	\$59,000
		ABBVIE		10/19/2012	12/31/2014	10/19/2012	12/31/2014	Gene expression profiling in autoimmune disease	\$254,625	\$184,324	\$438,949
		ACDS		9/1/2013	8/31/2014	9/1/2013	8/31/2014	Development of tandem patch test series and in vitro assays using vitiligo patient melanocytes for clinical screening of household chemicals that worsen their disease	\$5,000	\$0	\$5,000
		COMBE		5/2/2013	8/31/2014	5/2/2013	5/1/2014	Screening hair dye chemicals to identify those that induce exosome production	\$30,015	\$19,985	\$50,000
		GLIKNIK		1/1/2014	12/31/2014	1/1/2014	12/31/2014	Testing G019 as a treatment in a mouse model of vitiligo	\$5,970	\$4,030	\$10,000
		NIH	3 K08 AR061437-03S1	7/15/2011	6/30/2016	12/19/2013	6/30/2014	Targeting IFN gamma and chemokines to treat vitiligo in a humanized mouse model	\$700	\$56	\$756
		NIH	5 K08 AR061437-03	7/15/2011	6/30/2016	7/1/2013	6/30/2014	Targeting IFN gamma and chemokines to treat vitiligo in a humanized mouse model	\$114,500	\$9,160	\$123,660
		UCSF	00sc	1/1/2014	12/31/2015	1/1/2014	12/31/2014	Role of CXCL10 and melanocyte stress in driving vitiligo	\$50,350	\$2,014	\$52,364
	Richmond, Jillian	AMERSKIN		1/1/2014	12/31/2014	1/1/2014	12/31/2014	Examining the Role of Non-Immune Cells in CD8+T Cell Recruitment and Activation in Vitiligo	\$15,000	\$0	\$15,000
	Wiss, Karen	JGSF		1/1/2013	12/31/2014	1/1/2014	12/31/2014	Epidermolysis Bullosa Clinical Characterization and outcome Database	\$1,440	\$0	\$1,440
Dermatology Total									\$511,823	\$244,346	\$756,169

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Diabetes	Alonso, Laura	NIH	5 R01 DK095140-03	4/1/2013	3/31/2017	4/1/2014	3/31/2015	Free Fatty Acids, p16 and Pancreatic Beta Cell Proliferation	\$217,500	\$145,181	\$362,681
	Harlan, David	BU	4500001477/NIH	9/30/2013	8/31/2015	9/30/2013	8/31/2014	A multicenter outpatient trial of bihormonal bionic pancreas	\$285,414	\$174,460	\$459,874
		NIH	5 U24 DK093000-04	9/16/2011	5/31/2016	6/1/2014	5/31/2015	UMass Mouse Metabolic Phenotyping Center: Analytical Core	\$47,435	\$30,596	\$78,031
		VAN	VUCM37016/NIH	9/10/2010	6/30/2015	7/1/2013	6/30/2014	Molecular Mechanisms of Human and Murine Beta Cell Proliferation and Regeneration	\$333,903	\$215,368	\$549,271
	Kent, Sally	BRI	2011PG-T1D058	4/1/2014	3/31/2016	4/1/2014	3/31/2015	Assessing the Stability and Phenotype of the CD4+ Autoreactive T Cell Response in Type 1 Diabetic Subjects with Long-term Type 1 Diabetes	\$50,000	\$5,000	\$55,000
		UFLORIDA VIACORD	UF13241	7/1/2012	6/30/2015	9/1/2013	8/31/2014	nPOD Viral Work Groups	\$22,727	\$2,273	\$25,000
				4/1/2014	3/31/2015	4/1/2014	3/31/2015	Human autoreactive T cell functional suppression by human umbilical cord stem cells	\$25,000	\$19,500	\$44,500
	Lock, John	JAEB		6/1/2013	4/30/2014			Severe Hypoglycemia in Older Adults	\$6,750	\$675	\$7,425
		JAEB		11/1/2013	10/31/2014			Efficacy and Safety of Intranasal Glucagon for Treatment of Induced Hypoglycemia in Adults with Diabetes	\$1,500	\$150	\$1,650
		NOVO		5/3/2012	6/30/2049			A trial comparing the efficacy, patient-reported outcomes and safety of insulin degludec 200 U/mL vs insulin glargine in subjects with type 2 diabetes mellitus requiring high dose insulin.	\$13,631	\$4,089	\$17,720
		NOVO		4/17/2014	4/16/2019			EX1250-4080, A trial comparing cardiovascular safety of insulin degludec VS insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events	\$8,649	\$2,595	\$11,244
	Lungu, Andree	ANDROMEDA		3/28/2012	6/30/2049			A Phase III, Multinational, Randomized, Double-Blind, Placebo-Controlled, parallel-group Study to investigate the Clinical Efficacy and Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Subjects	\$676	\$203	\$879
	Malkani, Samir	NOVO		12/5/2013	12/4/2018			Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 Diabetes	\$4,795	\$1,439	\$6,234
	Thompson, Michael	EOSHEALTH		4/2/2014	4/1/2015			Get in Touch Phase 1	\$7,692	\$2,308	\$10,000
		JDC	/NIH	9/30/2013	6/30/2018	9/30/2013	6/30/2014	A multicenter clinical trial of allopurinol to prevent GFR loss in T1D	\$36,532	\$15,343	\$51,875
Diabetes Total									\$1,062,204	\$619,180	\$1,681,384

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Endocrinology	Aronin, Neil	CHDI	A-6119	6/1/2013	11/30/2014	6/1/2014	11/30/2014	Exosome delivery of siRNA against huntingtin mRNA	\$50,704	\$7,580	\$58,284
		CHDI	RecID: A-5038	3/1/2012	2/28/2015	3/1/2014	2/28/2015	CHDI Multi Project Grant	\$1,162,333	\$151,850	\$1,314,183
		NIH	5 R01 NS038194-15	8/1/2010	4/30/2015	5/1/2014	4/30/2015	Signaling Mechanisms in Neuronal Degeneration	\$407,109	\$171,578	\$578,687
		NIH	1 UH2 TR000888-01	8/1/2013	7/31/2015	8/1/2013	7/31/2014	Exosome based therapeutics in Huntington's disease	\$335,616	\$164,384	\$500,000
	Mordes, John	ADA	7-11-BS-102	7/1/2011	6/30/2014	7/1/2013	6/30/2014	Towards new therapeutic approaches to type 1 diabetes based on rat immunobiology	\$89,978	\$11,168	\$101,146
		GROVE INST NEWTON	/NIH	11/15/2012	11/15/2014			Grove Glucometer Testing	\$62,866	\$12,573	\$75,439
				9/5/2013	9/4/2015			SBIR Phase 1: Continuous Non-Invasive Glucose Monitor	\$1,914	\$1,274	\$3,188
Endocrinology Total									\$2,110,520	\$520,407	\$2,630,927

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Gastroenterology	Barry, Curtis	BRISTOL		9/22/2012	6/30/2049			A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotypes 1 and 4	\$1,404	\$421	\$1,825
		BRISTOL		4/9/2010	6/30/2049			A Phase 2a/2b study of BMS-650032 in Combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection	\$2,052	\$534	\$2,586
		BRISTOL		5/22/2013	6/30/2049			Observational Study Protocol AI444058: Comparative Assessment of Effectiveness of Antiviral Therapies in Hepatitis C (CMPASS)	\$769	\$231	\$1,000
	Houghton, Jean	ABBVIE	1 R21 AA022770-01A1	11/26/2013	11/25/2014			Collaboration in Crohn's Disease	\$37,448	\$24,904	\$62,352
		NIH		3/5/2014	2/29/2016	3/5/2014	2/28/2015	Alcohol Effect on Human Breast Cancer Microenvironment [MPI]	\$71,271	\$47,870	\$119,141
		PFIZER		9/6/2012	6/30/2049			A Multicenter, Open-Label Extension Study to Assess Long Term Safety of PF-00547659 in Subject's with Crohn's Disease (OPERA II)	\$46,636	\$13,991	\$60,627
		PFIZER		7/16/2012	6/30/2049			A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-00547659 in Subjects with Crohn's Disease Who are Anti-TNF Inadequate Responders (OPERA)	\$7,970	\$2,391	\$10,361
		PFIZER		2/26/2013	6/30/2049			A Multicenter, Open-Label Extension Study to Assess Long-Term Safety of PF-00547659 in Subjects with Ulcerative Colitis (TURANDOT II)	\$9,636	\$2,890	\$12,526
		PFIZER		6/1/2012	5/31/2015			Longitudinal Immune Profiling of Blood, Serum, Plasma, Stool and Gut Biopsy from Normal and IBD Patients for Biomarker Discovery	\$39,985	\$10,396	\$50,381
		PFIZER		2/21/2014	2/20/2019			A Multicenter Open-Label Extension Study for Subjects who Participated in Study B0151003 (ANDANTE II)	\$5,577	\$1,673	\$7,250
		PFIZER		1/9/2013	6/30/2049			A Double-Blind, Randomized, Placebo-Controlled, Parallel, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-00547659 in Subjects with Moderate to Severe Ulcerative Colitis (TURANDOT)	\$7,692	\$2,308	\$10,000
		PFIZER		2/21/2014	2/20/2019			A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-04236921 in Subjects with Crohn's Disease Who are Anti-TNF Inadequate Responders (ANDANTE)	\$5,577	\$1,673	\$7,250
		NIH		5/15/2014	4/30/2017	5/15/2014	4/30/2015	Regulation of enteroendocrine cell differentiation by Neurogenin 3 gene dosage	\$200,000	\$134,667	\$334,667

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Gastroenterology	Leiter, Andrew	NIH	5 R01 DK090000-04	7/1/2010	5/31/2015	6/1/2013	5/31/2014	Transcriptional Regulation of Enteroendocrine Cell Differentiation by NeuroD	\$227,797	\$146,929	\$374,726
	Mandrekar, Pranoti	DAMD	W81XWH-11-1-0420	5/15/2011	5/14/2015	5/15/2013	5/14/2014	Moderate Alcohol-Induced Suppression: Role of Heat Shock Proteins	\$238,267	\$153,682	\$391,949
		DAMD	W81XWH-13-1-0498	9/30/2013	9/29/2016	9/30/2013	9/29/2014	Targeting CC-Chemokines in Alcoholic Liver Disease: Role for CCL2/MCP1	\$242,666	\$155,141	\$397,807
		NIH	1 R21 AA022770-01A1	3/5/2014	2/29/2016	3/5/2014	2/28/2015	Alcohol Effect on Human Breast Cancer Microenvironment [MPI]	\$72,480	\$48,682	\$121,162
		NIH	5 R01 AA017986-05	8/1/2009	6/30/2015	7/1/2013	6/30/2014	Role of heat shock protein 90 in alcoholic liver disease	\$210,182	\$135,567	\$345,749
	Nompleggi, Dominic	FURIEX		7/23/2012	6/30/2049			A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome	\$1,654	\$496	\$2,150
	Satishchandran, Abishek	NIH	1 F30 AA022283-01	7/17/2013	7/16/2018	7/17/2013	7/16/2014	The Role of miR-122 in Alcoholic Liver Disease	\$28,679	\$0	\$28,679
	Szabo, Gyongyi	CCF	345-SUB/NIH	9/15/2012	6/30/2014	7/1/2013	6/30/2014	Novel Therapies in Alcoholic Hepatitis - UMMS Clinical Trial	\$243,400	\$76,777	\$320,177
		GENFIT		2/15/2013	10/31/2015			A Multicentre, Randomized, Double Blind, Placebo-Controlled Study, with an Adaptive Design to Allow for Initial GFT505 80mg dosing versus placebo, followed by a second Phase including GFT505 120mg dose	\$19,334	\$5,801	\$25,135
	Szabo, Gyongyi	GILEAD		4/8/2013	6/30/2049			An Open-Label Study to Evaluate the Safety of GS-7977 + Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection Who Participated in Prior Studies Evaluating GS-7977	\$2,692	\$808	\$3,500
		GILEAD		9/27/2012	9/26/2015			A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection	\$3,234	\$970	\$4,204
		NIH	5 U01 AA021902-02	9/15/2012	6/30/2017	7/1/2013	6/30/2014	Novel Therapies in Alcoholic Hepatitis - UMMS Admin Core	\$23,250	\$15,461	\$38,711
		NIH	5 R01 AA017729-05	8/20/2009	7/31/2014	8/1/2013	7/31/2014	TLR4 Signaling in alcoholic liver disease	\$223,479	\$144,144	\$367,623
		NIH	3 R01 AA020744-03S1	9/18/2013	6/30/2016	9/18/2013	6/30/2014	Micro-RNA's in Alcoholic Liver Disease	\$28,291	\$16,021	\$44,312
		NIH	3 R37 AA014372-11S	9/15/2013	8/31/2018	9/20/2013	8/31/2014	HCV, Alcohol and Host Defense	\$9,000	\$6,001	\$15,001
		NIH	4 R37 AA014372-11	9/15/2013	8/31/2018	9/15/2013	8/31/2014	HCV, Alcohol and Host Defense	\$210,215	\$140,143	\$350,358
		NIH	5 U01 AA021907-02	9/15/2012	6/30/2017	7/1/2013	6/30/2014	Novel Therapies in alcoholic hepatitis - UMMS Translational Program	\$169,540	\$112,744	\$282,284
		NIH	5 R01 AA020744-03	9/10/2011	6/30/2016	7/1/2013	6/30/2014	Micro-RNA's in alcoholic Liver Disease	\$209,250	\$134,966	\$344,216
		NIH	1 T32 GM107000-01	7/1/2013	6/30/2018	7/1/2013	6/30/2014	Medical Scientist Training at UMMS	\$134,784	\$8,490	\$143,274
		TAKEDA		9/10/2013	9/9/2018				\$3,077	\$923	\$4,000
									A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects with Nonalcoholic Steatohepatitis		

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Gastroenterology	Szabo, Gyongyi	UFLORIDA		12/14/2011	6/30/2049			HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study	\$13,394	\$4,019	\$17,413
		VERTEX		11/30/2011	11/29/2036			A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN, and Ribavirin in Treatment-Naive and Prior Relapser Subjects with Genotype 1 Chronic Hepatitis C and IL28B CC Genotype	\$7,879	\$2,364	\$10,243
	Wassef, Wahid	COOK		1/31/2014	1/30/2019			Palliation of Biliary Neoplasms with the Cook Evolution Biliary Stent System	\$4,731	\$1,419	\$6,150
Gastroenterology Total									\$2,763,292	\$1,555,497	\$4,318,789

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
General Medicine	Lu, Shan	GATES	OPP1033112	9/14/2011	8/31/2014	9/1/2013	8/31/2014	HIV Vaccines Using Env Proteins Produced in Pichia with Unique Patterns of N-Glycans	\$809,636	\$65,964	\$875,600
		NIH	5 P01 AI082274-05	8/7/2009	7/31/2015	8/1/2013	7/31/2014	Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env: Project 3	\$736,956	\$0	\$736,956
		NIH	5 P01 AI082274-05	8/7/2009	7/31/2015	8/1/2013	7/31/2014	Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env: Core B	\$90,113	\$58,122	\$148,235
		NIH	5 P01 AI082274-05	8/7/2009	7/31/2015	8/1/2013	7/31/2014	Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env: Core A	\$181,664	\$0	\$181,664
		NIH	5 U19 AI082676-05	7/6/2009	6/30/2015	7/1/2013	6/30/2014	Optimization of HIV vaccines for the induction of cross-reactive antibodies: Core A	\$2,189,341	\$484,271	\$2,673,612
		NIH	5 P01 AI082274-05	8/7/2009	7/31/2015	8/1/2013	7/31/2014	Induction of Neutralizing Antibodies Targeting CD4 Binding Region of HIV-1 Env: Project 2	\$351,437	\$226,677	\$578,114
		NIH	5 U19 AI082676-05	7/6/2009	6/30/2015	7/1/2013	6/30/2014	Optimization of HIV vaccines for the induction of cross-reactive antibodies: Project 1	\$128,657	\$82,984	\$211,641
		RUTGERS	8092/NIH	7/1/2012	6/30/2016	7/1/2013	6/30/2014	Developing HIV vaccine targeting conserved targets in the V1/V2 domain of gp120	\$107,510	\$69,343	\$176,853
		SFU	14469/NIH	3/1/2012	2/28/2016	3/1/2014	2/28/2015	Vaccines that replicate the neutralization-competent structure of the gp41 MPER	\$142,200	\$91,719	\$233,919
		UWASH	756712	11/9/2011	10/31/2014	11/1/2013	10/31/2014	Unmasking Conserved Epitopes on HIV Envelope Protein for Vaccines	\$247,125	\$24,712	\$271,837
	Wang, Shixia	NIH	5 R33 AI087191-04	6/15/2010	6/30/2015	7/1/2013	6/30/2014	Production of neutralizing mAbs from HIV vaccinees	\$273,539	\$181,903	\$455,442
		NYU	14-A1-S1-112237-01/NIH	1/23/2014	1/22/2016	1/23/2014	1/22/2015	Epitope-Targeted Vaccines for HIV-1 Prevention (Sandy Supplement)	\$207,852	\$138,914	\$346,766
		NYU	G#11-02237;Project#1017	8/15/2012	7/31/2017	8/1/2013	7/31/2014	Epitope-Targeted Vaccines for HIV-1 Prevention	\$244,524	\$157,718	\$402,242
General Medicine Total									\$5,710,554	\$1,582,327	\$7,292,881

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Geriatric Medicine	Blanchard, Gary	HRSA	5 K01 HP20466-04	9/1/2010	8/31/2015	9/1/2013	8/31/2014	Geriatric Academic Career Awards	\$69,828	\$5,233	\$75,061
	Briesacher, Becky	HPHC	5R01AG028745-07/NIH	9/1/2011	5/31/2015	9/1/2013	5/31/2014	Changes in Cardiovascular Care and Outcomes in Eight Years after Medicare Part D	\$39,215	\$25,294	\$64,509
	Saczynski, Jane	NIH	5 K01 AG033643-05	9/1/2010	5/31/2015	6/15/2014	5/31/2015	Medical Illness & Cognitive Impairment in Older Adults: Heart Failure as a Model	\$116,981	\$9,361	\$126,342
	Tjia, Jennifer	ARNOLDGOLD		9/1/2013	8/31/2014	9/1/2013	8/31/2014	A Systematic Review of Mindfulness Interventions for Professional and Family Caregivers of Patients with Advanced Illness	\$5,000	\$0	\$5,000
		DONAGHUE		1/1/2014	12/31/2015	1/1/2014	12/31/2014	Evaluating a Resident-Centered Elder Care Intervention	\$60,860	\$6,090	\$66,950
Geriatric Medicine Total									\$291,884	\$45,978	\$337,862

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Hematology & Oncology	Brettler, Doreen Geary, Margaret	MSSM NHF	5-H30-MC24048-02-01	6/1/2012 10/1/2013	5/31/2017 9/30/2015	6/1/2013 10/1/2013	5/31/2014 9/30/2014	Regional Hemophilia Network Capacity-Building Grant for HTC's to address the Access to Care at HTC's and Beyond	\$29,584 \$9,737	\$2,367 \$0	\$31,951 \$9,737
	Li, Shaoguang	NIH	5 R21 HL113603-02	9/26/2012	6/30/2015	7/1/2013	6/30/2014	Identification of novel target genes for polycythemia vera (PV)	\$119,000	\$79,135	\$198,135
	Raffel, Glen	NIH	5 R01 HL116392-02	8/1/2013	4/30/2018	5/1/2014	4/30/2015	Hematopoietic regulation through Ott1- dependent alternative splicing	\$245,000	\$165,375	\$410,375
	Hematology & Oncology Total								\$403,321	\$246,877	\$650,198

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Hospital Medicine	Kapoor, Alok	BUMEDC	0305801/NIH	2/1/2014	1/31/2016	2/1/2014	1/31/2015	Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement Center for Health Insurance Reform, Cardiovascular Outcomes & Disparities	\$13,766	\$9,234	\$23,000
		BUMEDC	3903/NIH	2/1/2014	3/31/2015	4/1/2014	3/31/2015		\$22,682	\$15,254	\$37,936
Hospital Medicine Total									\$36,448	\$24,488	\$60,936

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Infectious Disease & Immunology	Atianand, Maninjay	AHA	14POST18930001	1/1/2014	12/31/2015	1/1/2014	12/31/2014	Long non-coding RNA Eps regulates inflammasome signaling by epigenetic silencing of ASC	\$45,300	\$0	\$45,300
	Co, Mary Dawn	BAYLORRI	41000411345/NIH	5/1/2013	4/30/2015	5/1/2013	4/30/2014	PRE-ILLNESS INTERFERON RESPONSES ND INFLUENZA ILLNESS IN YOUNG CHILDREN	\$117,149	\$77,751	\$194,900
	Daly, Jennifer	ASTELLAS		8/3/2012	6/30/2013			A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 VS Voriconazole for Primary Treatment of Invasive Fungal Disease	\$5,481	\$1,644	\$7,125
		ASTELLAS		7/28/2011	6/30/2049			A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections	\$1,228	\$368	\$1,596
		DUKE	/NIH	2/1/2013	10/31/2013			A Multi-Centered, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Patients with Blood Stream Infections due to Staphylococci	\$64,286	\$16,714	\$81,000
		HRSA	5 H76 HA00689-13	4/1/2010	3/31/2015	4/1/2014	3/31/2015	Ryan White Part C Outpatient EIS Program	\$440,279	\$5,680	\$445,959
	Ennis, Francis	URHODE	09032013/3758/NIH	7/18/2013	6/30/2018	7/18/2013	6/30/2014	Administrative Core B for Flavivirus Infections: Pathogenesis and Prevention	\$20,094	\$13,337	\$33,431
	Fingerroth, Joyce	NIH	7 R03 AI103521-03	4/17/2014	12/31/2014	4/17/2014	12/31/2014	Development of Robust Culture Systems for the Human Splenic Littoral Cell	\$50,000	\$33,626	\$83,626
	Fitzgerald, Katherine	NIH	5 R01 AI083713-05	7/1/2009	6/30/2015	7/1/2013	6/30/2014	Role of PISA: a PYHIN Family Member of Intracellular DNA Recognition [MPI]	\$115,163	\$74,280	\$189,443
		NIH	5 R01 AI079293-05	9/24/2009	8/31/2014	9/1/2013	8/31/2014	Innate Immune Activation in Malaria [MPI]	\$169,651	\$109,425	\$279,076
		NIH	5 R01 AI093752-03	2/15/2012	1/31/2017	2/1/2014	1/31/2015	DNA Sensors and Associated Signaling Pathways in the Innate Immune Response	\$258,800	\$90,300	\$349,100
	Gibson, Laura	VIROPHARMA		1/4/2012	7/31/2015			A Phase 2, Randomized Study to Assess the Safety and Anti-Cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections	\$7,205	\$2,161	\$9,366
								Innate Immune Activation in Malaria [MPI]	\$156,211	\$100,756	\$256,967
	Golenbock, Douglas	NIH	5 R01 AI079293-05	9/24/2009	8/31/2014	9/1/2013	8/31/2014	Innate and Adaptive Immunity in Experimental and Human Gonococcal Infection: Project 1	\$171,437	\$110,577	\$282,014
		NIH	5 R37 GM054060-19	7/1/2013	4/30/2018	5/1/2014	4/30/2015	Phagocyte Receptors for Lipid A	\$294,759	\$119,079	\$413,838
		NIH	5 R03 TW009007-02	3/1/2013	2/29/2016	3/1/2014	2/28/2015	Innate Immune Activation in Malaria	\$46,058	\$9,362	\$55,420
		NIH	5 R03 TW009007-02	3/1/2013	2/29/2016	3/1/2014	2/28/2015	Humoral Immune Responses to Japanese Encephalitis Virus	\$144,216	\$95,784	\$240,000
	Green, Sharone	BAYLORRI	41000411349/NIH	5/1/2013	4/30/2015	5/1/2013	4/30/2014	Project 1 Clinical Studies on the Mechanisms of DF/DHF-Flavivirus	\$62,231	\$41,306	\$103,537
		URHODE	09032013/3753/NIH	4/1/2013	3/31/2018	7/18/2013	6/30/2014				

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Infectious Disease & Immunology	Huh, Jun	NIH	4 R00 DK091508-03	9/16/2013	7/31/2016	8/15/2013	7/31/2014	Chemical and genetic studies of RORgamma and its critical roles in IBD	\$149,438	\$99,562	\$249,000
		NYU	13-A0-00-001463-01	8/15/2013	6/30/2016	8/15/2013	6/30/2014	Roles of RORgamma-t and pro-inflammatory Th17 cells in ASD	\$62,108	\$12,422	\$74,530
		RSSFF		2/1/2014	1/31/2017	2/1/2014	1/31/2015		\$95,238	\$4,762	\$100,000
	Latz, Eicke	MGH	R01HL112661/NIH	9/27/2012	6/30/2017	7/1/2013	6/30/2014	Bacterial Regulators of Immunity and their Modulation of Host Transcription Factors	\$155,716	\$103,551	\$259,267
		NIH	5 P01 AR050256-11	2/11/2010	6/30/2015	7/1/2013	6/30/2014	HDL Prevention of Cholesterol Crystal Inflammation in HIV Disease	\$69,509	\$44,833	\$114,342
		NIH	5 R01 AI083713-05	7/1/2009	6/30/2015	7/1/2013	6/30/2014	Toll-Like Receptors in Systemic Autoimmune Disease: Core B	\$115,161	\$74,279	\$189,440
		NIH	5 R01 HL093262-05	5/1/2009	4/30/2015	5/1/2013	4/30/2014	Role of PISA: a PYHIN Family Member of Intracellular DNA Recognition [MPI]	\$235,620	\$151,975	\$387,595
	Levitz, Stuart	NIH	1 R01 AI02618-01A1	8/6/2013	7/31/2017	8/6/2013	7/31/2014	Inflammasome Activation by Cholesterol Crystals	\$375,403	\$149,095	\$524,498
		NIH	5 R01 HL112671-02	2/1/2013	1/31/2017	2/1/2014	1/31/2015	Glucan Particles as a Vaccine Platform for Protective Immunity	\$245,000	\$163,334	\$408,334
	Libraty, Daniel	NIH	5 R01 AI091820-03	8/1/2011	7/31/2016	8/1/2013	7/31/2014	Interactions of pDCs with Aspergillus A Clinical Study of Protective and Pathogenic Immunity to Dengue during Infancy	\$376,563	\$132,324	\$508,887
		GATES	OPP1106893	5/1/2014	10/31/2015	5/1/2014	4/30/2015		\$67,742	\$0	\$67,742
	Lien, Egil	NIH	5 R01 AI075318-05	4/1/2009	3/31/2015	4/1/2013	3/31/2014	TLR11-deficient mice and humanized mice as novel model systems for live typhoid	\$240,357	\$155,030	\$395,387
		NIH	5 R21 AI103650-02	5/23/2013	4/30/2015	5/1/2014	4/30/2015	The Role of LPS-TLR4 Signaling in Live Vaccine Induced Protective Responses	\$125,000	\$84,167	\$209,167
	Mathew, Anuja	NIH	09032013/3757/NIH	7/18/2013	6/30/2018	7/18/2013	6/30/2014	Human Monoclonals to Dengue Virus Project 3 Flavivirus Infections: Pathogenesis and Prevention	\$39,930	\$26,553	\$66,483
		NIH	5 U19 AI084048-05	9/25/2009	8/31/2015	9/1/2013	8/31/2014	Innate and Adaptive Immunity in Experimental and Human Gonococcal Infection: Project 4	\$180,290	\$116,286	\$296,576
	Ram, Sanjay	NIH	5 R01 AI054544-11	2/1/2010	1/31/2015	2/1/2014	1/31/2015	Complement Activation on Neisseria Meningitidis	\$222,750	\$143,674	\$366,424
		NIH	1 R21 AI111728-01	3/1/2014	2/28/2016	3/1/2014	2/28/2015	Novel immunotherapeutics against multi-drug resistant Neisseria gonorrhoeae [MPI]	\$66,151	\$44,329	\$110,480
		UMISSMED	66103650115-UM/NIH	2/1/2014	1/31/2017	2/1/2014	1/31/2015	Mechanisms of Haemophilus Influenzae Pathogenesis in the lung	\$10,524	\$6,998	\$17,522
		NIH	5 U19 AI084048-05	9/25/2009	8/31/2015	9/1/2013	8/31/2014	Innate and Adaptive Immunity in Experimental and Human Gonococcal Infection: Project 2	\$290,303	\$0	\$290,303
	Rice, Peter	NIH	5 U19 AI084048-05	9/25/2009	8/31/2015	9/1/2013	8/31/2014	Innate and Adaptive Immunity in Experimental and Human Gonococcal Infection: Core A	\$180,139	\$0	\$180,139
		NIH	5 U19 AI084048-05	9/25/2009	8/31/2015	9/1/2013	8/31/2014	Innate and Adaptive Immunity in Experimental and Human Gonococcal Infection: Project 3	\$280,726	\$0	\$280,726
		NIH	5 U19 AI084048-05	9/25/2009	8/31/2015	9/1/2013	8/31/2014	Innate and Adaptive Immunity in Experimental and Human Gonococcal Infection: Core B	\$178,986	\$0	\$178,986
		NIH	5 U19 AI084048-05	9/25/2009	8/31/2015	9/1/2013	8/31/2014		\$178,986	\$0	\$178,986

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Infectious Disease & Immunology	Rice, Peter	NIH	5 U19 AI084048-05	9/25/2009	8/31/2015	9/1/2013	8/31/2014	Innate and Adaptive Immunity in Experimental and Human Gonococcal Infection: Core E	\$84,044	\$54,208	\$138,252
		NIH	5 U19 AI084048-05	9/25/2009	8/31/2015	9/1/2013	8/31/2014	Innate and Adaptive Immunity in Experimental and Human Gonococcal Infection: Project 5	\$248,188	\$160,081	\$408,269
	Shaughnessy, Jutamas	NIH	1 R21 AI111728-01	3/1/2014	2/28/2016	3/1/2014	2/28/2015	Novel immunotherapeutics against multi-drug resistant Neisseria gonorrhoeae [MPI]	\$58,849	\$39,525	\$98,374
	Silverman, Neal	BIMR	56154-11670-UMMS-04/NI	4/1/2011	3/31/2016	4/1/2014	3/31/2015	Genetic Analysis of Drosophila Functional Aging: Project 2 - Genetic Analysis of Immunosenescence	\$62,418	\$40,260	\$102,678
		NIH	5 R01 AI099708-02	9/24/2012	8/31/2017	9/1/2013	8/31/2014	Interplay between the Endocrine and Innate Systems of Drosophila [MPI]	\$162,956	\$108,637	\$271,593
		NIH	5 T32 AI095213-03	9/15/2011	8/31/2016	9/1/2013	8/31/2014	Innate Immunity Training Program	\$118,984	\$8,714	\$127,698
		NIH	5 R01 AI060025-11	12/1/2011	11/30/2016	12/1/2013	11/30/2014	Activation of Insect Immunity by Gram-Negative Bacteria	\$250,000	\$161,250	\$411,250
	Specht, Charles	WASHU	WU-14-364/NIH	1/1/2014	12/31/2015	1/1/2014	12/31/2014	Host factors required for Leishmania infection	\$150,000	\$100,500	\$250,500
				6/1/2014	5/31/2019	6/1/2014	5/31/2015	Chitosan in Cryptococcus	\$69,966	\$47,226	\$117,192
				7/18/2013	3/31/2018	7/18/2013	6/30/2014	Core C Clinical Research Laboratory - Flavivirus Infections	\$128,689	\$85,417	\$214,106
	Thatcher, Elizabeth	LIFE		8/1/2012	7/31/2015	8/1/2013	7/31/2014	Impact of Redundant microRNA Networks in an Activated RAS Cancer Model	\$56,000	\$0	\$56,000
				5/1/2014	4/30/2016	5/1/2014	4/30/2015	Regulation of Inflammation by the Mevalonate Pathway in a Mouse Model of RA	\$92,593	\$7,407	\$100,000
	Wang, Donghai	ARTHRITIS						Evaluation of the role of MDA5 in virus-mediated type I diabetes	\$235,000	\$151,575	\$386,575
	Wang, Jennifer	NIH	5 R01 AI092105-03	7/15/2011	6/30/2016	7/1/2013	6/30/2014		\$235,000	\$151,575	\$386,575
Infectious Disease & Immunology Total									\$7,649,889	\$3,380,124	\$11,030,013

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Preventive & Behavioral Medicine	Brewer, Judson	NIH	1 R21 CA184254-01	4/16/2014	3/31/2016	4/16/2014	3/31/2015	Mobile Mindfulness for Smoking Cessation	\$108,750	\$73,134	\$181,884
	Carmody, James	RUSH	1R01NR013910-01A1/NIH	9/25/2013	6/30/2018	9/25/2013	6/30/2014	Mechanisms of Psychosocial Chronic Pain Treatments	\$10,041	\$6,702	\$16,743
	Crawford, Sybil	UMICHIGAN	3002222579/NIH	9/1/2011	8/31/2014	9/1/2013	8/31/2014	Study of Women's Health Across the Nations (SWAN) Repository	\$11,884	\$7,665	\$19,549
		UPITTSBURGH	0007084/NIH	6/1/2009	6/30/2014	7/1/2013	4/30/2014	Swan IV (Study of Women Across the Nation)	\$108,956	\$68,097	\$177,053
	Gaskins, Ronnesia	NIH	7 R21 HL114083-02	5/1/2013	10/30/2014	5/1/2013	4/30/2014	Helping Ethnically Diverse Teen Moms Prevent Obesity in their Preschool Children	\$263,608	\$162,261	\$425,869
	Lemon, Stephenie	CDC	3 U48 DP001933-05S1	9/30/2009	9/29/2014	9/30/2013	9/29/2014	CDC UMMS Prevention Research Center for Obesity and Related Conditions Category 2	\$55,555	\$14,445	\$70,000
		CDC	5 U48 DP001933-05	9/30/2009	9/29/2014	9/30/2013	9/29/2014	CDC UMMS Prevention Research Center for Obesity and Related Conditions Category 2	\$215,595	\$56,055	\$271,650
		NIH	5 P60 MD006912-03	6/14/2012	1/31/2017	2/1/2014	1/31/2015	UMass Center for Health Equity Intervention Research: Project 1	\$67,597	\$45,347	\$112,944
		NIH	5 P60 MD006912-03	6/14/2012	1/31/2017	2/1/2014	1/31/2015	UMass Center for Health Equity Intervention Research - Comm. Engage & Outreach Core	\$38,971	\$26,142	\$65,113
		NIH	5 R01 MH085653-04	5/1/2011	2/28/2015	3/1/2014	2/28/2015	Barriers and Facilitators of Mental Health Services Utilization Among Latinos [MPI]	\$85,117	\$36,051	\$121,168
		NIH	1 R25 CA172009-01A1	6/1/2014	5/31/2019	6/1/2014	5/31/2015	Implementation Research Training Program in Cancer Prevention and Control [MPI]	\$45,113	\$3,609	\$48,722
	Li, Wenjun	BIDMC	01025090-COREA3/NIH	7/15/2011	6/30/2016	7/1/2013	6/30/2014	Consortium for AIDS Vaccine Research in Nonhuman Primates - Core A-3: Administrative Core: Biostatistics	\$79,867	\$51,514	\$131,381
		MAHB		12/1/2013	5/31/2015	12/1/2013	11/30/2014	Analyzing the impact on cigar smoking by youths of an innovative packaging regulations in Boston	\$22,474	\$2,697	\$25,171
		MDPH	INTF4120HH2706811023	9/30/2012	6/30/2014	7/1/2013	6/30/2014	Evaluation of Mass in Motion and Community Transformation Grant	\$369,335	\$36,934	\$406,269
		MDPH	INTF4250HH2706811001	12/3/2013	6/30/2014	12/3/2013	6/30/2014	PWTF Program Planning and Evaluation	\$22,182	\$2,218	\$24,400
		NIH	5 R01 MD006231-03	6/9/2011	3/31/2015	4/1/2013	3/31/2014	Health Care Reform and Disparities in the Care and Outcomes of Trauma Patients	\$273,208	\$100,435	\$373,643
	Ma, Yunsheng	SUNY	1116975/6/55773	10/1/2013	9/30/2014	10/15/2013	9/30/2014	Feasibility of hemoglobin AL c measurement by mail for diabetic women in the WHI	\$12,345	\$0	\$12,345
	Ockene, Judith	NIH	5 R01 CA136888-05	7/6/2009	5/31/2015	6/1/2013	5/31/2014	RCT For Smoking Cessation in 10 Medical Schools	\$433,885	\$138,336	\$572,221
		NSF	HRD-1208589	9/15/2012	8/31/2015	9/1/2013	8/31/2014	Collaborative Research: Institutional Networks and Continuous Learning to UnDo Effects of Micro-inequities on Women (INCLUDE-Women)	\$71,955	\$47,820	\$119,775
	Pagoto, Sherry	CDC	3 U48 DP001933-05S1	9/30/2009	9/29/2014	9/30/2013	9/29/2014	UMMS Prevention Research Center for Obesity and Related Conditions- Category 2	\$259,788	\$39,001	\$298,789

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Preventive & Behavioral Medicine	Pagoto, Sherry	NIH	5 R21 DK098556-02	9/15/2013	5/31/2015	6/1/2014	5/31/2015	Feasibility Trial of a Problem-Solving Weight Loss Mobile Application	\$136,642	\$70,633	\$207,275
		NIH	5 R21 CA161576-02	4/1/2012	3/31/2015	4/1/2013	3/31/2014	Pilot Investigation of Behavioral Alternatives to Indoor Tanning	\$102,225	\$65,935	\$168,160
	Pbert, Lori	AAPED	697100-4M/NIH	7/1/2010	4/30/2015	5/1/2014	4/30/2015	Adolescent Smoking Cessation in Pediatric Primary Care	\$2,652	\$1,711	\$4,363
		NIH	1 R21 HL119665-01	8/15/2013	7/31/2015	8/15/2013	7/31/2014		\$119,000	\$79,135	\$198,135
								Mindfulness Training to Promote Healthy Diet and Physical Activity in Teens [MPI]			
	Reed, George	NIH	5 U19 AI084048-05	9/25/2009	8/31/2015	9/1/2013	8/31/2014	Innate and Adaptive Immunity in Experimental and Human Gonococcal Infection: Core D	\$161,287	\$66,172	\$227,459
	Rosal, Milagros	NIH	5 P60 MD006912-03	6/14/2012	1/31/2017	2/1/2014	1/31/2015	UMass Center for Health Equity Intervention Research: Project 1	\$67,481	\$45,268	\$112,749
		NIH	5 R01 MH085653-04	5/1/2011	2/28/2015	3/1/2014	2/28/2015		\$55,655	\$35,897	\$91,552
	UMASS/AMHER	13-007352 B 02/NIH	9/4/2012	6/30/2016	7/1/2013	6/30/2014	Barriers and Facilitators of Mental Health Services Utilization Among Latinos [MPI]	\$13,001	\$8,656	\$21,657	
	UMASS/AMHER	14-007792 D 00/NIH	4/1/2013	6/30/2018	8/1/2013	4/30/2014	Randomized Trial of a Post-Partum Diabetes Prevention Program for Hispanic Women	\$13,001	\$8,656	\$21,657	
								Randomized Lifestyle Intervention in Overweight and Obese Pregnant Hispanic Women	\$8,543	\$5,681	\$14,224
Preventive & Behavioral Medicine Total									\$3,222,712	\$1,297,551	\$4,520,263

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Pulmonary Medicine	Kornfeld, Hardy	CRDF	USB1-31149-XX-13	8/1/2013	7/31/2016	8/1/2013	7/31/2014	Effects of Diabetes on Tuberculosis Severity	\$106,049	\$10,605	\$116,654
		NIH	5 R01 HL081149-09	4/1/2011	3/31/2015	4/1/2014	3/31/2015	Impact of Diabetes and Hyperlipidemia on Host Defense	\$245,000	\$158,025	\$403,025
Pulmonary Medicine Total									\$351,049	\$168,630	\$519,679

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Rheumatology	Gravallese, Ellen	ABBVIE		12/6/2013	12/31/2016	12/6/2013	12/5/2014	Mechanisms of Periosteal and Entesial Bone Formation in Spondyloarthritis	\$150,469	\$100,837	\$251,306
		NIH	5 R01 AR055952-05	7/17/2009	6/30/2015	7/1/2013	6/30/2014	Inhibition of Osteoblast Function in Bone Erosion in Rheumatoid Arthritis	\$182,833	\$117,927	\$300,760
	Kay, Jonathan	ABBVIE		10/23/2013	10/22/2018			A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Continuing VS Withdrawing Adalimumab Therapy in Maintaining remission in Subjects with Non-Radiographic Axial Spondyloarthritis	\$2,308	\$692	\$3,000
		ARDEA		2/3/2012	6/30/2049			Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)	\$645	\$193	\$838
		ARDEA		6/8/2012	6/30/2049			A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response	\$24,301	\$7,291	\$31,592
		ARDEA		11/25/2013	11/24/2018			A Long-Term Extension Study of Lesinurid in Combination with Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurid and Allopurinol	\$7,229	\$2,168	\$9,397
		BWH		1/23/2012	6/30/2049			Teriparatide for Joint Erosions in Rheumatoid Arthritis: the TERA Trial	\$4,994	\$1,298	\$6,292
		FIDIA		3/18/2011	6/30/2049			A Multi-Centre, Parallel, Double-Blind, Blinded Evaluator, Randomized, Placebo Controlled Study to Evaluate the Safety and Effectiveness of a New Viscoelastic Hydrogel in the Treatment of Knee Osteoarthritis with an Open-Label Extension	\$4,266	\$1,109	\$5,375
		GENENTECH		8/8/2011	6/30/2049			A Critical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade with Tocilizumab (TCZ) in Comparison with Etanercept (ETA) on the Rate of Ischemic Cardiovascular Events in Patients with Moderate to Severe Rheumatoid Arthritis	\$26,069	\$7,821	\$33,890
		ROCHE		1/8/2010	7/31/2013			A multi-center, randomized, double-blind, parallel group study of the safety, disease remission and prevention of structural joint damage during treatment with tocilizumab (TCZ), as a monotherapy and in combination with methotrexate (MTX)...	\$15,568	\$4,047	\$19,615
	Marshak-Rothstein, Ann	LRI		11/1/2012	10/31/2016	11/1/2013	10/31/2014	DNA-and RNA-associated Autoantigens in the Activation of Human B Cells	\$250,000	\$0	\$250,000
		NIH	5 P01 AR050256-11	2/11/2010	6/30/2015	7/1/2013	6/30/2014	Toll-Like Receptors in Systemic Autoimmune Disease: Project 3	\$334,008	\$0	\$334,008
		NIH	5 P01 AR050256-11	2/11/2010	6/30/2015	7/1/2013	6/30/2014	Toll-Like Receptors in Systemic Autoimmune Disease: Core C	\$14,799	\$0	\$14,799

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Rheumatology	Marshak-Rothstein, Ann	NIH	5 P01 AR050256-11	2/11/2010	6/30/2015	7/1/2013	6/30/2014	Toll-Like Receptors in Systemic Autoimmune Disease: Project 2	\$292,801	\$0	\$292,801
		NIH	5 P01 AR050256-11	2/11/2010	6/30/2015	7/1/2013	6/30/2014	Toll-Like Receptors in Systemic Autoimmune Disease: Project 1	\$315,840	\$157,963	\$473,803
		NIH	5 P01 AR050256-11	2/11/2010	6/30/2015	7/1/2013	6/30/2014	Toll-Like Receptors in Systemic Autoimmune Disease: Core A	\$49,114	\$31,678	\$80,792
		SCHEPENS	R21EY022433-01A1SUB1	9/1/2012	8/31/2014	9/1/2013	8/31/2014	Regulation of Vascular Leakage in Age Related Macular Degeneration	\$35,325	\$22,564	\$57,889
	Salomon-Escoto, Karen	PFIZER		12/20/2012	6/30/2049			A Randomized, Double-Blind Study Comparing the Pharmacokinetics and Pharmacodynamics and Assessing the Safety of PF-05280586 and Rituximab in Subjects with Active Rheumatoid Arthritis	\$5,864	\$1,760	\$7,624
		PFIZER		2/7/2013	6/30/2049			Extension Study Evaluating Treatment with PF-05280586 Versus Rituximab in Subjects with Active Rheumatoid Arthritis Who have Participated in Other PF-05280586 Clinical Trials	\$4,704	\$1,411	\$6,115
	Shaw, Anita	ARTHRITIS	5427	12/1/2013	11/30/2014	12/1/2013	11/30/2014	Effects of IL-17 on osteoblast inhibition in rheumatoid arthritis	\$50,000	\$0	\$50,000
Rheumatology Total									\$1,771,137	\$458,759	\$2,229,896

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Neurology	Bosco, Daryl	ALSTA		7/1/2012	6/30/2014	7/1/2013	6/30/2014	Investigating the Link between DNA damage and FUS-dependent cell death	\$100,000	\$0	\$100,000
		NIH	5 R01 NS078145-03	4/1/2012	3/31/2017	4/1/2014	3/31/2015	Investigating a Toxic Gain-of-Interaction Between FUS/TLS & Stress Granules	\$196,875	\$126,984	\$323,859
		NIH	5 R01 NS067206-04	7/15/2010	4/30/2015	5/1/2013	4/30/2014	Investigation of Post-Translational Modifications in WT SOD1 in Sporadic ALS	\$206,872	\$133,432	\$340,304
	Brown, Robert	ALSTA	2013-S-017	5/10/2013	5/10/2015	5/10/2013	5/10/2014	Proposal for Accelerated Development of AAV-Mediated Gene Silencing Therapy in Amyotrophic Lateral Sclerosis: Stage 1-Pre-Clinical Proof-of-Concept Study in Mice and Monkeys	\$244,190	\$0	\$244,190
		ALSTA		5/10/2013	5/10/2015	5/10/2014	5/10/2015	A novel immunosuppression intervention for the treatment of ALS	\$155,284	\$0	\$155,284
		DUKE		6/19/2012	6/18/2015	6/1/2014	6/18/2015	ALS Genome Sequencing Consortium	\$39,845	\$25,700	\$65,545
	Bucheli, Miriam	NIH	5 R01 NS079836-03	7/1/2012	4/30/2016	5/1/2014	4/30/2015	High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1	\$389,086	\$96,679	\$485,765
		PROJALS	2013-01	2/1/2014	1/31/2015	2/1/2014	1/31/2015	SOD1 Gene Silencing in ALS	\$100,000	\$0	\$100,000
		ALSTA	2013-S-016	5/10/2013	5/10/2015	5/10/2013	5/10/2014	Project Als-Ecuador: Identification of Genetic Determinants of Amyotrophic Lateral Sclerosis in South America	\$139,896	\$0	\$139,896
	Carandang, Raphael	MGH	223334/NIH	9/30/2013	8/31/2018	9/30/2013	7/31/2014	New England Regional Coordinating Center for the NINDS Stroke: Trials Network	\$5,000	\$1,300	\$6,300
		REMEDY		6/4/2013	6/30/2049			Glyburide Advantage in Malignant Edema and Stroke "GAMES-RP"	\$1,923	\$577	\$2,500
	Esteves, Miguel	NTSAD		10/25/2013	10/24/2014	10/25/2013	10/24/2014	Selection of a new AAVrh8 vector design and safety testing in NHP	\$260,464	\$12,347	\$272,811
		TAY SACHS		8/13/2013	8/12/2014	8/13/2013	8/12/2014	Selection of a new AAVrh8 vector design and safety testing in NHP	\$224,719	\$11,236	\$235,955
	Gao, Fen Biao	ALSA	2179	8/1/2013	7/31/2016	8/1/2013	7/31/2014	Use of Patient-Specific IPS Cells to Investigate Pathogenic Mechanisms of Hexanucleotide Repeats in C9ORF72	\$80,000	\$0	\$80,000
		ALSTA	2013-S-018	5/10/2013	5/10/2016	5/10/2014	5/9/2015	Generation & Characterization of Novel Cellular and Animal Models of Amyotrophic Lateral Sclerosis	\$125,000	\$0	\$125,000
		COLUMBIA		1/1/2014	12/31/2014	1/1/2014	12/31/2014	Target ALS: Identification of small molecules that block RNA-mediated toxicity in c9ALS/FTD	\$51,000	\$0	\$51,000
		COLUMBIA	6 (PG004827)	5/1/2013	4/30/2016	5/1/2014	4/30/2015	Examining C9ORF72 Repeats Toxicity in a Novel	\$46,000	\$0	\$46,000
		HOPKINS	200175766	1/1/2013	12/31/2014	1/1/2014	12/31/2014		\$85,000	\$0	\$85,000
		JDGLADSTONE /NIH		9/30/2013	6/30/2017	9/30/2013	6/30/2014	Identification of Genetic Modifiers of GGGGCC Repeats Toxicity in Drosophila Frontotemporal Dementia Induced Pluripotent Stem Cell Consortium	\$133,588	\$86,195	\$219,783
		NIH	5 R21 NS077294-02	4/1/2012	3/31/2015	4/1/2013	3/31/2014	Generation and Characterization of Novel Drosophila Models of TDP-43 Toxicity	\$144,750	\$93,364	\$238,114
		NIH	5 R01 NS057553-08	12/1/2012	11/30/2017	12/1/2013	11/30/2014	Animal Models for Studying Human Frontotemporal Dementia	\$216,563	\$144,917	\$361,480
		ALSA	2186-14-IIP-146	8/1/2013	7/31/2016	8/1/2013	7/31/2014	Mouse models of FUS/TLS expression in ALS	\$80,000	\$0	\$80,000
	Hayward, Lawrence										

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Neurology	Hayward, Lawrence	ALSTA		8/31/2011	9/1/2014	9/1/2013	9/1/2014	Understanding How Mutant FUS/TLS Impairs Neuronal Homeostasis	\$176,259	\$0	\$176,259
		ALSTA	2013-F-069	5/1/2014	4/30/2016	5/1/2014	4/30/2015	Genome-wide Mapping of Chromatin Modifications in Mice Expressing ALS Mutant FUS/TLS [MPI]	\$103,289	\$0	\$103,289
	Ionete, Carolina	BIOGEN-IDEC		3/22/2011	3/21/2016			Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon B-1a) in Patients with Relapsing-Remitting MS	\$24,412	\$7,323	\$31,735
		BIOGEN-IDEC		7/18/2013	7/17/2018			A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis Who Have Completed Study 205MS301	\$12,188	\$3,656	\$15,844
		BIOGEN-IDEC		1/3/2014	1/2/2019			An Open-Label, Two-Arm, Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning from Current Interferon Beta Therapies to BIIB017	\$5,590	\$1,677	\$7,267
		CODMAN		9/18/2013	9/17/2020			Long-term Surveillance of the Medstream Programmable Infusion System for the Intrathecal Infusion of Baclofen in the Treatment of Spasticity	\$4,250	\$1,275	\$5,525
		DIOGENIX		12/12/2012	12/11/2014			A Longitudinal Study to Identify and Validate Biomarkers from Serum and Cerebrospinal Fluid in Patients Evaluated by Neurologists	\$13,077	\$3,923	\$17,000
		ALSA	2411	7/1/2013	6/30/2014	7/1/2013	6/30/2014	Development of a public searchable variant database for ALS exomes	\$120,000	\$0	\$120,000
	Landers, John	IAI		2/1/2013	1/31/2015	2/1/2014	1/31/2015	Identification of De Novo Mutations in Amyotrophic Lateral Sclerosis Using a Trio-based exome sequencing approach	\$21,022	\$1,051	\$22,073
		MOTOR	June13/6604	5/1/2013	4/30/2014	5/1/2013	4/30/2014	Development of a public searchable variant database for ALS exomes	\$24,000	\$0	\$24,000
		NIH	5 R01 NS065847-05	4/15/2010	3/31/2015	4/1/2014	3/31/2015	Characterization of KIFAP3, A Modifier of Survival in Sporadic ALS	\$212,231	\$136,889	\$349,120
		NIH	5 R01 NS073873-04	7/15/2011	3/31/2015	4/1/2014	3/31/2015	Identification of Genes Causative for familial ALS gene using exome sequencing	\$196,875	\$126,984	\$323,859
	Levin, Seth	CMSC		7/1/2013	6/30/2014	7/1/2013	6/30/2014	The Relationship Between Bipolar Disorder & Multiple Sclerosis	\$5,000	\$0	\$5,000
	Moonis, Majaz	EMMES		2/10/2010	9/28/2013			Platelet-Oriented Inhibition in New TIA (POINT Study)	\$27,857	\$7,243	\$35,100
	Muehlschlegel, Susanne	BIDMC	01026743/NIH	7/1/2012	6/30/2017	9/1/2013	8/31/2014	Futility Study of Deferoxamine Mesylate in Intracerebral Hemorrhage	\$38,751	\$21,442	\$60,193

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Neurology	Novak, Peter	CHELSEA		3/18/2014	3/17/2019			PHOENIX: A clinical study of patients with symptomatic neurogenic orthostatic hypotension to assess sustained effects of droxidopa therapy	\$6,269	\$1,881	\$8,150
	Paydarfar, David	BIDMC	/NIH	9/1/2012	6/30/2015	7/1/2013	6/30/2014	Research Resources for Complex Physiologic Signals	\$35,784	\$23,798	\$59,582
		WYSS	815066-0001	3/1/2010	6/30/2014	1/1/2014	6/30/2014	Development of AMD for Detection and Prevention of Apnea of Prematurity	\$105,684	\$21,137	\$126,821
	Perrone, Christopher Ramirez, Juan	AOAHS		7/1/2013	6/30/2014	7/1/2013	6/30/2014	The role of multiple sclerosis as a risk factor for osteoporosis	\$5,000	\$0	\$5,000
		CMSC		9/1/2013	8/31/2014	9/1/2013	8/31/2014		\$5,000	\$0	\$5,000
	Ravin, Paula	ACADIA		11/12/2008	11/11/2013			Study of prevalence and risk factors for JCV antibody seroconversion in multiple sclerosis patients from Umass MS Center A Multi-Center, Open Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease	\$973	\$253	\$1,226
	Riskind, Peter	BIOGEN-IDECD		10/29/2013	10/28/2018			A Multicenter, Open-Label, 12 Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera Delayed-Release Capsules in Patients with Relapsing Forms of MS	\$1,933	\$580	\$2,513
								TYGRIS: TYSABRI Global Observational Program in Safety			
		BIOGEN-IDECD		5/16/2008	6/30/2049			JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: STRATIFY-2	\$766	\$199	\$965
				7/27/2010	6/30/2049				\$1,605	\$417	\$2,022
		GENENTECH		9/19/2011	6/30/2049				\$9,105	\$2,732	\$11,837
	Salameh, Johnny	CYTOKINETICS		1/22/2013	6/30/2049			A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a in Patients with Relapsing Multiple Sclerosis	\$23,147	\$6,018	\$29,165
								An Extension Protocol for Multiple Sclerosis Patients who Participated in Genzyme-Sponsored Studies of Alemtuzumab			
								A Phase iib, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients with ALS			
	Salisbury, Elisabeth	NIH	1 R21 DA035355-01A1	9/15/2013	8/31/2015	9/15/2013	8/31/2014	A Safety and Tolerability Study of Mexiletine in Patients with Sporadic Amyotrophic Lateral Sclerosis (SALS)	\$150,000	\$84,750	\$234,750
								Abstinence and Drug Withdrawal: Innovative Translational Methods for Neonates			
	Schwartz, William	ALSTA		1/1/2013	1/1/2015	1/1/2014	1/1/2015	Defective Daily Thermoregulation in a Mouse Model of ALS	\$114,584	\$0	\$114,584

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Neurology	Tran, Helene	ALSA	69WF1R	8/1/2012	7/31/2014	8/1/2013	7/31/2014	A Drosophila model of The Hexanucleotide Repeats-Induced Toxicity in ALS	\$50,000	\$0	\$50,000
Neurology Total									\$4,600,746	\$1,199,803	\$5,800,549

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Neurosurgery	Pennings, Federik	LDR SPINE		4/10/2014	4/9/2019			An Open Label, Multicenter, Clinical Study of the Safety and Efficacy of the LDR ROI-A Interbody Fusion System Using the VertebBridge Plating System	\$7,600	\$2,280	\$9,880
		TRANS1		12/14/2012	6/30/2049			Prospective, Randomized, Multicenter Clinical Study Comparing Axial Lumbar Interbody Fusion (AxiaLIF) and Transforaminal Lumbar Interbody Fusion (TLIF) Spinal Procedures	\$2,852	\$855	\$3,707
Neurosurgery Total									\$10,452	\$3,135	\$13,587

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Obstetrics & Gynecology	Moore Simas, Tiffany	ABBVIE		6/29/2012	6/28/2017			A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis Associate Pain	\$8,569	\$2,571	\$11,140
		W&I		6/15/2012	3/31/2014			Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial	\$19,525	\$5,076	\$24,601
	Zweizig, Susan	AMGEN		1/29/2013	6/30/2049			A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 with Paclitaxal and Carboplatin as First line Treatment of Subjects With FIGO Stage III-IV Cancers	\$3,188	\$957	\$4,145
		GOG VENTIRX		1/15/2004	6/30/2049			Gynecologic Oncology Group	\$47,587	\$7,138	\$54,725
				4/26/2013	4/25/2038			A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination with Pegylated Liposomal Doxorubicin in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer	\$9,038	\$2,712	\$11,750
Obstetrics & Gynecology Total									\$87,907	\$18,454	\$106,361

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Orthopedics	Connolly, Patrick	APATECH		11/13/2009	6/30/2049			A Prospective Patient Registry For Bone Graft Substitutes In Spinal Fusion	\$3,294	\$856	\$4,150
	Franklin, Patricia	AHRQ	5 P50 HS018910-04	9/30/2010	9/29/2014	9/30/2013	9/29/2014	Improving Orthopedic Outcomes Through a National TJR Registry	\$2,072,031	\$874,298	\$2,946,329
		JRGOS		1/3/2013	1/2/2014	1/3/2013	1/2/2014	Disparities in total joint replacement patients form the FORCE national database	\$10,000	\$0	\$10,000
		UAB	000413884-006	3/1/2012	2/28/2015	9/1/2013	8/31/2014	UAB Deep South Arthritis and Musculoskeletal CERTs	\$104,832	\$67,616	\$172,448
		UMASS/LOWEL	S51110000014503/NIH	9/1/2011	8/31/2014	9/1/2013	8/31/2014	A New Technology to Preserve Patient Privacy and Data Quality in Health Research	\$64,544	\$41,631	\$106,175
	Jones, Marci	OMEGA		11/1/2013	10/31/2014	11/1/2013	10/31/2014	Challenging the traditional methods of intra-operative learning: Comparing the effectiveness of computer-based video tutorial with one-on-one expert teaching for Zone II flexor tendon repairs	\$5,000	\$0	\$5,000
	Most, Matthew	DEPUY		3/6/2006	12/31/2012			Sigma CoCr Tibial Tray Using GVF vs. Crosslinked Polyethylene	\$159	\$41	\$200
	Nguyen, Uyen-Sa	ARTHRITIS	5840	10/1/2013	12/31/2014	1/1/2014	12/31/2014	The True Impact of Cardiovascular Risk Factors in Rheumatoid Arthritis	\$46,296	\$3,704	\$50,000
		NIH	5 K01 AR064351-03	4/1/2013	3/31/2018	4/1/2014	3/31/2015	Collider Bias and the Risk Factor Paradoxes in Rheumatic Disease Research	\$114,425	\$8,804	\$123,229
	Wixted, John	NIH	5 K08 AR062591-02	9/19/2012	8/31/2015	9/1/2013	8/31/2014	Is impaired fracture healing in smokers related to CO exposure?	\$82,822	\$6,626	\$89,448
Orthopedics Total									\$2,503,403	\$1,003,576	\$3,506,979

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Pediatrics	Alario, Anthony	PFIZER		12/13/2010	6/30/2049			A 6-Month, Open-Label, Safety Trial of Pregabalin in Adolescent Patients with Fibromyalgia	\$7,676	\$1,995	\$9,671
		PFIZER		12/13/2010	6/30/2049			A 15 Week, Randomized, Double Blind, Placebo-Controlled Parallel Group Efficacy Study of Pregabalin in Adolescents (12-16 Years Old) with Fibromyalgia	\$397	\$103	\$500
	Bateman, Scot	MCOW		5/1/2010	6/30/2013			Genetic Variation and Biomarkers in Children with Acute Lung Injury	\$1,111	\$289	\$1,400
	Bram, Jennifer Candela, Ninfa	EMMC CENTOCOR		1/1/2014	12/31/2014	1/1/2014	12/31/2014	Let's Go Healthcare 2014	\$22,051	\$0	\$22,051
				2/9/2010	4/30/2032			A Multicenter, Prospective, Long-term Observational Registry of Pediatric Patients with Inflammatory Bowel Disease	\$19,614	\$5,099	\$24,713
		SCHERING		11/4/2011	3/31/2014			Assessment of the safety, efficacy, tolerability and pharmacokinetics of PEG-Intron plus REBETOL in pediatric patients with chronic Hepatitis C, study P02538	\$709	\$185	\$894
	Greenough, Thomas	NIH	5 P01 AI049320-12	7/15/2012	6/30/2017	7/1/2013	6/30/2014	Evolution & Maintenance of Memory CD8 T Cells: Core B	\$158,739	\$105,561	\$264,300
		NIH	5 U19 AI057319-10	4/1/2009	3/31/2014	4/1/2013	3/31/2014	Cellular Immunity to Category A-C Viruses in Humans: Core E1	\$51,511	\$33,225	\$84,736
	Grossman, Neil	TUFTS		1/21/2014	12/7/2014	1/21/2014	12/7/2014	Canines and Childhood Cancer Animal-Assisted Therapy Research Study	\$51,905	\$10,381	\$62,286
	Hermos, Christina	SANOFIPAST		7/16/2012	7/31/2015			A Phase IV, open-label administration, randomized (Group1 and 2), parallel-group, multicenter trial to evaluate the immunogenicity and safety of 2 doses of Menactra when administered alone at 9 months and concomitantly with Penactel at 15 to 18 months.	\$1,831	\$549	\$2,380
								Children's Oncology Group			
	Keuker, Christopher	CHOP	CHOP/NIH	3/1/2012	6/30/2015	3/1/2012	6/30/2015	A Randomized, Multi-center Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming with Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) subjects	\$38,385	\$11,515	\$49,900
		EISAI		4/26/2011	6/30/2049			A Randomized, Multi-center Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming with Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) subjects	\$1,542	\$401	\$1,943
	Lee, Mary	BU	4500001272/NIH	5/1/2013	1/31/2017	2/1/2014	1/31/2015	Transitional studies of a bionic pancreas for out-patient diabetes management	\$16,376	\$10,986	\$27,362
		HSPH	23515-112110/NIH	2/1/2011	12/31/2015	1/1/2014	12/31/2014	Dioxins and Male Pubertal Growth and Development - PHASE 2	\$18,200	\$11,740	\$29,940
		USOFLORIDA	/NIH	3/1/2009	6/30/2013			TrialNet Natural History of the Development of Type 1 Diabetes	\$2,683	\$402	\$3,085
	Luzuriaga, Katherine	NIH	3 UM1 AI069516-07S1	2/1/2007	5/30/2014	1/1/2014	5/30/2014	Western New England Maternal Pediatric Adolescent AIDS Clinical Trials Unit	\$52,721	\$35,059	\$87,780

**University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014**

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Pediatrics	Luzuriaga, Katherine	S&SS	/NIH	11/15/2010	12/31/2013			A Multicenter, Open-Label, Noncomparative Study of IMPAACT Group to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of MK-0518 in HIV-1 Infected Children	\$10,465	\$2,616	\$13,081
	McLaughlin, Thomas	NIH	HHSN275201400146P	4/1/2014	9/30/2014	4/1/2014	9/30/2014	Publications Committee Services to NCS	\$6,250	\$2,250	\$8,500
		NORC	7562.UMASS.TO7/NIH	9/26/2013	9/25/2015	9/26/2013	9/25/2014	A Methodological Study to Assess Mental Disorders for NCS Birth Mothers and Fathers	\$558,722	\$372,947	\$931,669
	Moormann, Ann	THRASHER		12/1/2011	11/30/2014	12/1/2013	11/30/2014	Immunologic and viral predictors of survival for children with endemic Burkitt lymphoma in Kenya	\$105,349	\$7,374	\$112,723
	Newburger, Peter	APSSPR		10/1/2013	9/30/2014	10/1/2013	9/30/2014	Effects of Interferon-gamma on Gene Expression and Splicing in Leukocytes from Chronic Granulomatous Disease Patients	\$25,000	\$0	\$25,000
		NIH	5 R01 DK054369-14	7/1/2010	6/30/2014	7/1/2013	6/30/2014	HOX cluster intergenic non-coding RNAs in myeloid differentiation and function	\$399,504	\$133,100	\$532,604
	Nwosu, Benjamin	NOVO		9/16/2010	6/30/2049			Glycemic Control in Children and Adolescents with Double Diabetes: Trial of Optimized Insulin-Metformin Regimen	\$35,760	\$9,297	\$45,057
	O'Sullivan, Brian	CFF	CC087-130	7/1/2002	6/30/2014	7/1/2013	6/30/2014	CF Foundation Grant	\$68,320	\$0	\$68,320
		CFF	OSULLI14Y0	1/1/2014	12/31/2014	1/1/2014	12/31/2014	Therapeutics Development Network-Cystic Fibrosis Foundation	\$57,290	\$4,583	\$61,873
		CFF		9/12/2012	6/30/2022			A Long-Term Prospective Observational Study of the Incidence of Risk Factors for Fibrosing Colonopathy in US Across Sponsors	\$4,514	\$1,355	\$5,869
		CHRC VERTEX		4/1/2009	3/31/2014			The EPIC Observational Study	\$3,246	\$260	\$3,506
				5/18/2010	6/30/2049			Determination of bromide elimination rate in Cystic Fibrosis (CF) patients and healthy controls	\$8,557	\$2,225	\$10,782
		VERTEX		6/3/2013	6/30/2049			A Phase 3, randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the efficacy and Safety of Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis	\$152,352	\$45,706	\$198,058
		VERTEX		12/4/2013	12/3/2018			A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation	\$43,473	\$13,041	\$56,514
								An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients with Atypical Hemolytic-Uremic Syndrome			
	Salerno, Ann	ALEXION		6/26/2013	6/25/2018			Assessment of Intranasal Glucagon in Children and Adolescents with Type 1 Diabetes	\$2,308	\$692	\$3,000
	Soyka, Leslie	JAEB		9/1/2013	8/31/2014				\$1,500	\$150	\$1,650

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Pediatrics	Soyka, Leslie	NOVO NOVO		3/24/2004	3/23/2014			Norditropin national registry	\$595	\$155	\$750
				4/3/2013	6/30/2049			Efficacy and Safety of Liraglutide in Combination with Metformin versus Metformin Monotherapy on Glycaemic Control in Children and Adolescents with Type 2 Diabetes	\$2,500	\$750	\$3,250
		NOVO		2/12/2014	2/11/2019			A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart once daily plus Insulin Aspart for the Remaining Meals VS Insulin Detemir once or twice daily plus Meal Time Insulin Aspart in Children and Adolescents	\$13,693	\$4,108	\$17,801
		NOVO		4/9/2012	6/30/2049			A trial investigating the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus	\$29,528	\$8,859	\$38,387
		VERSARTIS		1/29/2013	6/30/2049			A Long-Acting Human Growth Hormone in Pre-pubertal Children with Growth Hormone Deficiency: A Randomized, Open-label, Multi-center, Phase 1b/2a Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy	\$2,779	\$834	\$3,613
		WPS		10/1/2013	6/30/2014	10/1/2013	6/30/2014	Pilot Program to address the Disparities Type I Diabetes Care for School Age Child	\$17,143	\$857	\$18,000
	Usmani, Naheed	DANA FARBER		12/17/2012	11/30/2013			Understanding Barriers to Long Term Pediatric Cancer Survivorship Care in New England	\$769	\$231	\$1,000
	Zimmerman, Andrew	HUSSMAN		12/1/2013	11/30/2015	12/1/2013	11/30/2014	Hussman Foundation	\$100,000	\$0	\$100,000
Pediatrics Total									\$2,095,068	\$838,880	\$2,933,948

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Psychiatry	Davis, Maryann	EBADC USDE	H133B090018-13	10/1/2013 10/1/2009	9/30/2014 9/30/2014	10/1/2013 10/1/2013	9/30/2014 9/30/2014	MST-EA DC Evaluation Learning and Working During the Transition to Adulthood	\$14,608 \$721,409	\$5,259 \$78,979	\$19,867 \$800,388
	Deligiannidis, Kristina	NIH	5 K23 MH097794-02	4/8/2013	12/31/2017	1/1/2014	12/31/2014	Neuroendocrine and Neuroimaging Endophenotypes in Postpartum Depression	\$162,966	\$12,867	\$175,833
	Ellison, Marsha	RUTGERS	8094	10/1/2012	9/30/2017	10/1/2013	9/30/2014	A Career Development Manual for TAYYA	\$78,125	\$52,149	\$130,274
	Fan, Xiaoduo	STANLEY		2/1/2014	1/31/2017	2/1/2014	1/31/2015	Exenatide weekly injection as an adjunctive treatment in patients with schizophrenia	\$219,418	\$30,560	\$249,978
	Feldman, Barry	VA	VA241-12-D-0222	12/27/2013	9/29/2015	12/27/2013	9/29/2015	Ending Homelessness	\$666,647	\$0	\$666,647
		VA	VA241-P-2045	12/27/2013	9/30/2014	12/27/2013	9/30/2014	The augmentation of HUD-VASH substance abuse and mental health services	\$64,166	\$0	\$64,166
	Frazier, Jean	AUTISMCONS	UMM-002-00070-06	6/29/2009	12/31/2014	1/1/2014	12/31/2014	Autism Consortium Family Support Network	\$46,808	\$4,681	\$51,489
		AUTISMCONS BMC	2266/NIH	8/1/2013 9/15/2011	7/31/2015 8/31/2015	8/1/2013 9/1/2013	7/31/2014 8/31/2014	Discovering Biomarkers in Autism	\$25,058 \$103,172	\$5,012 \$66,545	\$30,070 \$169,717
		GLAXOSMITH		7/31/2008	6/30/2049			Neonatal Biomarkers in extremely Preterm Babies Predict Childhood Brain Disorders The Evaluation of LAMICTAL as an Add- on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age	\$2,971	\$772	\$3,743
		HOFFMANN		11/28/2012	6/30/2049			A Randomized, Parallel Group, Double- Blind, Placebo-Controlled Safety and Exploratory Efficacy and Pharmacokinetic Study of RO4917523 in Pediatric Patients with Fragile X Syndrome	\$38,672	\$11,601	\$50,273
		HOFFMANN		6/12/2012	10/31/2013			Controlled Study of the Efficacy and Safety of RO4917523 in Patients with Fragile X Syndrome	\$7,414	\$2,224	\$9,638
		NEUREN		3/24/2014	4/15/2015			A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Fixed Dose Study of NNZ-2566 in Fragile X Syndrome	\$7,500	\$2,250	\$9,750
		NIH	5 R01 MH083320-05	9/19/2012	6/30/2016	7/1/2013	6/30/2014	A Knowledge Environment for Neuroimaging in Child Psychiatry [MPI]	\$321,468	\$213,776	\$535,244
		SEASIDE		5/2/2011	6/30/2049			A Randomized, Double-Blind, Placebo- Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Children with Fragile X Syndrome	\$3,148	\$944	\$4,092
		SEASIDE		12/6/2011	6/30/2049			An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects with Fragile X Syndrome	\$27,272	\$8,181	\$35,453
	Fulwiler, Carl	NIH	5 R34 AT006963-02	5/1/2013	2/29/2016	3/1/2014	2/28/2015	Mind and health: developing a neural marker for mindfulness a pathway to health [MPI]	\$84,875	\$56,442	\$141,317

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Psychiatry	Gonzalez, Gerardo VA			9/30/2012	9/29/2017	9/30/2012	9/29/2015	Ending Homelessness	\$415,000	\$0	\$415,000
	Griffin-Ludy, Jessica	BAYSTATE	2	9/30/2012	9/29/2015	9/30/2013	9/29/2014	Therapy House Calls	\$37,283	\$13,422	\$50,705
		LUK	09C01057	3/25/2014	9/30/2016	3/24/2014	9/30/2014	Integrating Trauma - Informed and Trauma-Focused Practice in Children	\$36,669	\$3,667	\$40,336
		SAMHSA	5 U79 SM061071-02	9/30/2012	9/29/2016	9/30/2013	9/29/2014	The U Mass Medical School Child Trauma Training Center	\$285,138	\$105,788	\$390,926
	Grisso, Thomas	MACF	12-100893-000-USP	7/1/2012	12/31/2014	7/1/2013	6/30/2014	National Youth Screening Assistance Project	\$162,348	\$24,352	\$186,700
	Kennedy, David	BWH	109443/NIH	8/1/2013	5/31/2018	8/1/2013	5/31/2014	Neuroimaging Analysis Center (NAC)	\$17,446	\$11,253	\$28,699
		NIH	5 R01 MH083320-05	9/19/2012	6/30/2016	7/1/2013	6/30/2014	A Knowledge Environment for Neuroimaging in Child Psychiatry [MPI]	\$0	\$0	\$0
		NIH	5 P30 HD004147-41	8/1/2010	6/30/2015	7/1/2013	6/30/2014	Intellectual and Developmental Disabilities Research Center - Core C	\$133,817	\$86,312	\$220,129
		OMNITEC	SA 13-001	2/2/2013	6/30/2014	1/1/2014	6/30/2014	Computational Image QA Support for the NDAR Database	\$41,717	\$20,983	\$62,700
	Kim, Sun	NIH	5 K23 DA021243-05	4/15/2009	9/30/2014	4/1/2013	3/31/2014	Tobacco Dependence Treatments for Asian Americans	\$151,389	\$11,663	\$163,052
	King, Jean	NIH	5 R01 DA025690-05	5/1/2010	4/30/2015	5/1/2014	4/30/2015	Possible Significance of Cholinergic Influence in ADHD	\$211,171	\$136,205	\$347,376
		NIH	1 S10 OD018132-01	4/15/2014	4/14/2015	4/15/2014	4/14/2015	4.7T Magnet System Upgrade	\$598,000	\$0	\$598,000
		NIH	5 R34 AT006963-02	5/1/2013	2/29/2016	3/1/2014	2/28/2015	Mind and health: developing a neural marker for mindfulness a pathway to health [MPI]	\$84,875	\$56,442	\$141,317
		PSU	4912-UMMS-DHHS-8003/1	9/1/2013	4/30/2018	5/1/2014	4/30/2015	Longitudinal assessment of trauma on neural circuitry development into adulthood	\$17,911	\$12,089	\$30,000
		TUFTS		12/1/2013	11/30/2014	12/1/2013	11/30/2014	Effects of Early Life Chronic Stress on Neural Activity of F1 and F2 Lacta	\$56,760	\$17,028	\$73,788
	Kolodziej, Monika	HEALTHLINK	SM59721	9/30/2010	9/29/2014	9/30/2013	9/29/2014	Integration of Primary Health Care & Wellness Services Into a Community Mental Health Center	\$69,822	\$24,089	\$93,911
	Larson, Kimberly	PRA	9022-S03 Yr. 2	1/1/2013	12/31/2014	1/1/2014	12/31/2014	UMass Juvenile Competence to Stand Trial Legislation	\$109,181	\$16,377	\$125,558
	Marsh, Wendy	NARSAD	19727	1/15/2013	1/14/2015	1/15/2014	1/14/2015	A Randomized Double-Blind Placebo-controlled Pilot Study of Vitamin D Supplementation for the Treatment of Bipolar Depression	\$30,000	\$0	\$30,000
	Nino-Gomez, Johanna	JANSSEN		8/3/2013	2/2/2015			Acute Psychotic Depressive Episodes in Bipolar I	\$3,000	\$0	\$3,000
	O'Hea, Erin	POLARIS	STTR/NIH	5/10/2013	4/30/2015	5/1/2014	4/30/2015	Polaris Oncology Survivor Transition System: POST	\$35,926	\$9,342	\$45,268
	Rothschild, Anthony	CYBERON		10/6/2005	8/31/2013			A long-term, observational, multi-center patient outcome registry to collect data in patients with treatment-resistant depression	\$8,100	\$2,106	\$10,206
		NIH	5 U01 MH062624-09	6/1/2011	3/31/2016	4/1/2014	3/31/2015	2/4-Sustaining Remission of Psychotic Depression	\$202,500	\$103,460	\$305,960
		NNDC		1/1/2012	12/31/2012			Sustaining Remission of Psychotic Depression	\$13,000	\$0	\$13,000
		NNDC		10/1/2011	8/31/2014			NNDC Common Assessment Package	\$13,000	\$0	\$13,000

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Psychiatry	Rothschild, Anthony	STJUDE		3/15/2010	6/30/2049			A Clinical Evaluation For the Management of Patients with Major Depressive Disorder, Single or Recurrent Episode, With Deep Brain Stimulation	\$13,387	\$3,481	\$16,868
		STJUDE		4/29/2010	4/28/2016			A Long-Term Follow Up Study for the Evaluation of Patients Who Have a Deep Brain Stimulation System for the Adjunctive Treatment of Major Depressive Disorder	\$3,602	\$936	\$4,538
		TAKEDA		12/9/2010	6/30/2049			A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects with Major Depressive Disorder	\$3,287	\$854	\$4,141
	Smelson, David	UTORONTO	R01MH099167/NIH	12/10/2013	11/30/2016	12/1/2013	11/30/2014	Effects of Maintenance Treatment with Olanzapine vs. Placebo on Brain Structure	\$36,348	\$24,323	\$60,671
		MDPH		9/11/2013	6/30/2016	9/11/2013	6/30/2014	MISSION FORWARD (Maintaining Independence and Sobriety through Systems Integration	\$100,207	\$23,883	\$124,090
		SAMHSA	5 UD1 TI023562-03	9/30/2011	9/29/2014	9/30/2013	9/29/2014	Ending Chronic Homelessness through Permanent Housing, Integrated Treatment, Case	\$474,382	\$22,401	\$496,783
	Vincent, Gina	CJCA		3/1/2014	12/31/2014	3/1/2014	12/31/2014	Mississippi Statewide SAVRY Implementation	\$21,739	\$3,261	\$25,000
		MACF	13-1 03826-000- USP	7/1/2013	6/30/2015	7/1/2013	6/30/2014	Adolescent Domestic Battery Typologies Validation Study	\$115,012	\$17,252	\$132,264
		MACF	13-105740-000-USP	5/1/2014	4/30/2016	5/1/2014	4/30/2015	Improving Implementation in Risk/Needs Assessment in Juvenile Probation Project	\$130,435	\$19,565	\$150,000
	Wachholtz, Amy	NIH	5 K01 DA026502-04	8/1/2010	7/31/2015	8/1/2013	7/31/2014	Neuroimaging Youth with Callous-Unemotional CD & Comorbid Substance Abuse	\$167,508	\$13,241	\$180,749
		NIH	5 K23 DA030397-03	8/15/2011	7/31/2016	8/1/2013	7/31/2014	Co-Morbid Opioid Addiction and Chronic Pain	\$127,112	\$10,169	\$137,281
		FEMHC		9/15/2012	9/14/2014	9/15/2013	9/14/2014	Adapting the Open Dialogue Model in the United States; Developing and Piloting an Organizational Change Approach and Behavioral Therapy	\$100,000	\$0	\$100,000
		PHYSICIAN	9600860	5/1/2014	8/31/2015	5/1/2014	4/30/2015	Mindful Physician Leadership Program	\$56,588	\$8,488	\$65,076
Psychiatry Total									\$6,679,357	\$1,354,674	\$8,034,031

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Brudnick Neuropsychiatric Institute	Casserty, Alison	NIH	1 F30 DA036312-01A1	4/10/2014	4/9/2017	4/10/2014	4/9/2015	Modulation of Nicotine Reward-Associated Behaviors by MicroRNAs	\$29,578	\$0	\$29,578
	Derner - Guildford, Melissa	NIH	1 F31 AA022567-01	7/18/2013	7/17/2016	7/18/2013	7/17/2014	a6 subunit-containing nicotinic receptors in alcohol consumption and reward	\$31,235	\$0	\$31,235
	Futai, Kensuke	JAPAN		3/1/2013	3/31/2014	3/1/2013	3/31/2014	The roles of Neuroligin-Neurexin interactions in the balance of excitatory and inhibitory synapses	\$11,000	\$0	\$11,000
		WHITEHALL	2012-08-44	9/1/2012	8/31/2015	9/1/2013	8/31/2014	The Roles of Trans-Synaptic Adhesion Molecules in Synapse Validation	\$73,927	\$1,073	\$75,000
	Gardner, Paul	NIH	5 R01 DA033664-03	4/1/2012	3/31/2017	4/1/2014	3/31/2015	Transgenerational Effects of Nicotine [MPI]	\$87,351	\$56,341	\$143,692
		NIH	1 R01 DA035371-01A1	3/15/2014	2/28/2019	3/15/2014	2/28/2015		\$112,500	\$75,656	\$188,156
		NIH	5 R21 DA033543-02	2/1/2013	1/31/2015	2/1/2014	1/31/2015	Neurocircuitry of Nicotine Dependence MicroRNA Regulation of Nicotine Dependence Susceptibility Locus	\$150,000	\$100,500	\$250,500
		NIH	5 R21 DA031952-02	2/1/2012	1/31/2014	2/1/2013	1/31/2014	CHRNA5/A3/B4 microRNA Regulation of Nicotine-Mediated Behaviors	\$72,000	\$46,440	\$118,440
	Martin, Gilles	NIH	5 R01 AA020501-03	5/1/2012	4/30/2017	5/1/2014	4/30/2015	EtOH Modulation of Synaptic Plasticity in Nucleus Accumbens	\$196,425	\$126,694	\$323,119
	Melikian, Haley	NIH	2 R01 DA015169-11A1	9/15/2013	8/31/2018	9/15/2013	8/31/2014	Trafficking and Regulation on Monoamine Transporters	\$217,500	\$145,000	\$362,500
		NIH	5 R01 DA035224-02	5/1/2013	1/31/2018	2/1/2014	1/31/2015	Dopamine Transporter Cell Surface Dynamics	\$191,250	\$128,617	\$319,867
	Ngolab, Jennifer	NIH	1 F31 DA034490-01A1	7/15/2013	7/14/2016	7/15/2013	7/14/2014	The Role of VTA GABAergic Neurons in Nicotine Addiction	\$28,787	\$0	\$28,787
	Tapper, Andrew	NIH	2 R01 AA017656-06A1	3/15/2014	2/28/2019	3/15/2014	2/28/2015	Neuronal nicotine acetylcholine receptors and the response to alcohol	\$225,000	\$151,125	\$376,125
		NIH	5 R21 DA031952-02	2/1/2012	1/31/2014	2/1/2013	1/31/2014	MicroRNA Regulation of Nicotine-Mediated Behaviors	\$72,000	\$46,440	\$118,440
		NIH	1 R21 DA036041-01A1	4/15/2014	3/31/2016	4/15/2014	3/31/2015	Nicotine-Mediated behavioral Consequences of Nicotinic Receptor Upregulation	\$125,000	\$84,062	\$209,062
		NIH	1 R01 DA035371-01A1	3/1/2014	2/28/2019	3/15/2014	2/28/2015	Neurocircuitry of Nicotine Dependence [MPI]	\$112,500	\$75,656	\$188,156
		NIH	5 R01 DA033664-03	4/1/2012	3/31/2017	4/1/2014	3/31/2015	Transgenerational Effects of Nicotine [MPI]	\$87,351	\$56,341	\$143,692
Brudnick Neuropsychiatric Institute Total									\$1,823,404	\$1,093,945	\$2,917,349

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Radiation Oncology	Fitzgerald, Thomas	AMGENLTD	3100066616	9/1/2010	9/30/2015	9/1/2010	9/30/2015	Long Term Storage - 2006079 and 20062080	\$11,468	\$2,982	\$14,450
		MGH		3/1/2012	12/31/2014	1/1/2014	12/31/2014		\$123,500	\$32,110	\$155,610
		NORTHWESTF	60028476UM/NIH	6/1/2011	5/31/2014	6/1/2013	5/31/2014	Pediatric Proton Research Data Registry Cardiac Sparing Whole Lung IMRT in Children and Young Adults with Lung Metastases	\$94,099	\$24,466	\$118,565
		SARC		4/1/2013	3/31/2018	4/1/2014	3/31/2015	SARCO11: R1507 IGFIR, a recombinant human monoclonal antibody for the treatment of patients with recurrent or refractory Ewing's sarcoma & other soft tissue sarcoma	\$38,500	\$9,625	\$48,125
Radiation Oncology Total									\$267,567	\$69,183	\$336,750

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Radiology	Bogdanov, Alexei	NIH	1 R21 AI108529-01	3/1/2014	2/29/2016	3/1/2014	2/28/2015	Optimization and In vivo Testing of a Novel Combination HIV Microbicide	\$137,193	\$91,919	\$229,112
		NIH	2 R01 EB000858-10	9/30/2013	8/31/2017	9/30/2013	8/31/2014	MR Signal Amplification for Receptor Imaging	\$225,000	\$129,600	\$354,600
	Glick, Stephen	NIH	5 R01 CA140400-04	5/1/2010	2/28/2014	3/1/2013	2/28/2014	Development of a Photon Counting Detector for CT Breast Imaging	\$424,136	\$96,892	\$521,028
		TMRI		10/1/2009	9/30/2014	10/1/2013	9/30/2014	Modeling of PET Imaging Systems	\$74,074	\$25,926	\$100,000
	Gounis, Matthew	WPI	14-210730-02/NIH	9/1/2012	8/30/2017	5/17/2013	4/30/2014	MR-Guided Precision Conformal Ablation Therapy for Brain Tumors	\$38,149	\$24,287	\$62,436
		WYSS		5/1/2014	8/31/2014	5/1/2014	8/31/2014	Revascularization in Thromboembolic Vascular Occlusion Using Nanoparticles aggregates impregnated with tissue plasminogen activator	\$36,866	\$7,373	\$44,239
	Janko, Matthew	RSNA R&E	RMS1319	1/19/2014	3/31/2014	1/19/2014	3/31/2014	Evaluation of Topical Immunomodulatory Therapy on Interleukin-1 Dependent Radiodermatitis Using Multiple Imaging Modalities	\$3,000	\$0	\$3,000
	King, Michael	IIT	SA557-0614-8907/NIH	5/1/2014	4/30/2019	5/1/2014	4/30/2015	Probing dose limits in cardiac SPECT with reconstruction and personalized imaging Combined Multi-Pinhole and Fan-Beam Brain SPECT	\$249,474	\$167,771	\$417,245
		NIH	1 R21 EB016391-01A1	7/1/2013	6/30/2015	7/1/2013	6/30/2014	Patient Motion Detection and Compensation in SPECT	\$150,000	\$99,750	\$249,750
		NIH	3 R01 EB001457-09S1	4/1/2010	3/31/2014	7/1/2013	3/31/2014	Patient Motion Detection and Compensation in SPECT	\$54,466	\$36,220	\$90,686
		NIH	5 R01 EB001457-09	4/1/2010	3/31/2014	4/1/2013	3/31/2014	Motion tracking and correlation for PET brain imaging	\$417,806	\$194,709	\$612,515
		PHILIPS		12/15/2012	1/1/2015	12/15/2012	1/1/2015		\$27,018	\$17,982	\$45,000
	Liu, Guozheng	VAN	/NIH	9/15/2011	8/31/2016	9/1/2013	8/31/2014	Islet Imaging With Monoclonal Antibodies Solitaire FR with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Clinical Trial	\$123,466	\$79,635	\$203,101
	Puri, Ajit	COVIDIEN		12/6/2013	12/5/2018			TARGET Intracranial Aneurysm Coiling Registry: A Prospective Clinical Efficacy and Safety Study of MCW Target 360 and Target 2D Coils	\$2,308	\$692	\$3,000
		MCOW		6/7/2013	12/31/2015				\$9,000	\$2,700	\$11,700
		MICROVENTION		2/3/2014	2/2/2019			Pivotal Study of the MicroVention Neurovascular self-Expanding Retrievable Stent System in the Treatment of Intracranial Artery Aneurysms (LVIS)	\$2,500	\$750	\$3,250
		MUSC		4/3/2014	3/31/2018			POSITIVE: Perfusion imaging Selection of Ischemic Stroke Patients EndoVascular Therapy	\$4,615	\$1,385	\$6,000
		STRYKER		2/27/2014	2/26/2019			WEAVE Trial: Wingspan Stent System post Market Surveillance Study	\$4,615	\$1,385	\$6,000
	Vedantham, Srinivasan	NIH	1 R21 CA176470-01	8/1/2013	7/31/2015	4/1/2013	3/31/2014	Quantitative Breast Cancer Risk Index from Routine 3-D Imaging	\$130,500	\$86,892	\$217,392

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Radiology	Wakhloo, Ajay	BSC		2/5/2007	6/30/2015			MAPS Trial: Matrix and Platinum Science A Prospective, Randomized, Multi-center Trial Investigating Matrix and GDC Coils for the Treatment of Intracranial Saccular Aneurysms	\$794	\$206	\$1,000
		MICRUS		5/18/2009	5/17/2034			VISSIT: Vitesse Intracranial Stent Study for Ischemic Therapy	\$540	\$140	\$680
	Zhang, Surong	NIH	1 R21 EB017980-01	12/15/2013	11/30/2015	12/15/2013	11/30/2014	Engineering of multi-functional nucleolin- targeted nucleic acid delivery system	\$125,000	\$83,333	\$208,333
Radiology Total									\$2,240,520	\$1,149,547	\$3,390,067

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Surgery	Anderson, Frederick	PFIZER		4/24/2012	4/23/2014	4/24/2012	4/23/2014	Examination of the Global Longitudinal Study of Osteoporosis in Women-Subset of GLOW	\$74,074	\$25,926	\$100,000
		UAB	000401948-004/NIH	9/1/2011	8/31/2016	9/1/2013	8/31/2014	Activating Patients to Reduce Osteoporosis (APROPOS)	\$118,783	\$76,615	\$195,398
		UEDINBUR	006	4/1/2014	3/31/2015	4/1/2014	3/31/2015	International differences in survival following acute myocardial infarction: Insights from the Global Registry of Acute Coronary Events	\$20,000	\$7,200	\$27,200
		UEDINBUR	001	5/1/2014	4/30/2015	5/1/2014	4/30/2015	A Prediction Model for 30-day Hospital Readmission Following an Acute Coronary Syndrome Estimating the Risk-hospitalization in an International Registry	\$20,000	\$7,200	\$27,200
	Bozorgzadeh, Adel Novartis			2/1/2010	5/11/2013			A 12-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled Everolimus with low dose tacrolimus to Cellcept with standard dose tacrolimus in de novo renal transplant recipients	\$12,853	\$3,342	\$16,195
	Castle, John	AIRXPAND		2/6/2012	6/30/2049			AirXpanders Patient Activated Controlled Tissue Expander System for Breast Reconstruction	\$7,254	\$2,176	\$9,430
	Dunn, Raymond	DAVOL		8/15/2013	8/14/2018			A Prospective, Multi-Center Study of Phasix Mesh for Ventral or Incisional Hernia Repair	\$31,354	\$9,407	\$40,761
	Emhoff, Timothy	SMITH & NEPHEW		10/1/2013	4/30/2014	10/1/2013	4/30/2014	PIG NPWC Safety Evaluation	\$38,290	\$26,803	\$65,093
		BHR		8/10/2010	6/30/2049			A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Progesterone in Patients with Severe Traumatic Brain Injury	\$24,818	\$6,453	\$31,271
		BRUINBIO		8/13/2013	8/12/2018			An Investigational, Non-Significant Risk Study to Collect Data needed to Analyze Readings given by the SEM Scanner Point of Care 200 Series (SEM POC 200) and its Ability to Detect Subepidermal Moisture	\$97,692	\$29,308	\$127,000
	Graeber, Geoffrey	NEOMEND		2/10/2012	2/10/2014			Airtight: A prospective Controlled Post-Approval Study of NeoMend ProGel Pleural Air Leak Sealant in the Treatment of Visible Pleural Air Leaks after Standard Pleural Closure	\$13,497	\$4,049	\$17,546
	Ignotz, Ronald Kelly, John	WPI	12-202760-00	9/1/2011	8/31/2015	9/1/2013	8/31/2014	Patient-Centered Wound Care	\$35,300	\$22,770	\$58,070
		FSF		7/1/2013	6/30/2014	7/1/2013	6/30/2014	2013-2014 Foundation for Surgical Fellowships	\$62,500	\$0	\$62,500
		FSF		7/1/2014	6/30/2015	7/1/2014	6/30/2015	2014-2015 Foundation for Surgical Fellowships	\$50,000	\$0	\$50,000

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Surgery	Kelly, John	GIDYNAM		7/15/2013	7/14/2018			A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Line System vs Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects (ENDO Trial)	\$3,077	\$923	\$4,000
	Litwin, Demetrius	BSC		12/1/2013	8/31/2014	12/1/2013	8/31/2014	Crohn's Disease Needs Finding and Concept Generation	\$73,529	\$26,471	\$100,000
	Messina, Louis	AASTROM		2/14/2012	6/30/2049			A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of IXMYELOCEL-T in Subjects with Critical Limb Ischemia and No Options for Revascularization	\$16,584	\$4,975	\$21,559
		BIOMETBIO		11/13/2013	11/12/2018			MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects with Severe Peripheral Arterial Disease (PAD)	\$7,025	\$2,108	\$9,133
		DERMASC		7/15/2013	7/14/2018			Randomized, Parallel-Group, Double Blind, Vehicle -Controlled Phase III Clinical trial to Evaluate the Effectiveness of DSC127 in Treating Non-Healing Diabetic Foot Ulcers	\$15,528	\$4,658	\$20,186
		NIH	5 R01 HL075353-09	8/1/2010	4/30/2014	5/1/2013	4/30/2014	Mesenchymal Stem Cells in the Treatment of Hindlimb Ischemia in Diabetic Mice	\$235,620	\$151,975	\$387,595
	Robinson, William	DUKE LOMBARD		1/8/2013	6/1/2016			Examining Use of ticagrel in pad	\$14,196	\$4,259	\$18,455
				5/27/2010	6/30/2049			PYTHAGORAS: Prospective Aneurysm Trial: High Angle Aorfix Bifurcated Stent Graft Study	\$2,381	\$619	\$3,000
	Schanzer, Andres	ABBOTT/CV		2/20/2012	6/30/2049			Absolute Pro Self Expanding Stent System and Absolute Pro LL Self Expanding Stent System. A Prospective, Multicenter, Single Arm Clinical Trial	\$10,907	\$3,272	\$14,179
		BOLTONMED		6/1/2011	5/31/2017			A Phase I Clinical Study of the Safety and Performance of the Treovance Stent-Graft with Navitel Delivery System for Patients with Infrarenal Abdominal Aortic Aneurysms	\$2,360	\$708	\$3,068
		BOLTONMED		9/11/2013	9/10/2018			A Phase II Clinical Study of the Safety and Performance of the Treovance Stent-Graft with Navitel Delivery System for Patients with Infrarenal Abdominal Aortic Aneurysms	\$4,000	\$1,200	\$5,200
		COOK		8/25/2009	6/30/2049			Zenith TX2 TAA Endovascular Graft - P070016 Post-Approval Study	\$4,841	\$1,259	\$6,100
		COOK COOK		1/27/2014 9/23/2011	1/26/2019 6/30/2049			Zenith p-Branch Multicenter Study Zenith Fenestrated AAA Endovascular Graft Clinical Study	\$6,538 \$1,505	\$1,962 \$452	\$8,500 \$1,957

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Surgery	Schanzer, Andres	COOK		9/12/2012	6/30/2049			Use of the Zenith Dissection Endovascular System in the Treatment of Patients with Acute, Complicated Type B Aortic Dissection. Protocol CIP 11-007	\$1,615	\$485	\$2,100
		COOK		1/14/2011	6/30/2049			Clinical Study to Evaluate the Safety and Effectiveness of the Zenith Branch Endovascular Graft-Iliac Bifurcation with the Zenith Connection Endovascular Covered Stent	\$3,171	\$825	\$3,996
		MMC		2/24/2014	2/23/2019			Investigational Device Exemption #G130210 Complex Aortic Aneurysm Repair Using Physician-Modified Endografts	\$30,000	\$0	\$30,000
		PROTEON		3/7/2011	6/30/2049			Multi-Center, Double-blind, Placebo-controlled Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients with Chronic Kidney Disease	\$900	\$270	\$1,170
	Tseng, Jennifer	ACS	MRSB-10-003-01-CPHPS	1/1/2010	12/31/2014	1/1/2014	12/31/2014	Determining the Optimal Sequencing Strategy for Pancreatic Cancer Treatment	\$134,815	\$10,785	\$145,600
	Whalen, Giles	AGALIMMUNE		7/1/2013	9/30/2014	1/1/2014	9/30/2014	Agalimmune: Cancer	\$85,567	\$34,227	\$119,794
		MAYO	5U01CA149950-03/NIH	8/3/2011	5/31/2016	6/1/2013	5/31/2014	ACOSOG Community Clinical Oncology Program (CCOP) Research Base	\$12,430	\$8,266	\$20,696
	Surgery Total								\$1,273,004	\$480,948	\$1,753,952

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Gene Therapy Center	Flotte, Terence	AGTC		1/21/2009	1/21/2014			A Multiple Site, Phase I/II Safety and Efficacy Trial of a Recombinant Adeno-Associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients with Leber Congenital Amaurosis Type 2	\$2,994	\$778	\$3,772
		GENZYME		1/1/2013	11/30/2034			A Phase 1, Open-Label, Multi-Center, dose Escalating, Safety & Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients with Neovascular Age-Related Macular Degeneration	\$5,379	\$1,398	\$6,777
	Gao, GuangPing	NIH	5 R01 HL069877-11	7/9/2009	4/30/2014	5/1/2013	4/30/2014	Preclinical and Phase I/II Trials of AAV-AAT Vectors	\$235,620	\$148,999	\$384,619
		NIH	5 R01 DK098252-02	5/27/2013	4/30/2017	5/1/2014	4/30/2015	Dual-function vectors for in vivo gene therapy of AAT Liver disease	\$217,500	\$146,450	\$363,950
		MERCK		8/1/2012	7/12/2014	8/1/2012	7/12/2014	Use of rAAV for target-evaluation: in Vivo Evaluation	\$161,858	\$79,200	\$241,058
		MERCK	8100659915	8/1/2012	7/12/2014	8/1/2012	7/12/2014	Use of rAAV for target-evaluation: shRNA design, cloning, in vitro screening and vector packaging	\$455,684	\$262,489	\$718,173
		NIH	5 R01 NS076991-02	9/1/2012	8/31/2017	9/1/2013	8/31/2014	Novel gene therapy strategies for Canavan disease	\$321,834	\$132,689	\$454,523
		SCRIPPS	5-20598/NIH	12/1/2012	3/31/2017	4/1/2014	3/31/2015	Core B: AVV Core	\$142,593	\$95,893	\$238,486
		SCRIPPS	5-20599/NIH	12/1/2012	3/31/2017	4/1/2014	3/31/2015	Project 2: Minimizing Transgene Clearance	\$180,537	\$121,411	\$301,948
		UFLORIDA	UF13125/NIH	7/1/2013	6/30/2014	7/1/2013	6/30/2014	Safety and efficiency of optimized AAV3 vectors in murine and NHP livers	\$162,623	\$108,145	\$270,768
		UPENN	552448/NIH	7/1/2009	6/30/2014	7/1/2013	6/30/2014	Project III, Molecular Biology of AAV in Liver	\$211,727	\$140,798	\$352,525
		Khanna, Hemant	FFB	BR-CMM-0612-0578-UMA	6/30/2012	6/29/2015	6/30/2014	6/29/2015	Molecular Mechanisms and Treatment Strategies for CEP290-Mediated Severe Early Onset Retinal Degeneration in Leber Congenital Amaurosis	\$100,000	\$0
	NIH		5 R01 EY022372-03	5/1/2012	4/30/2017	5/1/2014	4/30/2015	Function of ciliary disease protein Retinitis Pigmentosa GTPase Regulator (RPGR)	\$245,000	\$164,967	\$409,967
	NNRI/FFB		C-CMM-0710-0499-UMAS	7/1/2010	6/30/2015	7/1/2013	6/30/2014	Molecular Mechanisms of Pathogenesis of X-linked Retinal Dystrophies, Module IV	\$45,261	\$0	\$45,261
	Mueller, Christian	ALPHA1		12/1/2012	12/31/2014	1/1/2014	12/31/2014	Resurrection and Characterization of a PiZ specific Antibody	\$50,000	\$0	\$50,000
		NIH	1 R24 OD018259-01	5/15/2014	2/28/2018	5/15/2014	2/28/2015	Development and Validation of Novel NSG Mouse Models for Human Stem Cell Therapy	\$100,000	\$67,376	\$167,376
	Punzo, Claudio	IRRFI		10/1/2013	9/30/2014	10/1/2013	9/30/2014	Modulation of the mTOR pathway: A novel approach to extend vision in dry Age-related Macular Degeneration	\$91,857	\$4,593	\$96,450
		NIH	1 R01 EY023570-01	8/1/2013	7/31/2018	8/1/2013	7/31/2014	Delaying Cone Death in Retinitis Pigmentosa	\$250,000	\$159,800	\$409,800
Gene Therapy Center Total									\$2,980,467	\$1,634,986	\$4,615,453

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Program in Systems Biology	Dekker, Job	HFSP	RGP0044/2011	12/1/2011	11/30/2014	12/1/2013	11/30/2014	Conformational changes of chromosomes during the cell cycle	\$90,909	\$9,091	\$100,000
		NIH	5 R01 HG003143-09	8/22/2011	5/31/2015	6/1/2013	5/31/2014	Structural Annotation of the Human Genome	\$446,485	\$287,983	\$734,468
		UWASH	755783/NIH	9/21/2012	7/31/2016	8/1/2013	7/31/2014	A Comprehensive Catalog of DNaseI Hypersensitive Sites	\$101,990	\$67,313	\$169,303
	Fuxman Bass, Juan	PEW TRUSTS	00002932	8/1/2012	7/31/2014	8/1/2013	7/31/2014	A Human Cytokine Gene Regulatory Network	\$30,000	\$0	\$30,000
	Kaplan, Noam	HFSP	LT000706/2012	4/1/2012	3/31/2015	4/1/2014	3/31/2015	The Three-dimensional Organization of spermatozoan Chromosomes	\$60,300	\$0	\$60,300
	McCord, Rachel	NIH	5 F32 GM100617-02	2/1/2012	1/31/2014	2/1/2013	1/31/2014	The Effects of Physical Disruption on Genome Organization and Integrity	\$52,190	\$0	\$52,190
	Ritter, Ashlyn	NIH	5 F31 AG041605-03	9/30/2011	9/29/2016	9/30/2013	9/29/2014	Insulin Networks in aging and obesity	\$30,422	\$0	\$30,422
	Walhout, Albertha	NIH	1 R01 GM104904-01A1	6/1/2014	3/31/2018	6/1/2014	3/31/2015	microRNA gene networks regulating responses to environment	\$101,834	\$68,653	\$170,487
		NIH	5 R01 GM082971-06	4/1/2013	3/31/2017	4/1/2014	3/31/2015	Gene regulatory network structure, function and evolution	\$463,749	\$257,120	\$720,869
		NIH	5 R01 DK068429-09	9/15/2010	8/31/2014	9/1/2013	8/31/2014	Gene Regulatory Networks in Development and Physiology	\$333,269	\$214,959	\$548,228
Program in Systems Biology Total									\$1,711,148	\$905,119	\$2,616,267

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
RNA Therapeutics Institute	Bicknell, Alicia	HHWF	F-1028	12/1/2011	11/30/2014	12/1/2013	11/30/2014	TASeD at the Synapse: Understanding the Role of Translation-dependent mRNA	\$54,500	\$0	\$54,500
	Braun, Joerg	HFSP	LT000166/2013	6/1/2013	5/31/2016	6/1/2014	5/31/2015	Single-molecular analysis of human spliceosome assembly	\$53,640	\$0	\$53,640
	Grunwald, David Khvorova, Anastasia	UUTAH	10027535-10-M/NIH	2/1/2013	7/31/2014	8/1/2013	7/31/2014	Single Molecule Imaging of HIV	\$62,564	\$41,605	\$104,169
		NOVARTIS		5/15/2013	5/14/2016	5/15/2014	5/14/2015	Inter and intra-cellular trafficking pathways for natural and therapeutic oligonucleotides	\$122,910	\$86,037	\$208,947
	Korostelev, Andrei	NIH	5 R01 GM106105-02	8/1/2013	5/31/2018	6/6/2014	5/31/2015	Structural bases for cellular stress responses mediated by stalled translation	\$190,000	\$128,092	\$318,092
	Lee, Heng-Chi	NIH	5 F32 GM099372-03	8/1/2011	7/31/2014	8/1/2013	7/31/2014	Investigating the Biogenesis and Function of piRNAs in Germline Development	\$55,670	\$0	\$55,670
	Li, Xin	NIH	1 K99 HD078482-01	11/25/2013	10/31/2015	11/25/2013	10/31/2014	Dissect the piRNA regulatory mechanism during spermatogenesis	\$83,333	\$6,667	\$90,000
	Limoncelli, Kelly	NIH	1 F31 GM109753-01	1/6/2014	1/5/2018	1/6/2014	1/5/2015	Investigating the functional roles of RPS3 in RNA and DNA damage	\$29,231	\$0	\$29,231
	Mello, Craig	HUGHES		9/1/2000	8/31/2014	9/1/2013	8/31/2014	Howard Hughes Medical Institute	\$752,913	\$318,872	\$1,071,785
		NIH	5 R01 GM058800-16	4/1/2011	3/31/2015	4/1/2014	3/31/2015	RNA Mediated Genetic Interference in C. Elegans	\$210,000	\$135,450	\$345,450
	Moore, Melissa	GATES	OPP1086170	8/30/2013	9/30/2015	8/30/2013	9/30/2015	siRNA based Therapeutics for Preeclampsia	\$907,304	\$90,730	\$998,034
		HUGHES MODERNA		9/1/2007	8/31/2014	9/1/2013	8/31/2014	Howard Hughes Medical Institute	\$721,027	\$276,760	\$997,787
	Saini, Harleen			2/25/2014	2/24/2015	2/25/2014	2/24/2015	Modernera Sponsored Research Agreement	\$240,000	\$160,000	\$400,000
		NIH	5 R01 GM053007-18	1/15/2011	12/31/2014	1/1/2014	12/31/2014	Pre-mRNA Splicing Mechanisms	\$236,285	\$152,404	\$388,689
	Seth, Meetu	HUGHES		9/1/2013	8/31/2016	9/1/2013	8/31/2014	Investigating the function of partially-spliced and/or unspliced Mrna transcripts	\$43,000	\$0	\$43,000
								Investigate how Small RNA pathways distinguish between self and non-self transcripts in the c. elegans germline	\$43,000	\$0	\$43,000
	Zamore, Phillip	HUGHES		9/1/2008	8/31/2014	9/1/2013	8/31/2014	Howard Hughes Medical Institute	\$687,640	\$286,205	\$973,845
		NIH	1 DP7 OD018421-01	9/20/2013	8/31/2018	9/20/2013	8/31/2014	An Integrated Curriculum and Community-Based Approach to Career Development [MPI]	\$0	\$0	\$0
		NIH	5 R01 HD049116-10	3/18/2010	1/31/2015	2/1/2014	1/31/2015	piRNA biogenesis and function in germline development [MPI]	\$18,368	\$11,847	\$30,215
		NIH	5 R01 GM065236-12	1/10/2011	12/31/2014	1/1/2014	12/31/2014	Understanding microRNA Biogenesis and Function	\$306,304	\$197,566	\$503,870
		NIH	5 R37 GM062862-13	7/1/2010	6/30/2015	7/1/2013	6/30/2014	Understanding the Mechanism of RNA Interference	\$291,174	\$187,807	\$478,981
RNA Therapeutics Institute Total									\$5,108,863	\$2,080,042	\$7,188,905

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Diabetes Center of Excellence	Brehm, Michael	JDRF	2-2011-416	8/1/2011	7/31/2016	8/1/2013	7/31/2014	Immune therapy for beta-cell replacement in mice with human immune systems	\$136,364	\$13,636	\$150,000
		NIH	5 P01 AI046629-14	6/1/2010	5/31/2015	6/1/2014	5/31/2015	Viral Infection Influence on Transplantation Tolerance: Core A	\$83,745	\$54,016	\$137,761
	Greiner, Dale	HARVARD	108960/JDRF	2/1/2013	1/31/2015	2/1/2014	1/31/2015	Improved Mass Transport to Maximize Function of Encapsulated Beta Cells	\$90,000	\$9,000	\$99,000
		HELMSLEY	2012-PG-T1D018	9/1/2012	8/31/2015	9/1/2013	8/31/2014		\$415,867	\$29,087	\$444,954
		JACKSON		11/1/2012	10/31/2014	11/1/2013	10/31/2014	Humanized mice for the study of iPS cells Optimization of Humanized Mice for Engraftment and Immunity	\$136,364	\$13,636	\$150,000
		NIH	1 R21 AI112321-01	2/1/2014	1/31/2016	2/1/2014	1/31/2015	Retrogenic humaized mice for the study of T1D	\$187,500	\$83,854	\$271,354
		NIH	1 R24 OD018259-01	5/15/2014	2/28/2018	5/15/2014	2/28/2015	Development and Validation of Novel NSG Mouse Models for Human Stem Cell Therapy	\$444,263	\$168,783	\$613,046
		NIH	5 P01 AI046629-14	6/1/2010	5/31/2015	6/1/2014	5/31/2015	Viral Infection Influence on Transplantation Tolerance: Project 1	\$318,212	\$205,246	\$523,458
		NIH	5 P01 AI046629-14	6/1/2010	5/31/2015	6/1/2014	5/31/2015	Viral Infection Influence on Transplantation Tolerance: Core B	\$88,217	\$56,901	\$145,118
		NIH	HHSN2722010000341	3/22/2010	3/21/2017	3/22/2014	3/21/2015	Humanized Mice as Small Animal Models of Infectious Agents	\$0	\$0	\$0
		VAN	5U01DK089572-04/NIH	9/10/2010	6/30/2015	7/1/2013	6/30/2014	Molecular Mechanisms of Human and Murine Beta Cell Proliferation and Regeneration	\$38,558	\$25,464	\$64,022
	Maehr, Rene	HELMSLEY	2014PG-T1D026	2/1/2014	7/31/2014	2/1/2014	7/31/2014		\$150,000	\$15,000	\$165,000
		HELMSLEY	2012PG-T1D041	2/1/2013	1/31/2014	2/1/2013	1/31/2014	Development of Thymic Epithelial Cells Identification of small molecules that promote the differentiation of pluripotent stem cell-derived anterior foregut to pharyngeal pouch fates	\$250,000	\$25,000	\$275,000
		HOOD		1/1/2014	12/31/2015	1/1/2014	12/31/2014	Development of a Pluripotent Stem Cell-based Approach to model DiGeorge Syndrome	\$68,182	\$6,818	\$75,000
Diabetes Center of ExcellenceTotal									\$2,407,272	\$706,441	\$3,113,713

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
MASS Biologics of UMMS	Cavacini, Lisa	NIH	7 R01 AI106478-02	5/1/2014	4/30/2017	5/1/2014	4/30/2015	Mechanism of Potent Neutralization of HIV by IgA CD4i Antibody	\$289,400	\$75,244	\$364,644
	Klempner, Mark	CRDF	TKB1-31126-IS-13	1/1/2013	12/31/2013	2/15/2014	2/14/2015	Collaborative Initiation of a Human Monoclonal Antibody Development Project for Crimean Congo Hemorrhagic Fever Post-Exposure Prophylaxis and Treatment	\$4,545	\$455	\$5,000
		DARPA	W911NF-13-1-0346	7/1/2013	5/30/2017	7/1/2013	8/31/2014	Vectored Delivery of Oligoclonal Antibodies for Protection Against EMDD	\$2,500,692	\$213,264	\$2,713,956
	Reimann, Keith	NIH	HHSN272201300031C	9/29/2013	9/28/2014	9/29/2013	9/28/2014	Non-Human Primate Reagent Resources	\$1,484,267	\$325,837	\$1,810,104
		NIH	5 R24 OD010976-15	6/4/2013	4/30/2015	5/1/2014	4/30/2015	Resource for Nonhuman Primate Cell Depleting Antibodies	\$548,376	\$122,414	\$670,790
	Wang, Rijian	EMORY	T142870/NIH	8/1/2013	7/31/2017	8/1/2013	7/31/2014	Transplant Tolerance in Nonhuman Primates	\$26,212	\$6,328	\$32,540
MASS Biologics of UMMS Total									\$4,853,492	\$743,542	\$5,597,034

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Meyers Primary Care Institute	Andrade, Susan	HPHC	HHSF22301001T	8/21/2013	8/20/2014	8/21/2013	8/20/2014	Maintenance and Operation of Medication Exposure in Pregnancy Risk Evaluation Program	\$10,926	\$7,284	\$18,210
		HPHC	HHSF22301007T-0012	6/13/2014	7/30/2015	6/13/2014	7/30/2015	Adverse Metabolic Effects of Second Generation Antipsychotics in Youth Sub-project 3 Examining Longitudinal Change in BMI for Youth Initiative	\$8,863	\$5,956	\$14,819
		HPHC	HHSF22301013T-0002	4/8/2013	4/7/2014	4/8/2013	4/7/2014	Influenza Vaccines and Birth Outcomes	\$17,205	\$11,570	\$28,775
		HPHC	T.O. HHSF2232009T-0012	9/23/2013	9/22/2014	9/23/2013	9/22/2014	Mini-Sentinel Year 5 Infrastructure	\$53,664	\$35,776	\$89,440
		HPHC	HHSF22301006T-0009	5/1/2014	11/30/2014	5/1/2014	11/30/2014	Protocol-based Assessment of Thromboembolic Events after Immunoglobulin Administration-Chart Validation	\$1,576	\$1,062	\$2,638
		HPHC	HHSF22301006T-0005	8/15/2013	1/31/2015	8/15/2013	1/31/2015	Protocol-based Assessment of Thromboembolic Events after Immunoglobulin Administration	\$4,381	\$2,920	\$7,301
		HPHC	HHSF22301007T-0005-2	10/1/2013	6/30/2014	10/1/2013	6/30/2014	Parental Iron Procedure and Anaphylactoid Reactions	\$73,722	\$49,025	\$122,747
		HPHC	HHSF22301007T-0011	10/1/2013	6/30/2014	10/1/2013	6/30/2014	Identification of Pregnant Women in the MS Distributed Database on Live Birth and Determination of Drug Use	\$3,423	\$2,277	\$5,700
		HPHC		12/18/2013	5/17/2015	12/18/2013	5/17/2015	A Protocol-based Assessment of Selected Medications and Death, with Linkage of MS Distributed Database with NDI+	\$12,279	\$8,240	\$20,519
		HPHC	HHSF22301007T-0000	11/1/2013	9/30/2015	11/1/2013	9/30/2014	Analytical Support for Workgroup Activities on Task Oder 7	\$8,965	\$5,991	\$14,956
	Cutrona, Sarah	KAISER	115-9341-MPCI-04/NIH	9/1/2013	8/31/2014	9/1/2013	8/31/2014	Building the capability to conduct population-based research on cancer drug pregnancy	\$3,010	\$2,007	\$5,017
		PFIZER		1/1/2014	6/30/2016	1/1/2014	12/31/2014	System Alignment for VaccinE Delivery (SAVED)	\$230,097	\$37,108	\$267,205
		KAISER	115-9341-MPCI-03/NIH	9/1/2013	8/31/2014	9/1/2013	8/31/2014	Are 2 Jars Sufficient for Pathology Examination of Extended Core Prostrate Biopsy?	\$32,312	\$21,541	\$53,853
	Epstein, Mara	KAISER	115-9341-MPCI-02/NIH	4/1/2013	8/31/2014	9/1/2013	8/31/2014	CRN Scholars Award	\$13,118	\$8,746	\$21,864
		RTI Triangle	15-312-0211965-51702L	11/22/2013	6/30/2014	11/22/2013	6/30/2014	Cost of Colorectal Cancer Treatment by Stage at Diagnosis and Insurance Status	\$6,558	\$4,361	\$10,919
		ADGAP		7/1/2013	6/30/2015	7/1/2013	6/30/2014	Chief Resident Immersion Training (CRIT) Program	\$34,091	\$3,409	\$37,500
	Gurwitz, Jerry	AHRQ	5 R18 HS020831-03	7/1/2012	4/30/2015	5/1/2014	4/30/2015	Improving Indwelling Catheter Use to Reduce CAUTI in the Nursing Home	\$338,182	\$154,705	\$492,887
		NIH	5 R21 AG045320-02	9/1/2013	5/31/2015	6/1/2014	5/31/2015	Impact of Comorbidity Dyads on Heart Failure Treatment in Older Persons	\$141,658	\$76,142	\$217,800
		AHRQ	1 R18 HS022757-01	9/30/2013	7/31/2018	9/30/2013	9/29/2014	Detecting, Addressing and Learning From Patient-Perceived Breakdowns in Care	\$427,313	\$68,128	\$495,441
	Mazor, Kathleen	BAystate	1R18HL108810-01/NIH	8/3/2011	7/31/2016	8/1/2013	7/31/2014	Implementation and Outcomes of Non-Invasive Ventilation in COPD	\$14,368	\$9,267	\$23,635

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Meyers Primary Care Institute	Mazor, Kathleen	BAYSTATE	FED724-12270-01/AHRQ	10/15/2012	8/31/2015	9/1/2013	8/31/2014	Reducing Disparities in the Use of Publicly Reported Quality Measures	\$8,101	\$5,225	\$13,326
		KFRI	5-P20-CA137219/NIH	9/1/2011	8/31/2014	9/1/2013	8/31/2014	Patient Centered-Communication and Care Coordination	\$45,787	\$30,525	\$76,312
		KFRI	115-9341-MPCI-01/NIH	9/25/2012	8/31/2017	9/1/2013	8/31/2014	CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems	\$106,488	\$70,992	\$177,480
		UMICHIGAN	3003018835/NIH	3/1/2014	2/28/2016	3/1/2014	2/28/2015	A Stroke Preparedness Assessment Instrument	\$17,381	\$11,689	\$29,070
Meyers Primary Care Institute Total									\$1,613,468	\$633,946	\$2,247,414

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Program in Bioinformatics & Integrative Biology	Bailey, Jeffrey	NIH	5 R01 AI099473-02	8/27/2012	7/31/2016	8/1/2013	7/31/2014	Human copy number polymorphism and severe malaria	\$332,749	\$221,555	\$554,304
		UNCAROLINA	5-34141/NIH	2/11/2014	1/31/2016	2/11/2014	1/31/2015	Dissecting Chloroquine Resistance in the Plasmodium vivax Cross	\$48,858	\$32,776	\$81,634
	Garber, Manuel	BROADINST	7010033-5500000589/NIH	9/1/2012	4/30/2014	5/1/2013	4/30/2014		\$49,081	\$32,394	\$81,475
		DARPA	D13AP00074	9/1/2013	8/31/2014	9/1/2013	8/31/2014	Center for Cell Circuits Evolutionary profiling of the transcriptional and post-transcriptional wiring of the circadian clock in normal and perturbed conditions	\$107,565	\$50,377	\$157,942
		NIH	1 R01 HD080224-01A1	4/14/2014	2/28/2019	4/14/2014	2/28/2015		\$60,310	\$40,608	\$100,918
		UMASS/AMHERST		7/1/2012	6/30/2015	7/1/2012	6/30/2014	Dietary effects on the sperm epigenome	\$22,500	\$0	\$22,500
	Weng, Zhiping	ALSTA	2013-F-069	5/1/2014	4/30/2016	5/1/2014	4/30/2015	Designating Cloud and Big Data Platform for Data-intensive Scientific Applications Genome-wide Mapping of Chromatin Modifications in Mice Expressing ALS Mutant FUS/TLS [MPI]	\$36,424	\$0	\$36,424
		BU	4500001134/NIH	7/1/2011	3/31/2016	5/1/2014	4/30/2015		\$68,006	\$43,864	\$111,870
		BU	4500001647/NIH	9/1/2010	6/30/2014	7/1/2013	6/30/2014	Epigenetic Markers of HD Brain	\$22,095	\$14,251	\$36,346
		NIH	5 R01 HD049116-10	3/18/2010	1/31/2015	2/1/2014	1/31/2015	Single Molecule Sequencing by Nanopore Induced Photon Emission (SM-SNIPE)	\$10,335	\$6,666	\$17,001
		NIH	3 U41 HG007000-02S1	9/21/2012	7/31/2016	8/1/2013	7/31/2014	piRNA biogenesis and function in germline development [MPI]	\$99,035	\$16,645	\$115,680
		NIH	5 U41 HG007000-02	9/21/2012	7/31/2016	8/1/2013	7/31/2014	EDAC: ENCODE Data Analysis Center	\$1,676,922	\$194,917	\$1,871,839
		NIH	5 R01 GM103773-02	4/1/2013	3/31/2017	4/1/2014	3/31/2015	EDAC: ENCODE Data Analysis Center	\$236,867	\$64,740	\$301,607
	Zeldovich, Konstantin	DARPA	D13 AP00041	4/30/2013	4/29/2016	4/30/2013	4/29/2014	Development of a Computational Framework for TCR Engineering	\$149,786	\$99,483	\$249,269
								Robust Analysis and Prediction of Influenza Reassortment (RAPleR)			
Program In Bioinformatics & Integrative Biology Total									\$2,920,533	\$818,276	\$3,738,809

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Program in Gene Function & Expression	Acharya, Usha	NIH	5 R01 EY016469-08	4/1/2011	3/31/2015	4/1/2013	3/31/2014	Ceramide Metabolism and Photoreceptor Homeostasis	\$213,750	\$137,869	\$351,619
	Bach, Ingolf Michael	NIH	5 R01 CA131158-07	4/1/2013	3/31/2018	4/1/2014	3/31/2015	Regulation of mammary gland biology by RLIM/Rnf12 and the paternal X chromosome	\$195,237	\$131,296	\$326,533
	Bai, Robert	HUGHES	57007734	8/30/2013	8/29/2014	8/30/2013	8/29/2014	Exploring the potential of IGFBP7 as a therapeutic treatment for BRAF(V600E)-positive melanoma	\$40,000	\$0	\$40,000
	Benanti, Jennifer	RSSFF		3/1/2012	2/28/2015	3/1/2014	2/28/2015	Mapping the Proteolytic Regulatory Network that Controls Cell Division	\$95,238	\$4,762	\$100,000
	Castilla, Lucio	ASH		8/1/2013	7/31/2014	8/1/2013	7/31/2014	Cooperating Genes in inv(16) Acute Myeloid Leukemia	\$100,000	\$0	\$100,000
	Fazzio, Thomas	CONCERN		7/1/2012	6/30/2014	7/1/2013	6/30/2014		\$60,000	\$0	\$60,000
		NIH	5 R01 HD072122-03	8/15/2012	4/30/2018	5/1/2014	4/30/2015	Function of the Mbd3/NURD chromatin remodeling complex in myeloid leukemias	\$201,690	\$135,805	\$337,495
		PEW TRUSTS	2010-000224-002	7/1/2011	6/30/2016	7/1/2013	6/30/2014	Roles of Chromatin Regulation in Embryonic Stem Cell Self-Renewal	\$55,556	\$4,444	\$60,000
	Gottlinger, Heinrich	NIH	1 DP1 DA038034-01	6/1/2014	5/31/2019	6/1/2014	5/31/2015	Chromatin Regulatory Networks in stem Cell Self Renewal	\$500,000	\$336,875	\$836,875
		NIH	2 R01 AI029873-26	6/1/2014	5/31/2019	6/1/2014	5/31/2015	Mechanism of HIV Cell-Cell Transmission of Relevance to Substance Users	\$343,144	\$231,337	\$574,481
	Green, Michael	HUGHES		9/1/1997	8/31/2014	9/1/2013	8/31/2014	Molecular Biology of HIV-Gag Proteins	\$850,069	\$520,593	\$1,370,662
		NIH	1 R01 CA163926-01A1	9/11/2013	6/30/2018	9/11/2013	6/30/2014	Howard Hughes Medical Institute Identification and Characterization of Genes that Suppress BCR-ABL+ Leukemia	\$207,500	\$137,988	\$345,488
		NIH	5 R01 GM035490-28	4/1/2010	3/31/2015	4/1/2013	3/31/2014		\$191,070	\$123,240	\$314,310
		NIH	5 R01 GM033977-28	4/1/2010	3/31/2015	4/1/2013	3/31/2014	Splicing of mRNA Precursors	\$181,517	\$117,079	\$298,596
		RETT		5/1/2013	4/30/2016	5/1/2014	4/30/2015	Mechanisms of Eukaryotic Transcriptional Regulation	\$227,709	\$22,771	\$250,480
	Hainer, Sarah	LEUKEMIA	5219-14	7/1/2013	6/30/2016	7/1/2013	6/30/2014	Reactivation of the Inactive X-linked MECP2 Gene as a Therapeutic Strategy for Rett Syndrome	\$52,381	\$2,619	\$55,000
								Functional interplay between 5hmc and the NURD complex in regulating ESC state			
	Kaufman, Paul	NIH	5 R01 GM055712-16	8/1/2011	7/31/2015	8/1/2013	7/31/2014	Regulation of repetitive chromatin structures during the human cell cycle	\$234,013	\$150,939	\$384,952
	Lawson, Nathan	AHA	13IRG14770046	1/1/2013	12/31/2014	1/1/2014	12/31/2014	A screen for transcriptional regulators of artery identity	\$68,182	\$6,818	\$75,000
		HANMS		1/1/2014	11/30/2018	1/1/2014	6/30/2015		\$130,644	\$13,064	\$143,708
		NIH	5 R01 HL093467-05	4/6/2009	6/30/2014	4/1/2013	3/31/2014	Network for Vascular MicroRNAs	\$235,620	\$151,975	\$387,595
		NIH	5 R01 HL101374-09	7/1/2010	11/30/2014	6/1/2013	5/31/2014	Role of Notch in Artery Development	\$235,620	\$151,975	\$387,595
		NIH	5 R01 HL079266-09	7/1/2010	12/30/2014	7/1/2013	6/30/2014	Transcriptional Control of Endothelial Differentiation	\$235,620	\$151,975	\$387,595
		NIH	2 R01 HL093766-06	8/1/2013	7/31/2018	8/1/2013	7/31/2014	Reverse Genetic Screening for Vascular Mutants Using Zinc Finger Nucleases	\$0	\$0	\$0
								Using site-specific nucleases to manipulate the zebrafish genome (MPI)			

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Program in Gene Function & Expression	Lewis, Brian	NIH	5 R01 CA155784-04	4/8/2011	3/31/2016	4/1/2014	3/31/2015	Dissecting Hedgehog, TGF Beta and BMP Signaling During Pancreatic Tumorigenesis	\$199,099	\$113,561	\$312,660
	Pulikkan, John	ASH		7/1/2012	6/30/2014	7/1/2013	6/30/2014	The role of Runx2 in Hematopoietic Stem Cells and Acute Myeloid Leukemia	\$50,000	\$0	\$50,000
	Quattrochi, Brian	NIH	5 F30 CA168063-03	4/1/2012	3/31/2016	4/1/2014	3/31/2015	Roles of MiR-17-92 Cluster MicroRNAs in K-Ras-Induced Pancreatic Tumorigenesis	\$29,190	\$0	\$29,190
	Tissenbaum, Heidi	NIH	5 R01 AG025891-10	7/1/2010	5/31/2015	6/1/2014	5/31/2015	Life span, Fat Storage and Insulin-like Signaling	\$197,046	\$127,095	\$324,141
	Torres, Eduardo	RSSFF		12/1/2012	11/30/2015	12/1/2013	11/30/2014	Role of Protein Turnover Pathways in Aneuploid Cells	\$95,238	\$4,762	\$100,000
		SEARLE	13-SSP-268	7/1/2013	6/30/2016	7/1/2013	6/30/2014	Role of Protein Turnover Pathways in Aneuploid Cells	\$100,000	\$0	\$100,000
	Tupler, Rossella	MDA	MDA240880	8/1/2012	7/31/2014	8/1/2013	7/31/2014	Dissecting the Complexity of FSHD Molecular Pathogenesis	\$118,182	\$11,818	\$130,000
	Wang, Yong-Xu	ADA	7-13-BS-179-BR	11/1/2013	10/31/2014	11/1/2013	10/31/2014	MicroRNA-378 controls brown fat expansion and function	\$52,174	\$7,826	\$60,000
		NIH	2 R01 DK076118-06A1	7/1/2013	5/31/2017	7/1/2013	5/31/2014	Regulation of brown fat metabolism by histone demethylation	\$217,500	\$144,638	\$362,138
	Wolfe, Scot	NIH	2 R01 HL093766-06	8/1/2013	7/31/2018	8/1/2013	7/31/2014	Using site-specific nucleases to manipulate the zebrafish genome (MPI)	\$238,000	\$158,270	\$396,270
Program in Gene Function & Expression Total									\$5,950,989	\$3,101,394	\$9,052,383

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Cancer Research Office (CRO)	Bathini, Venu	CELGENE		3/6/2014	3/5/2019			MPACT Extension Study: Multicenter, Survival Data Collection in Subjects previously Enrolled in Protocol CA046	\$3,462	\$1,038	\$4,500
		HALOZYME		8/7/2013	8/6/2018			A Phase 2, Randomized, Multicenter Study of PEGPH20 Combined with nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer	\$11,979	\$3,594	\$15,573
		MEDPACE		3/26/2012	6/30/2049			A randomized Phase 2 study of Ruxolitinib Efficacy and safety in combination with Capecitabine for subjects with recurrent or treatment refractory metastatic Pancreatic cancer (The RECAP trial)	\$5,219	\$1,566	\$6,785
		THRESHOLD		10/28/2011	6/30/2049			A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination with Gemcitabine Compared with Gemcitabine Alone in Previously Untreated Patients with Locally Advanced Unresectable or Metastatic Pancreatic Canc	\$5,034	\$1,309	\$6,343
	Brettler, Doreen	GENENTECH		7/1/2013	6/30/2018			A Phase II, Open-label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients with Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated with GA101 (RO5072759) in Combination with CHOP	\$14,369	\$4,311	\$18,680
		JANSSEN		9/27/2012	3/30/2016			A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress After Bortezomib Therapy	\$7,984	\$2,395	\$10,379
		NORTHWESTEF/NIH		3/8/2012	12/31/2013			A Phase II Trial of Sequential SGN-35 Therapy with Adriamycin, Vinblastine, and Dacarbazine (SAVD) for Older Patients with Untreated Hodgkin Lymphoma	\$5,516	\$1,104	\$6,620
	Cerny, Jan	ALPHA		7/31/2013	7/30/2018			Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission	\$5,962	\$1,788	\$7,750
		ARIAD		7/10/2013	7/9/2018			A Phase 3 Randomized, Open-Label Study of Ponatinib VS Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase	\$6,354	\$1,906	\$8,260
		BRISTOL		12/16/2013	12/15/2018			Phase I Study to Evaluate the Safety of Zileuton in Combination with Dasatinib in Patients with Chronic Phase of Cronic Myelogenous Leukemia	\$7,769	\$2,331	\$10,100

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Cancer Research Office (CRO)	Cerny, Jan	BRISTOL		4/9/2012	6/30/2049			Studying Interventions for managing patients with chronic myeloid leukemia in chronic phase: The 5-Year prospective cohort study (SIMPLICITY)	\$2,105	\$631	\$2,736
		CELGENE		7/25/2013	7/24/2018			A Phase 3, Randomized, Double-Blind Placebo Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care VS Best Support Care as Maintenance Therapy	\$6,354	\$1,906	\$8,260
		CELLERANT		11/17/2011	6/30/2049			A Phase I/II trial of CLT-008 myeloid progenitor cells in patients receiving post-remission therapy for acute leukemia or high risk myelodysplasia	\$105,120	\$31,536	\$136,656
		JANSSEN		9/3/2013	9/2/2018			An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects with Relapsed or Refractory Mantle Cell Lymphoma	\$3,769	\$1,131	\$4,900
		NMDP	/NIH	10/1/2009	6/30/2049			A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life	\$1,723	\$517	\$2,240
		Novartis		1/15/2013	4/30/2016			An open-label Phase II Study of BKM120 in Patients with Relapsed and Refractory Diffuse large B-cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma	\$7,508	\$2,252	\$9,760
		PFIZER		8/27/2013	8/26/2018			An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)	\$6,354	\$1,906	\$8,260
	Evens,Andrew M	MILLENNIUM		7/12/2013	7/11/2018			A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma	\$308	\$92	\$400
	Kasturi, Vijay	AVEO		2/7/2013	6/30/2049			Treated with Rituximab and Vincristine A Phase 2 Randomized, Double-blind, Crossover, Controlled, Multi-center, Subject Preference Study of Tivozanib Hydrochloride versus Sunitinib in the Treatment of Subjects with Metastatic Renal Cell Carcinoma	\$23,689	\$7,106	\$30,795
		FST		6/1/2011	6/30/2049			Frontier Science and Technology Research Foundation as the Coordinating Center for the ECOG FSTRF Contract No. PSAUMWAE00	\$65,634	\$19,690	\$85,324
	Nath, Rajneesh	CSS		11/11/2012	6/30/2049			A Multi-Center Phase Ib, Open-Label Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone	\$3,654	\$1,096	\$4,750

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Cancer Research Office (CRO)	Nath, Rajneesh	GLAXOSMITH		11/22/2010	11/21/2035			A Phase 1 Study to Evaluate the Safety and Clinical Activity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic in Adult Patients with WT1-positive Acute Myeloid Leukemia in Partial Remission or Complete Remission	\$4,132	\$1,074	\$5,206
		GLAXOSMITH		11/11/2010	11/10/2035			A Phase 1 Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic as Post-Consolidation Therapy in Elderly Patients with WT1-positive Acute Myeloid Leukemia in First Complete Remission.	\$7,765	\$2,019	\$9,784
		LIGAND		1/18/2013	6/30/2049			A Phase IIb, Multicenter, Open-Label, Safety and Efficacy Study of High Dose Melphalan HCl for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation	\$141,535	\$42,460	\$183,995
		NMDP		10/22/2010	10/21/2035			Transplant Center Participation Agreement between National Marrow Donor Program (NMDP) and University of Massachusetts-Worcester ("Transplant Center")	\$6,254	\$1,876	\$8,130
	Ramanathan, Muthalagu	CELGENE		7/25/2013	7/24/2018			A Phase 3, Multicenter, Randomized, Doubleblind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care	\$6,354	\$1,906	\$8,260
		CELGENE		7/11/2013	7/10/2018			A phase II multicenter, single-arm, open-label study to determine the efficacy and safety of single-agent, lenalidomide (Revlimid) in subjects with Mantle Cell Non-Hodgkin's Lymphoma who have relapsed or progressed after treatment with bortezomib	\$738	\$222	\$960
		GLAXOSMITH		7/25/2013	12/31/2020			A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment VS No Further Treatment in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL) who have responded to Induction Therapy	\$6,154	\$1,846	\$8,000
		JANSSEN		12/17/2012	11/1/2018			Randomized, Double-blind Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (Btk) Inhibitor, in combination with Bendamustine and Rituximab (BR) in Subjects with Relapsed or Refactory Chronic B-Cell Lymphocytic Leukemia	\$11,912	\$3,574	\$15,486

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Cancer Research Office (CRO)	Ramanathan, Muthalagu	PHARMACYC		6/18/2013	6/30/2049			A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosene Kinase Inhibitor PCI-32765 VS Chlorambucil in Patients 65 or Older with Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	\$8,841	\$2,652	\$11,493
		SPECTRUM		3/13/2012	6/30/2049			A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin versus Zevalin and Motexafin Gadolinium in Patients with Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma	\$8,064	\$2,420	\$10,484
	Siddiqui, Ahmad	MERCK		1/18/2013	6/30/2049			A Double-Blind, Randomized, Phase II Study of MK-3475 VS Chemotherapy in Patients with Ipilimumab Refractory Advanced Melanoma	\$8,989	\$2,697	\$11,686
	Switzer, Bradley	BAYERHEALTH		8/14/2013	8/13/2018			A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study of Regorafenib in Patients with Hepatocellular Carcinoma (HCC) after Sorafenib	\$6,354	\$1,906	\$8,260
	Toke, Madhavi	ASTRAZENECA		8/5/2013	8/4/2018			A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to compare the Efficacy and Tolerability of Fulvestrant 500 mg with Anastrozole 1 mg as Hormonal Treatment for Postmenopausal Women	\$6,354	\$1,906	\$8,260
	Walsh, William	MERCK		1/2/2014	1/1/2019			Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Histology Non-Small Cell Lung Cancer	\$5,969	\$1,791	\$7,760
	Yunus, Shakeeb	RIH		8/23/2011	6/30/2049			PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma without MGMT Methylation: A Randomized Phase II Study	\$18,195	\$5,459	\$23,654
	Cancer Research Office (CRO) Total								\$547,476	\$163,013	\$710,489

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Center for Clinical & Translational Science	Ash, Arlene	NIH	5 UL1 TR000161-05	7/1/2010	3/31/2015	4/1/2014	3/31/2015	University of Massachusetts Center for Clinical and Translational Science - BERD	\$376,913	\$97,997	\$474,910
	Houston, Thomas	NIH	5 UL1 TR000161-05	7/1/2010	3/31/2015	4/1/2014	3/31/2015	University of Massachusetts Center for Clinical and Translational Science - Biomedical Informatics	\$292,858	\$188,894	\$481,752
	Luzuriaga, K., Flotte, T.	NIH	5 UL1 TR000161-05	7/1/2010	3/31/2015	4/1/2014	3/31/2015	University of Massachusetts Center for Clinical and Translational Science	\$1,443,100	\$713,689	\$2,156,789
		NIH	5 KL2 TR000160-05	7/1/2010	3/31/2015	4/1/2014	3/31/2015	University of Massachusetts Center for Clinical and Translational Sciences	\$535,500	\$42,840	\$578,340
	Ockene, Ira	NIH	5 UL1 TR000161-05	7/1/2010	3/31/2015	4/1/2014	3/31/2015	University of Massachusetts Center for Clinical and Translational Science - Community Engagement	\$217,454	\$56,538	\$273,992
Center for Clinical & Translational Science Total									\$2,865,825	\$1,099,958	\$3,965,783

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Wellstone Program	Emerson, Charles	MDA	MDA216652	3/1/2013	1/31/2015	2/1/2014	1/31/2015	Evaluating DUX4 as a Therapeutic Target for FSHD	\$181,818	\$18,182	\$200,000
		NIH	2 U54 HD060848-07	9/16/2013	5/31/2018	9/16/2013	5/31/2014	Biomarkers for Therapy of FSHD (U54): Project 1	\$33,122	\$17,552	\$50,674
		NIH	2 U54 HD060848-07	9/16/2013	5/31/2018	9/16/2013	5/31/2014	Biomarkers for Therapy of FSHD (U54): Core B	\$87,860	\$46,559	\$134,419
		NIH	2 U54 HD060848-07	9/16/2013	5/31/2018	9/16/2013	5/31/2014	Biomarkers for Therapy of FSHD (U54): Core C	\$205,727	\$109,018	\$314,745
		NIH	2 U54 HD060848-07	9/16/2013	5/31/2018	9/16/2013	5/31/2014	Biomarkers for Therapy of FSHD (U54): Project 2	\$141,504	\$74,985	\$216,489
		NIH	2 U54 HD060848-07	9/16/2013	5/31/2018	9/16/2013	5/31/2014	Biomarkers for Therapy of FSHD (U54): Project 3	\$42,220	\$22,373	\$64,593
		NIH	2 U54 HD060848-07	9/16/2013	5/31/2018	9/16/2013	5/31/2014	Biomarkers for Therapy of FSHD (U54): SUBAWARDS	\$639,608	\$26,496	\$666,104
		NIH	2 U54 HD060848-07	9/16/2013	5/31/2018	9/16/2013	5/31/2014	Biomarkers for Therapy of FSHD (U54): Core A	\$34,627	\$18,349	\$52,976
		NIH	5 R01 HD007796-44	3/18/2013	5/31/2015	6/1/2013	5/31/2014	Control of Muscle Protein Synthesis During Myogenesis	\$327,431	\$217,605	\$545,036
	Jones, Peter	AFM		3/1/2013	9/30/2014	10/1/2013	9/30/2014		\$24,000	\$0	\$24,000
		CARRINO		7/15/2013	7/14/2014	7/15/2013	7/14/2014	DUX4, epigenetics, and pathogenesis of facioscapulohumeral muscular dystrophy	\$25,000	\$0	\$25,000
		FSH	FSHS-22012-01	3/1/2013	11/30/2014	6/1/2013	5/31/2014	An FSHD model for therapeutic development	\$43,895	\$0	\$43,895
		NIH	1 R01 AR062587-01A1	7/3/2013	6/30/2018	7/3/2013	6/30/2014	A transgenic model of DUX4-mediated FSHD	\$340,327	\$159,299	\$499,626
								Mechanisms of DUX4-mediated FSHD pathology			
Wellstone Program Total									\$2,127,139	\$710,418	\$2,837,557

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Environmental Health & Safety	Sotolongo, Charleen	MEMA		9/22/2011	9/21/2014	9/22/2011	9/21/2014	UMASS Multi-Hazard Mitigation Plan	\$157,500	\$0	\$157,500
Environmental Health & Safety Total									\$157,500	\$0	\$157,500

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Faculty Affairs	Thorndyke, Luanne	SLOANF	2012-5-35 CFA	12/1/2012	11/30/2014	12/1/2013	11/30/2014	The Alfred P. Sloan Award for Faculty Career Flexibility for Medical Schools	\$125,000	\$0	\$125,000
Faculty Affairs Total									\$125,000	\$0	\$125,000

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Library	Martin, Elaine	ICFLLC	13EDPO0022/NIH	12/19/2013	9/16/2014	12/19/2013	9/16/2014	Women's Health Resources Dissemination Outreach Project 2013-2014	\$45,455	\$4,545	\$50,000
		NIH	HHSN276201100010C/NIH	5/1/2011	4/30/2016	5/1/2014	4/30/2015	National Network of Libraries of Medicine	\$1,162,368	\$147,098	\$1,309,466
Library Total									\$1,207,823	\$151,643	\$1,359,466

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Office of Global Health	Luzuriaga, Katherine	INDIANAU	BL-4111173-UMMS	10/1/2011	6/30/2015	10/1/2013	9/30/2014	University of Liberia Center for Excellence in Health and Life Sciences	\$252,298	\$21,774	\$274,072
Office of Global Health Total									\$252,298	\$21,774	\$274,072

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Animal Medicine	Silverman, Jerald	NIH	5 U24 DK093000-04	9/16/2011	5/31/2016	6/1/2014	5/31/2015	UMass Mouse Metabolic Phenotyping Center: Animal Core	\$19,535	\$12,600	\$32,135
		NIH	1 G20 OD018371-01	6/1/2014	5/31/2017	6/1/2014	5/31/2017	UMASS Small Animal Imaging Core Renovation	\$477,024	\$0	\$477,024
	Animal Medicine Total									\$496,559	\$12,600

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
School Services	Hines, Deborah Harmon	NIH	5 R25 HL092610-07	5/1/2013	1/31/2018	2/1/2014	1/31/2015	NIH Summer Research Program to Increase Diversity Among Biomedical Researchers	\$101,000	\$8,080	\$109,080
	Mayrand, Sandra	INTEL		7/1/2013	6/30/2014	7/1/2013	6/30/2014	Classroom Connections	\$9,874	\$0	\$9,874
School Services Total									\$110,874	\$8,080	\$118,954

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Graduate School of Biomedical Sciences	Fuhrmann, Cynthia	BURRWELL	1011612.01	6/1/2013	8/31/2014	5/1/2013	4/30/2014	Integrating career development into the graduate curriculum	\$47,005	\$0	\$47,005
		NIH	1 DP7 OD018421-01	9/20/2013	8/31/2018	9/20/2013	8/31/2014	An Integrated Curriculum and Community- Based Approach to Career Development [MPI]	\$242,501	\$161,667	\$404,168
Graduate School of Biomedical Sciences Total									\$289,506	\$161,667	\$451,173

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Graduate School of Nursing	Hale, Janet	HRSA	5 A10 HP25116-02-00	9/1/2012	6/30/2014	7/1/2013	6/30/2014	Advanced Education Nursing Traineeship	\$329,702	\$12,970	\$342,672
	Miller, Kathleen	HRSA	1 T57 HP20592-01-00	9/30/2010	9/29/2015	9/30/2010	9/29/2015	Advanced Nursing Education Expansion	\$748,000	\$12,816	\$760,816
		HRSA	5 D62 HP07458-08	7/1/2012	6/30/2015	7/1/2013	6/30/2014	Comprehensive Geriatric Education Program	\$237,255	\$12,839	\$250,094
	Sullivan-Bolyai, Susan	NIH	5 R01 NR011317-04	4/30/2010	9/30/2014	4/1/2013	3/31/2014	PETS-D: Parent Education Through Simulation-Diabetes	\$253,156	\$123,238	\$376,394
Graduate School of Nursing Total									\$1,568,113	\$161,863	\$1,729,976

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Center for Health Law & Economics	Grenier, Michael	NHINSUR	/NIH	4/23/2014	9/30/2015	4/23/2014	6/30/2014	New Hampshire Insurance Department Health Cost Analysis (2013-RRG-304)	\$29,413	\$7,648	\$37,061
	London, Katharine	JSMF	11114	3/24/2014	6/30/2014	3/24/2014	6/30/2014	Consultant Services to MDPH's Community Health Worker Workforce and Policy Development	\$4,010	\$1,030	\$5,040
	Williams, Karen	EOHHS		8/3/2013	7/31/2014	8/3/2013	7/31/2014	Massachusetts Demonstration to Integrate Care for Dual Eligible Individuals	\$3,153,467	\$378,118	\$3,531,585
		EOHHS	ISA CT EHS 11UMMSMFF	6/24/2011	6/30/2014	7/1/2013	6/30/2014	The Money Follows the Person Rebalancing Grant Demonstration	\$74,266	\$14,111	\$88,377
Center for Health Law & Economics Total									\$3,261,156	\$400,907	\$3,662,063

**University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014**

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Center for Health Policy & Research	Baxter, Jeffrey	NIH	5 R03 DA031374-02	5/1/2012	4/30/2015	5/1/2013	4/30/2014	The Quality of Buprenorphine Treatment for Medicaid Beneficiaries	\$48,000	\$31,881	\$79,881
	Clark, Robin	HEALTHRES	1C1CMS331039-01-00	1/1/2013	4/30/2016	7/1/2013	6/30/2014	Economic Evaluation of the New England Asthma Innovations Collaborative in Four New England States	\$50,743	\$18,267	\$69,010
	Ferguson, Warren	NIH	5 R13 DA030822-04	1/15/2011	12/31/2014	1/1/2014	12/31/2014	Academic and Health Policy Conference on Correctional Health Care	\$42,840	\$0	\$42,840
	Henry, Alexis	ABT	27033	11/1/2010	9/30/2017	12/7/2013	12/6/2014	Benefit Offset National Demonstration Implementation & Evaluation (BOND)	\$558,979	\$106,206	\$665,185
		MATHEMATICA	40112S03049	8/1/2012	9/29/2014	9/29/2013	9/29/2014	Social Security Administration Disability Research Consortium	\$127,949	\$84,495	\$212,444
		SSA	1 WIP12050388-01-00	8/1/2013	7/31/2015	8/1/2013	7/31/2014	The UMMS BenePLAN Program	\$247,671	\$47,057	\$294,728
	LaMothe, Nelson	STATE OF VT	25350	9/1/2013	12/31/2014	1/1/2014	12/31/2014	Vermont SIM Project Management	\$382,061	\$96,043	\$478,104
	Lawthers, Ann	EOHHS	CTEHS13UMMSADULTME	1/1/2013	12/20/2014	12/21/2013	12/20/2014	Implementing the CMS Adult Core Measures in MassHealth	\$448,227	\$85,163	\$533,390
		EOHHS	ISA CT EHA 0UMMSCHIP	6/1/2010	2/21/2015	2/22/2014	2/21/2015	Transformative Approaches to Improving Child Health Outcomes in Massachusetts	\$340,460	\$34,046	\$374,506
		MATHEMATICA	6816S02217	9/1/2013	6/30/2014	9/1/2013	6/30/2014	NCR D2 National Evaluation of CHIRPA Quality Demonstration Grant Program	\$8,433	\$2,193	\$10,626
	Martin, Brent	MDPH	INTF3327HH4300522083/I	11/26/2013	6/30/2014	11/26/2013	6/30/2014	Consultative Services to Division of Oral Health / MA Department of Public Health	\$34,082	\$6,475	\$40,557
	Mitra, Monika	MDMH	SCDMH821014080220000	10/1/2013	9/30/2016	10/1/2013	6/30/2014	Evaluation of Systems of Care Expansion Implementation	\$126,050	\$23,950	\$150,000
		MDPH	INTF3051HH2706811015	7/23/2012	6/30/2014	7/1/2013	6/30/2014	Improving the Health of People with Disabilities through State Based Public Health Programs	\$27,119	\$4,881	\$32,000
		NIH	5 R01 HD074581-02	2/5/2013	1/31/2016	2/1/2014	1/31/2015	Health Needs and Barriers to Perinatal Care for Women with Mobility Disabilities	\$270,957	\$95,687	\$366,644
	Murphy-Marticio, Colleen	EOHHS		10/1/2013	12/31/2014	10/1/2013	12/31/2014	Transitional Insurance Partnership Assistance	\$322,552	\$37,177	\$359,729
	Nickl, Dyana	FEDERALBU		10/1/2013	9/30/2014	10/1/2013	9/30/2014	Comprehensive Medical Services, FCI Berlin, NH	\$2,937,467	\$158,842	\$3,096,309
		FEDERALBU	DJBP020500000016	2/1/2013	1/31/2018	2/1/2014	1/31/2015	Comprehensive Medical Services, Fed. Medical Center, Fort Devens, MA	\$13,535,923	\$2,436,466	\$15,972,389
		FEDERALBU	DJBP021200000035	5/1/2014	4/30/2019	5/1/2014	4/30/2015	Comprehensive Medical Services FCI Ray Brook NY	\$1,231,042	\$185,004	\$1,416,046
	Oldham, Holly	STME	CDC-14-3023	5/15/2014	8/29/2014	5/15/2014	8/29/2014	Maine School Located Vaccine Clinic Billing Pilot Program	\$19,841	\$5,159	\$25,000
	Petkauskos, Kathleen	EOLWD		10/1/2012	9/30/2015	10/1/2013	9/30/2014	Disability Employment Initiative	\$112,383	\$20,229	\$132,612
	Sanchez, Jorge	EOHHS	/NIH	11/1/2013	6/30/2014	11/1/2013	6/30/2014	MassHealth Customer Service ISA	\$2,851,124	\$0	\$2,851,124
	Sloutsky, Alexander	JACKSONFDN	772068	1/15/2013	9/1/2014	1/15/2013	9/1/2014	MDR-TB Surveillance in Diverse Settings	\$48,196	\$32,130	\$80,326
	Steinberg, Judith	EOHHS	CTEHS14UMMSPCPRLEA	7/1/2013	12/31/2015	3/1/2014	12/31/2015	Primary Care Payment Reform Pre-Implementation	\$1,518,586	\$244,185	\$1,762,771
		NCBH	111104	4/1/2014	9/30/2014	4/1/2014	9/30/2014	How Behavioral Health is Implemented in Each PCMH Component	\$3,832	\$1,380	\$5,212
Center for Health Policy & Research Total									\$25,294,517	\$3,756,916	\$29,051,433

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Area Health Education Center	Cragin, Linda	EOHHS		3/1/2013	12/31/2014	9/28/2013	12/31/2014	Massachusetts Health Care Training Forum ACA and Exchange Learning Series	\$258,210	\$47,550	\$305,760
		HRSA	5 U77 HP03016-20	9/1/2012	8/31/2017	9/1/2013	8/31/2014	Model State-Supported AHEC Program	\$603,880	\$6,140	\$610,020
		MDE		11/13/2013	6/30/2016	11/13/2013	6/30/2014	HOSA: Health Occupation Students of America	\$33,318	\$6,682	\$40,000
	Winchester, Leanne	EOHHS	CT EHS 11UMMSPHCAST	10/1/2013	9/29/2014	10/1/2013	9/29/2014	Personal and Home Care Aide State Training Program (PHCAST)	\$71,278	\$5,702	\$76,980
Area Health Education Center Total									\$966,686	\$66,074	\$1,032,760

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
NE AIDS Education & Training Center	Gallagher, Donna	HRSA	5 H4 AHA00050-12	7/1/2012	6/30/2015	7/1/2013	6/30/2014	AIDS Education and Training Center	\$1,662,572	\$36,582	\$1,699,154
NE AIDS Education & Training Center Total									\$1,662,572	\$36,582	\$1,699,154

**University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014**

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Shriver Center	Bandini, Linda	HRSA	1 UA3MC25735-01	7/1/2013	6/30/2016	7/1/2013	6/30/2014	A Healthy Weight Research Network (HW-RN) for children with autism and development	\$151,675	\$48,325	\$200,000
		HRSA	5 R40 MC25678-02-00	2/1/2013	1/31/2015	2/1/2014	1/31/2015	MCH Research	\$197,154	\$53,323	\$250,477
	Bonardi, Alexandra	UAB	H133A120102-12A	1/3/2012	9/30/2014	10/1/2013	9/30/2014	UAB Obesity Research Project on Prevalence Adaptions and Knowledge Translations	\$6,159	\$2,341	\$8,500
		AHRQ	1 R03 HS022353-01	7/1/2013	6/30/2014	7/1/2013	6/30/2014	An Intervention to Reduce Falls Among Adults with Intellectual Disability	\$34,731	\$13,198	\$47,929
		CDC	5 U01 DD000914-02	9/30/2012	9/29/2015	9/30/2013	9/29/2014	Component B: Review of Oral Health Interventions for People with Intellectual Disability	\$121,620	\$32,246	\$153,866
		UNH	14-037/NIH	3/1/2013	9/29/2014	9/30/2013	9/29/2014	Component A - Reducing Health Disparities among People with Intellectual Disabilities	\$7,544	\$2,866	\$10,410
	Braden, Kathleen	HRSA	5 T73 MC00056-11-00	7/1/2011	6/30/2016	7/1/2013	6/30/2014	Training Long Term - LEND Neurodevelopmental Disabilities	\$613,350	\$31,388	\$644,738
	Curtin, Carol	NIH	5 P30 HD004147-41	8/1/2010	6/30/2015	7/1/2013	6/30/2014	Intellectual and Developmental Disabilities Research Center - Core D	\$234,312	\$151,132	\$385,444
	Deutsch, Curtis Dube, William	UCSD	90561886-01	9/1/2012	8/31/2014	9/1/2013	8/31/2014	Genomics of Neuropsychiatric Research	\$28,268	\$11,732	\$40,000
		KKI	915.271E/NIH	9/1/2009	6/30/2014	7/1/2013	6/30/2014	Translational Analyses of Chronic Aberrant Behavior Across the Life Span	\$90,504	\$37,560	\$128,064
	Gabovitch, Elaine	NIH	5 R01 HD062582-05	9/15/2010	5/31/2015	6/1/2014	5/31/2015	Contingency Analyses of Observing and Attending in Intellectual Disabilities	\$198,479	\$69,745	\$268,224
		UNH	11-105/NIH	4/10/2011	1/31/2016	2/1/2014	1/31/2015	Behavioral Persistence: Basic, Translational, and Clinical Studies	\$84,806	\$35,194	\$120,000
		AMCHP		5/1/2014	4/30/2016	5/1/2014	4/30/2015	Act Early Ambassador 2014-2016	\$2,000	\$0	\$2,000
		AMCHP		4/1/2013	4/30/2014	3/1/2013	4/30/2014	Learn the Signs. Act Early Ambassador	\$4,000	\$0	\$4,000
		HRSA	1 H6 MMC26244-01-00	9/1/2013	8/31/2015	9/1/2013	8/31/2014		\$54,315	\$20,652	\$74,967
		MDEEC	CTEEC0900ISAEECRTTT	6/20/2014	12/31/2014	6/20/2014	12/31/2014	State Planning Grants for Improving Services for Children and Youth with ASD	\$6,105	\$1,095	\$7,200
		NOONAN		9/1/2013	8/31/2014	9/1/2013	8/31/2014	Developmental Screening Webinar for Pediatricians	\$72,727	\$7,273	\$80,000
	Hamad, Charles	DHHS	90DD0675-02	7/1/2012	6/30/2017	7/1/2013	6/30/2014	Considering Culture in Autism Screening: A Culturally & Linguistically Competent Training Curriculum for Pediatric Providers	\$496,310	\$38,905	\$535,215
		PRAXIS	/NIH	8/3/2011	11/30/2014	8/1/2013	7/31/2014	University Center for Excellence in Developmental Education, Research and Services (UCEDD)	\$106,151	\$44,052	\$150,203
	Manning, Margaret	UMASS/BOSTON	UMMS/HRSA	12/12/2013	6/12/2014	12/12/2013	6/12/2014	Developmental Disabilities Dentistry Online	\$13,844	\$3,599	\$17,443
	McIlvane, William	KKI	920.271E/NIH	9/1/2009	6/30/2014	7/1/2013	6/30/2014	Addressing Health Disparities in Autism Diagnosis, Service Utilization, and School Engagement Among Young Children	\$20,378	\$8,457	\$28,835
		NIH	5 R01 MH090272-03	9/1/2011	5/31/2014	6/1/2013	5/31/2014	Living in the Circle of	\$241,536	\$91,632	\$333,168
		NIH	1 R21 HD075009-01A1	9/5/2013	8/31/2015	9/5/2013	8/31/2014	Translational Analyses of Chronic Aberrant Behavior Across the Life Span	\$150,000	\$100,000	\$250,000
		NIH	5 P30 HD004147-41	8/1/2010	6/30/2015	7/1/2013	6/30/2014	Optimizing Initial Communication for Children with Autism	\$111,635	\$72,004	\$183,639

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title	Direct Cost	Indirect Cost	Total Costs
Shriver Center	Mitchell, Teresa	ECOLLEGE	3452-UMMS/NIH	8/1/2013	7/31/2017	8/1/2013	7/31/2014	Verbal/non-verbal Asynchrony in Adolescents with High-functioning Autism	\$39,728	\$26,453	\$66,181
	Rubin, Emily	KLARMAN		1/1/2011	6/30/2014	7/1/2013	6/30/2014	Sibling Support Demonstration Project	\$30,000	\$0	\$30,000
		SRBAER		7/1/2012	6/30/2015	7/1/2013	6/30/2014	Sibling Support Demonstration Project	\$46,729	\$3,271	\$50,000
	Twyman, Janet	ADI		11/15/2012	9/30/2014	10/1/2013	9/30/2014	Center on Innovations in Learning	\$82,899	\$31,501	\$114,400
	Weinstock, Amy	DFF		1/1/2014	12/31/2014	1/1/2014	12/31/2014	Autism Insurance Resource Center	\$9,091	\$909	\$10,000
		MDDC		10/1/2013	9/30/2014	10/1/2013	9/30/2014	Autism Insurance Resource Center	\$22,727	\$2,273	\$25,000
		NLMFF		10/1/2012	8/31/2014	10/1/2013	8/31/2014	Core Funding for the Autism Insurance Resource Center	\$22,727	\$2,273	\$25,000
	Shriver Center Total								\$3,301,504	\$943,399	\$4,244,903

University of Massachusetts Medical School
Office of Research
Detail Listing of Grants and Contracts
as of June 30, 2014

Department/Division	PI Name	Sponsor	Award #	Project Start Date	Project End Date	Budget Start Date	Budget End Date	Project Title		Direct Cost	Indirect Cost	Total Costs
Grand Total										<u>\$178,848,716</u>	<u>\$65,384,788</u>	<u>\$244,233,504</u>